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Orbital floor fractures are a serious consequence of craniofacial trauma and 
account for approximately 60-70% of all orbital fractures.  Unfortunately, the body’s 
natural response to orbital floor defects generally does not restore proper function and 
facial aesthetics which is complicated by the thin bone and adjacent sinuses.  We 
propose using a tissue engineering strategy to regenerate orbital floor bone.  To this 
end, a functional biomaterial was investigated to enhance orbital floor regeneration.   
First, a bone marrow stromal cell population was isolated and differentiation 
assessed via coculture with chondrocytes and osteogenic media supplements.  A 
cyclic acetal biomaterial composed of the cyclic acetal monomer 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) and 
poly(ethylene glycol) diacrylate (PEGDA) was then developed for cell encapsulation.  
The previously investigated bone marrow stromal cells were then used to determine 
  
the effects of the ammonium persulfate/N,N,N’,N’-tetramethylethylenediamine 
initiator system used to crosslink the EH-PEG hydrogels on cell viability, metabolic 
activity, and osteogenic differentiation.  Next, EH-PEG hydrogels were implanted 
into orbital floor defects with bone morphogenetic protein-2, where tissue response 
and surrounding bone growth was analyzed.  To improve surrounding tissue 
interaction and cell infiltration, macroporous EH-PEG hydrogels were created using 
porogen-leaching.  These hydrogels were characterized using optical coherence 
tomography for pore size, porosity, and cell viability.  In addition, these macroporous 
hydrogels were created with varying architecture to analyze the effects on osteogenic 
signaling and differentiation.   This work outlines the potential application of EH-
PEG hydrogels for use in orbital floor repair. 
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Chapter 1:  Introduction 
 Orbital floor fractures are a severe form of craniofacial trauma.  In addition, 
the orbital floor is the wall most likely involved in orbital injuries.  Unfortunately, the 
body’s natural healing response to orbital floor fractures does not restore proper 
function and aesthetics; therefore, clinical intervention is necessary.  Current common 
clinical treatments include alloplastic implants and autologous grafts; however, each 
has associated disadvantages.   
 This project investigates the use of a tissue engineering approach to orbital 
floor repair.  An optimized orbital floor implant should regenerate orbital bone while 
supporting the orbital contents and eliciting minimal inflammatory response from the 
surrounding tissues.  As scaffold properties are very important to the success and 
function of the implant a number of polymers are currently under investigation; 
however, an ideal biomaterial has yet to be developed.  Our laboratory has developed 
a novel class of biomaterials based upon a cyclic acetal unit.  These materials may be 
advantageous as they degrade by hydrolysis into neutral primary degradation products 
of diols and carbonyls, and thus many not experience a change in local acidity 
associated with many synthetic biomaterials.  The acidity of hydrogel degradation 
products may be a concern to the stable phenotypic function of encapsulated cell 
populations.  Furthermore, acidic byproducts are thought to increase the inflammatory 
response and slow wound healing.  In addition, an increase in acidity is associated 
with an increase in the degradation rate which may affect the mechanical support the 




 In order to create a cyclic acetal based hydrogel for cell delivery, we followed 
the well described route of incorporating the hydrophilic polymer poly(ethylene 
glycol) (PEG).  Specifically, by including poly(ethylene glycol) diacrylate (PEGDA) 
within the radical polymerization of the cyclic acetal monomer 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD).  This 
hydrogel can act as a platform for orbital floor repair by incorporation of 



























Chapter 2:  Polymeric Scaffolds for Bone Tissue Engineering1 
 Orthopaedic injuries resulting from trauma or improper development often 
require surgical intervention to restore natural tissue function.  Currently, over one 
million operations are completed annually for bone surgical reconstruction[1].  The 
well known limitations associated with autografts, allografts, and bone cements have 
led to the investigation of synthetic polymers as support matrices for bone tissue 
engineering. Polymers are long chain molecules that are formed by linking 
repetitive monomer units and have been extensively studied for tissue engineering 
applications.  Constructs designed from these polymers can act as a support matrix to 
deliver cell populations or induce surrounding tissue ingrowth.  Scaffold properties 
directly determine their success in tissue engineering and must be designed 
specifically for each application.  A successful scaffold provides initial support, 
growth factors, and transitions through degradation to allow tissue regeneration and 
returned function.  This chapter will discuss the fabrication and properties of 
polymeric tissue engineering scaffolds including curing methods, polymer assembly, 
scaffold fabrication, surface properties, macrostructure, mechanical properties, 
biodegradation and biocompatibility, in addition to current synthetic polymers being 
investigated. 
 
                                                 
1 As published in MW Betz, DM Yoon, and JP Fisher. Engineering Polymeric Scaffolds for Bone 
Grafts. In: Engineering of Functional Skeletal Tissues. Topics in Bone Biology (Bronner, Farach-




2.1 Scaffold Formation 
2.1.1 Curing Methods 
 Scaffold curing method describes how polymer chains are formed into a bulk 
material and is dependant on the chemical nature of the polymer, specifically polymer 
length and functionality[2].  Two major curing methods often used are polymer 
entanglement and crosslinking. 
 Polymer entanglement is based on the principle that many polymers associate 
with one another in solution.  This is common with long, linear, as well as branched 
polymers.  The polymer is dissolved in an appropriate solvent and placed in a mold.  
The solvent is removed by evaporation, leaving the polymer in the shape of the mold 
using pressure, temperature, or both[3].  The process is advantageous because it is 
relatively simple, however there can be a lack of mechanical stability in the constructs 
formed exclusively by polymer entanglement. 
 Crosslinking of individual polymers through chemical bonds to form a bulk 
material is another curing method.  Individual polymer chains can form hydrogen or 
ionic bonds with one another through non-covalent interactions[2].  For the formation 
of covalent bonds, the polymer must contain a reactive site for crosslinking, such as a 
carbon-carbon double bond.  Covalent crosslinking is generally induced by a free 
radical that is initiated by heat, light, chemical accelerant, or time[4].  For example, 
photopolymerization is a commonly used technique based on photopolymer 
polymerization initiated by electromagnetic radiation[5].  The photopolymers used are 
typically low molecular weight monomers that react to form long-chain polymers 




response to a signal, the polymer may be used as an injectable material, and when 
exposed to the signal can form in situ.   However, the chemical reactions that are 
necessary for crosslinking are often associated with unreacted components as well as 
reaction byproducts that may be harmful to the surrounding tissue. 
 
2.1.2 Polymer Assembly  
 Polymer assembly may occur before implantation into the body, known as 
prefabrication, or during implantation in situ[6].  Prefabrication is common because 
the scaffold is formed outside of the body and any cytotoxic or non-biocompatible 
byproducts may be removed prior to transplantation.  In addition, this method allows 
for cell encapsulation and in vitro preculture before implantation.  However, the 
geometry of the construct generally will not precisely fit the host site.  This imperfect 
match may lead to host immune reactions such as fibrosis and therefore construct 
failure.  In situ fabrication techniques have been developed to address this concern.  
This technique involves curing the construct at the tissue defect site[4].  Liquid 
components are injected into the desired site and their deformability allows for 
improved integration into the host tissue.  Furthermore, as this method uses liquid 
components, it is less invasive than the surgical procedures sometimes necessary for 
prefabricated constructs.  However, in situ fabrication does not allow for the removal 
of harmful byproducts, and therefore the surrounding tissue can be exposed to toxic 
components.  This concern effectively reduces the possible chemical components that 






2.1.3 Conventional Scaffold Fabrication Methods  
 Fabrication is the process of forming a cured or curing polymer into a 
scaffold.  Scaffold fabrication can occur using conventional or rapid prototyping / 
solid freeform practices (See Table 1).  There are a number of conventional 
techniques that are used to create porous scaffolds including fiber bonding, solvent-





























































Fused Deposition Controlled pore size PCL [33-36] 
Table 1:  Fabrication methods and associated characteristics of synthetic 
polymers used in bone tissue engineering scaffolds. 
 
2.1.3.1  Fiber Bonding 
 Fibers are commonly processed from semicrystalline polymers, including 
poly(glycolic acid) (PGA).  These fibers can be used to create a fiber mesh, or a 
three-dimensional patterned structure with variable pore size through weaving or 
knitting.  These mesh constructs allow a large surface area and high porosity 
corresponding with greater cell attachment, nutrient diffusion, and waste removal[6].  
However, due to the increased porosity these scaffolds tend to be mechanically 
unstable.  This led to the formation of a fiber bonding technique to alleviate this 
issue[6,7].  Fiber bonding method has been used to dissolve poly(lactic acid) (PLA) in 
a solvent and cast it over a PGA mesh that is aligned in the desired shape[6].  Heating 
the construct above the melting temperature of PGA evaporates the solvent.  The 
PGA mesh becomes connected at fiber cross points when the construct is cooled and 
PLA is re-dissolved.  Fiber bonding has also been used to fabricate scaffolds from 
poly(ε-caprolactone) (PCL)[9].  While this technique allows for greater structural 




controlled.  In addition, the solvent used to dissolve the polymer can be harmful to an 
incorporated cell population and the surrounding tissue. 
 
2.1.3.2 Solvent-Casting Particulate Leaching 
 Solvent-casting particulate leaching is a technique where dispersed particles such 
as sodium chloride, tartrate, citrate, or saccharose, are mixed in solution with a 
polymer and mold casted[6,10].  Casting or freeze-drying is performed to evaporate the 
solvent.  The dispersed particles are leached out of the scaffold, leaving void spaces 
that form a porous and highly interconnected structure.  This process allows the 
independent control of porosity and pore size[6].  This technique has been used to 
form constructs with PLA, poly (D,L-lactic acid-co-glycolic acid) (PLGA) and 
poly(propylene fumarate) (PPF)[10-14]. 
 
2.1.3.3 Phase Separation 
 Phase separation is used to isolate components of a heterogeneous mixture.  In 
this process the polymer is first dissolved in a solvent such as molten phenol, 
naphthalene, or dioxane[6,15].  The polymer solvent solution is cooled, causing liquid-
liquid or solid-liquid phase separation with the polymer in a separate phase than the 
solvent.  The solvent is then evaporated forming a porous polymer membrane[6,16,37].  
One considerable advantage of this technique is the ability to incorporate 
biomolecules into the scaffold without exposing it to harsh chemical or thermal 
conditions.  In addition, changes to the polymer composition, polymer concentration, 




However, the effect of these modifications may be difficult to predict.  Phase 
separation has been used to create scaffolds of poly(L)lactic acid (PLLA), PLGA, and 
PLA[15-18].  
 
2.1.3.4 Melt Molding 
 Melt molding combines a polymer powder and microspheres to form a scaffold[6].  
This technique has been used with a fine PLGA powder and gelatin microspheres 
heated in a Teflon mold[6,19].  Heating the polymer above the glass transition 
temperature allows the polymer powder to melt.  The molded polymer is then 
removed and placed in water where the entrapped microspheres are removed, 
resulting in a three-dimensional porous structure.  There are a number of advantages 
to using this technique.  Pore size is directly related to the microsphere diameter, and 
changing the polymer to gelatin ratio modifies the porosity.  Furthermore, 
biomolecules can be incorporated into the scaffold, since this process is completed in 
a moderate environment without organic solvents.  Also, a defined construct shape 
can be chosen and created by changing the shape of the mold.  However, a 
disadvantage is that this technique may often require very high temperatures to heat 
semicrystalline polymers above their glass transition temperature[6]. 
 
2.1.3.5 Freeze Drying 
 Freeze drying is another method that uses temperature change to create a porous 
structure[20].  In this technique synthetic polymers such as PLGA are dissolved in 




solution is combined with water creating an emulsion[22].  Next, the emulsion is 
quickly frozen, creating ice crystals of solvent and water.  These crystals are removed 
through a freeze-drying technique, leaving a highly connected porous matrix.  An 
advantage to this technique is that the pore size can be controlled by altering the 
freezing rate; in general, a faster rate creates smaller pores[21].  Pore structure is 
difficult to control with freeze drying alone; however, it may be controlled by 
combining freeze drying with other techniques such as the above-described 
particulate-leaching method[38]. 
 
2.1.3.6 Gas Foaming 
 In gas foaming, pores are created within a scaffold from pressurized gases or 
gases created from a chemical reaction[24].  The presence of bubbles within the 
polymer leads to the formation of pores in the construct.  Variations in gas volume, 
rate of gas nucleation and diffusion modify the porosity and pore structure of the 
scaffold.  This method is advantageous because the scaffold is formed in a moderate 
environment without the use of organic solvents.  Similar to freeze-drying, this 
method can also be improved through combination with particulate leaching[25].  Gas 
foaming has been used with PLLA, PLGA and PLA to create scaffolds for bone 
tissue engineering applications[23-25]. 
 
2.1.4 Rapid Prototyping / Solid Free Form Fabrication 
 The conventional techniques described above are all generally limited in their 




and pore wall thickness.  This lack of fine control has led to the development of new 
techniques to produce scaffolds often directly from a computer-aided design model.  
Rapid prototyping, also known as solid freeform fabrication, has been used to guide 
surgical procedures based on patient computerized topography[5].  These techniques 
generally form reproducible three-dimensional scaffolds in a layer-by-layer fashion.  
The computer model used for scaffold formation can be precisely designed to form 
specific architecture.  In addition to the fine control of scaffold formation, this 
technique typically also has the advantage of being performed at room temperature.  
This moderate environment can allow for cell encapsulation and biomolecule 
incorporation without significantly affecting their viability.  However, this technique 
is not applicable to all polymers and therefore fabrication in this method is limited.  
Rapid prototyping techniques include sheet lamination, three-dimensional printing, 
laser stereolithography, and fused deposition modeling[5,32,39,40]. 
 
2.1.4.1 Sheet Lamination 
 Sheet lamination is a technique that creates scaffolds using a layer-by-layer 
approach.  A three-dimensional cross-section of the scaffold is built out of a roll of 
sheets that have been lined with an adhesive[5].  The layers are cut by a carbon 
dioxide laser and bonded by heat and or pressure.  One disadvantage to this method is 
that this technique does not allow for formation of small inner holes within the 






2.1.4.2 Three-dimensional Printing 
 Three-dimensional printing forms sequential powder layers of the scaffold by ink-
jet printing a binder[39,40].  In this technique a computer model is used to create a 
slicing algorithm defining the morphology of each layer of the scaffold.  A thin layer 
of powder is distributed over a powder bed, and then a binder material is printed on 
top where the scaffold is to be formed.  A piston is lowered to allow the next layer of 
powder to be spread and bonded.  An advantage of this technique is that the packing 
density of the powder particles can be used to control the adhesive bonding of the 
material and therefore mechanical strength[40].  This technique has been used to create 
scaffolds from polyethylene oxides  (PEOs), PLA, PCL and PLGA[26-28,39,40]. 
 
2.1.4.3 Laser Stereolithography  
 Laser stereolithography is another computer aided design method that allows for 
three-dimensional scaffold formation.  This method is similar to three-dimensional 
printing described above but utilizes a liquid polymer to fabricate a scaffold[39].  The 
computer model creates two-dimensional slices of the scaffold model and uses this to 
control a platform submerged in liquid photopolymer.  This liquid is then exposed to 
a focused laser light, which cures the polymer forming a solid at specific points.  A 
significant advantage of this technique is the ability to produce complex internal 
architecture.  Furthermore, different liquid solutions containing biomolecules can be 
used while forming each layer for incorporation into the scaffold[39].  This technique 




of pore sizes from 150-800 µm and porosity up to 90 percent[32].  Laser 
stereolithography has also been used to create scaffolds with PEG diacrylate[31]. 
 
2.1.4.4 Fused Deposition Modeling 
 Fused deposition modeling is a technique where the polymer is deposited in thin 
layers on a base which solidifies attaching to the previous layer[40].  Initially this 
technique was only used with non-resorbable materials but has recently be expanded 
to PCL and PCL/Hyaluronic acid scaffolds[33-35,40].  As with the other computer 
techniques, this process is highly reproducible.  Fused deposition modeling also 
supports incorporation of pores into the scaffold affecting mechanical strength and 
molecule diffusion. 
 
2.2 Synthetic Polymers for Scaffolds 
 The molecular structure and properties of synthetic polymers can be designed for 
specific applications, such as to support cell and tissue processes for engineered bone.  
This is perhaps an advantage over natural polymers whose modification is often less 
precise due to their variable molecular structure.  Synthetic polymers are most often 
present in a semicrystalline or an amorphous state.  A semicrystalline polymer 
contains dense chain regions randomly distributed throughout the material.  These 
regions act as physical crosslinks and contribute to the mechanical strength of the 
polymer network.  Amorphous polymers act similar to rubber above their glass 
transition temperature and analogous to glass below.  The structure of amorphous 




blending[41].  In their unmodified form, synthetic polymers lack biomolecules that are 
present in some natural polymers that can aid in cell attachment.  Advances have been 
made to modify synthetic polymer surfaces with biomolecules and therefore stimulate 
cell attachment and proliferation[42].  Common synthetic polymers include polyesters, 
polyanhydrides, polyphosphazenes, polycarbonates and poly(ethylene glycol). 
 
2.2.1 Polyesters 
2.2.1.1 Poly(D,L-lactic acid-co-glycolic acid) 
 Poly (D,L-lactic acid-co-glycolic acid) (PLGA), is a copolymer of poly(lactic 
acid) (PLA) and poly(glycolic acid) (PGA), and has distinct properties from the two 
homopolymers[22].  For example, PGA and PLA are semicrystalline polymers while 
PLGA is amorphous, and therefore a solid, non-crystalline structure.  Furthermore, 
PGA degrades slowly while PLGA can degrade rapidly[6,19,43,44].  When using 
comonomers, their ratio can be varied to achieve different mechanical, physical and 
degradation properties[25].  Degradation times have been shown to vary from six to 
twelve months with a monomer ratio of 85/15 to one to two months with a 50/50 
ratio, demonstrating the ability of this polymer to be engineered for an appropriate 
degradation rate[41].  PLGA is also known to degrade via bulk degradation (see 
Biodegradation Section below) due to its ester linkages, affecting its mechanical 
properties as it degrades[41].  The degradation products include glycolic acid and lactic 





 The ability to engineer PLGA properties has caused it to be of great interest for 
tissue engineering applications and has been found to support a variety of cell types.  
Osteoblasts have been shown to attach to PLGA[45,46].  Furthermore, extracellular 
matrix components such as osteopontin and osteonectin, known markers for 
osteogenic differentiation, were produced and present in abundant concentrations in 
addition to collagen, fibronectin, vitronectin and laminin[46].  The presence of these 
components is important to simulate the mature extracellular environment that 
osteoblasts require.   
 
2.2.1.2 Poly(ε-caprolactone) 
 Poly(ε-caprolactone) (PCL) is an aliphatic polyester with a repeating molecular 
structure of five nonpolar methylene groups and a single polar ester group[6].  A 
semicrystalline polymer, PCL has a melting point of approximately 60°C and is 
formed by the ring-opening polymerization of ε-capolactone [6].  PCL is known to be 
highly water soluble and degrades by hydrolytic mechanism at physiologic 
conditions[47].  Degradation occurs by bulk or surface mechanism into the byproduct 
caproic acid.  This acidic byproduct can affect the local environment of the scaffold 
and therefore degradation rate and byproduct concentration should be kept to a low 
level[6].  PCL is known to degrade very slowly and has a degradation time of 
approximately two years[6].  To modify the degradation rate and make it more 
appropriate for certain tissue engineering applications, PCL has been copolymerized 




support load-bearing applications and can maintain mechanical strength for an 
extended period of time[44]. 
 PCL has been used as a scaffold to support osteoblast growth.  A porous PCL 
scaffold facilitated osteoblast production of alkaline phosphatase, a known marker of 
bone mineralization, and attachment and proliferation of osteoblasts[51].  It has also 
been combined with hyaluronic acid to improve the compressive strength associated 
with the polymer and thus enhance its application in bone tissue engineering[51].   
 
2.2.1.3 Poly(propylene fumarate) 
 Poly(propylene fumarate) (PPF) is an aliphatic linear polyester composed of 
repeating units of two ester groups and one central unsaturated carbon-carbon double 
bond[52].  The polymer degrades by hydrolysis of an ester bond into degradation 
products of fumaric acid and propylene glycol[52].  These byproducts have been 
shown to cause mild and short inflammation suggesting that it is a biocompatible 
polymer[52].  PPF’s double bonds allow it to be covalently crosslinked.  This ability of 
crosslinking in response to a trigger allows scaffold fabrication in situ, therefore 
acting as an injectable biomaterial[53].  In addition, the cured form of PPF has 
demonstrated significant compressive and tensile strength and is a possible scaffold 
material for bone tissue engineering[53]. 
 PPF has been investigated for a number of different applications in bone tissue 
engineering.  PPF scaffolds with varying porosities and pore sizes were investigated 
to analyze tissue response in cranial defects.  In all cases the scaffolds only induced a 




scaffolds coated with transforming growth factor-β1 induced significant bone 
formation in cranial defects[42].  
 
2.2.1.4 Polyorthoester 
 Polyorthoesters (POEs) are a family of bioerodible polymers[55].  They are formed 
through a reaction of ketene acetals with hydroxy-containing molecules, such as 
diols[56].  POEs are hydrophobic substances and undergo surface degradation[56,57].  
However, properties of POEs can be modified through copolymerization.  For 
example, degradation of the polymer can be adjusted to an appropriate rate by 
incorporating short acid groups such as glycolic or lactic acid[57,58].  In addition, the 
orthoester linkages present within POEs have been found to be more susceptible to 
hydrolytic cleavage in acids than bases demonstrating another method of degradation 
control[41,47]. 
 POE polymers are desirable for bone tissue engineering because they degrade by 
surface degradation and maintain mechanical stability.  Therefore, they can be used in 
load bearing applications while the host tissue is reforming.  Scaffolds constructed of 
POEs were implanted into calvarial defects and analyzed for bone regrowth and 
demonstrated promotion of new bone formation[58].   
 
2.2.2 Other Synthetic Polymers 
2.2.2.1 Polyanhydrides 
 Polyanhydrides have a polymer backbone containing an anhydride bond[59].  They 




erosion[60].  Polyanhydrides are synthesized by a dehydration reaction of diacids, and 
degrade into these non-toxic diacid monomers which are removed from the body 
within weeks to months[59].  Polyanhydride degradation rate can be modified by 
changing the monomer concentrations: increasing hydrophobicity decreases 
degradation rate.  For example, polyanhydrides synthesized with 
carboxyphenoxypropane degrade over a period of 3-4 years.  However, when 
synthesized with 79% sebacic acid the construct degrades over two weeks[60].  
Furthermore, polyanhydride synthesis can be activated by a trigger such as 
photocrosslinking and therefore can be cured in situ [61,62]. 
 Polyanhydrides have initially been studied as a method for controlled release of 
bioactive molecules[59,63].  They tend to have limited mechanical stability and 
therefore may not be appropriate for load bearing applications involved in most bone 
tissue engineering.  However, research on polyanhydrides led to incorporation of 
imides into crosslinkable networks[44,64].  This increases the mechanical stability of 
the construct and it is thought that the strength is related to the rigidity of the aromatic 
imide group[64].  Specifically, scaffolds containing succinic acid have shown 
compressive strengths of 50-60 MPa and were degraded by hydrolysis of the 
anhydride bonds then imide bonds[63,64].  In addition, photocrosslinking has been used 
to increase mechanical properties of the polymer[61,65,66]. 
 
2.2.2.2 Polyphosphazene 
 Polyphosphazene contains a backbone composed of alternating nitrogen and 




is hydrophobic and degrades by surface degradation into phosphate and ammonium 
salt byproducts.  Variation in polyphosphazene constructs can be achieved by adding 
different hydrolytically labile substituents to the phosphorous atoms[68].  The 
degradation rate of phosphazenes are unable to be altered significantly and generally 
degrade slowly in vivo[68]. 
 Polyphosphazenes have been investigated for a number of different tissue 
engineering applications because of their ability to be highly modified.  Their slow 
degradation rate makes them of interest for long term controlled release devices[68].  It 
has also been applied as a material for orthopaedic uses due to its high strength and 
surface degradation properties[69].  Osteoblast cells have been seeded on three-
dimensional polyphosphazene scaffolds and shown to support proliferation and 
skeletal tissue formation[70].   
 
2.2.2.3 Polycarbonate 
 Tyrosine-derived polycarbonate (P(DTR carbonate)) is an amorphous 
polycarbonate, and is modifiable due to the presence of alkyl ester pendant groups 
located within its linear chain[71].    P(DTR carbonate) structure contains three bonds 
that can be hydrolytically degraded: amide, carbonate, and ester[71].  Carbonate bonds 
have been found to degrade faster than the ester bonds, and the amide bond is stable 
to hydrolysis at physiological temperature[71,72].  The ester bond is known to degrade 
into carboxylic acid and alcohol while the carbonate bond byproducts include two 




material because it is based on the natural amino acid tyrosine and degrades mostly 
into non-acidic byproducts[73]. 
 P(DTR carbonate) can be modified to degrade over months or years[73].  It has 
been investigated as a bone scaffold and shown to elicit a response of bone ingrowth 
at the bone-polymer interface[73].  In addition, research has demonstrated the ability of 
osteoblast cells to attach onto the surface of P(DTR carbonate) and maintain their 
phenotype[74].  Other investigations with poly(deasminotyrosyl-tyrosine ethyl ester 
carbonate) (poly(DTE carbonate)) have demonstrated that bone ingrowth occurs in 
cranial defects and that the patterns of bone formation mimicked the morphology of 
the scaffold[75].  This suggests that polycarbonate scaffolds can be designed to reflect 
the morphology of different bone tissue and therefore induce growth appropriate to 
the location.  Further studies with poly(DTE carbonate) show that it elicits more 
direct bone apposition when compared with other polycarbonates, and it is thought to 
occur due to the ethyl ester pendant group in the polymer[76].  The hydrolysis of these 
groups produces calcium chelation sites on the polymer surface which appear to be 
related to polymer-bone bonding[76].   
 
2.2.2.4 Poly(ethylene glycol) 
 Poly(ethylene glycol) (PEG) is a linear-chained polymer with an oxygen-carbon-
carbon repeating unit.  The number of units can be varied, which changes the length 
and molecular weight of the polymer[4,77].  PEG homopolymer is non-degradable, 
however it can be copolymerized with degradable polymers to allow degradation[78].  




backbone.  Copolymerization of PEG with other materials causes an increase in 
hydrophilicity of the subsequent material.  This property has led to investigation of its 
ability to function as a hydrogel.  However, linear PEG chains are susceptible to rapid 
diffusion and also low mechanical stability[79].  Networks of PEG can be formed by 
attaching functional groups to the ends of PEG chains and initiating their 
crosslinking[80-82]. 
 PEG has low mechanical stability and is therefore not often used in bone tissue 
engineering for load bearing applications.  However, its ability to be crosslinked into 
a network with other synthetic materials and affect degradation of those materials 
makes it attractive as a copolymer.  It can be copolymerized with various polymers to 
engineer a construct with controlled erosion methods and degradation rates.  PEG was 
copolymerized with poly(lactic acid), combined with a hydroxyapatite ceramic, and 
used to deliver bone morphogenetic protein and demonstrated complete repair of 
bone defects[83].  Similarly, PEG was combined with PLA and p-dioxanone and used 
to deliver bone morphogenetic protein where it exhibited osteoconductive capacity[84].  
PEG hydrogels have also been modified with cell adhesion peptides and used in 
tissue engineering.  These gels delivered growth factors, resulting in efficient and 
highly localized bone regeneration[85].  In addition, PEG has been copolymerized with 
PLGA to form a foam to deliver periosteal cells in vivo supporting osteochondral 





2.3 Scaffold Design Properties  
 Scaffold properties can be modified to mimic the mature tissue that is being 
regenerated, or engineered to induce ingrowth and proliferation of cells.  Properties 
that can be altered are discussed below and include: surface properties, 
macrostructure, mechanical properties, biodegradation, and biocompatibility. 
 
2.3.1 Surface Properties  
 The majority of cell types used in bone tissue engineering are anchorage 
dependant and thus the engineered scaffold should facilitate cell attachment.  The 
surface of the scaffold is the initial and primary interaction site to the surrounding 
tissue.  Therefore, tissue engineering strategies favor scaffolds that cells attach to 
abundantly and easily, making scaffolds with large accessible surface areas more 
favorable.  In addition, the surface of the scaffold should support cell proliferation.  It 
has been shown that strong cell adhesion promotes cell proliferation while a rounded 
morphology demonstrates their differentiation[43].  A highly wettable surface is 
present on hydrophilic polymers and this allows cells to be encapsulated through 
capillary action[87].  However, the most significant surface property of polymers is the 
ability to provide an environment for scaffold-host interaction.  Many natural 
polymers have the innate ability to facilitate attachment because they can contain a 
number of functional groups that vary in polarity, electrostatic charge, 
hydrophobicity, and the ability to interact via van der Waal’s forces.  In addition, 
natural polymer chemistry uses covalent and non-covalent assembly which can be 




polymers in tissue engineering is to mimic these natural polymer characteristics.  
Advances in polymer synthesis now allow for control of the polymer and side-chain 
architecture.  This enables inclusion of functional groups at the surface in addition to 
within the material.  The surface of the polymer can therefore be modified with short 
peptide sequences or long protein chains to promote interaction with the surrounding 
tissue[89].  Specifically, ligands that are common in the extracellular matrix such as, 
fibronectin, vitronectin, and laminin have been used as surface molecules[89].  This 
surface modification technique is being widely investigated for tissue engineering 
applications[88-90]. 
 
2.3.2 Macrostructure  
 A highly porous scaffold allows cells to integrate into the porous void space.  In 
addition, the porous nature of the scaffold is important for diffusion of nutrients and 
waste removal.  In general, it is advantageous for the scaffold to have a high surface 
area to volume ratio, which promotes small diameter pores that are larger than the 
diameter of the cell.  However, high porosity scaffolds are associated with poor 
mechanical integrity.  Engineering these properties to allow for appropriate diffusion 
and mechanical strength are important challenges in the construction of bone tissue 
engineering scaffolds.  Fiber meshes, foam scaffolds, and hydrogels demonstrate the 
varying polymer macrostructure of foams possible for bone tissue engineering 
applications. 
 Fiber meshes are formed into three-dimensional structures by knitting or weaving 




provide a large surface area to promote cell attachment[6].  In addition fiber mesh 
scaffolds are similar to the structure of the extracellular matrix allowing for nutrient 
diffusion and waste removal.  These scaffolds tend to have low mechanical integrity, 
however fiber bonding has been used to create a more stable structure[7]. 
 Foam scaffolds act as a three-dimensional structure for cell integration.  These 
scaffolds are generally prefabricated before implantation.  Similar to fiber meshes, the 
structure of foam scaffolds allow for sufficient nutrient diffusion and waste removal.  
However, foams tend to be more mechanically stable than fiber meshes, but still lack 
strong mechanical integrity.  Porosity and pore structure can be modified by using 
different processing techniques such as, solvent-casting particulate leaching, melt 
molding, freeze drying and gas foaming.   
 Hydrogels are formed from hydrophilic polymers by physical polymer 
entanglements or crosslinking[4,91].  The hydrophilic polymers are able to absorb large 
quantities of water, up to a thousand times their own dry weight[91].  The aqueous 
environment created in hydrogels simulates in vivo environments and therefore are an 
ideal setting for cell encapsulation.  In addition, the aqueous environment supports 
quick diffusion of nutrients, proteins, and waste, thus promoting cell growth and 
proliferation.  Some hydrogels, including PEG based hydrogels, are easily injectable 
and capable of being molded, allowing minimally invasive implantation[92].  






2.3.3 Mechanical Properties 
 The ability of a scaffold to provide the necessary mechanical support is a critical 
component of the construct.  However, the relatively strong mechanical strength of 
bone, compared to other tissues, presents challenges to tissue engineers.  
Mechanically, compact bone acts as a semibrittle, viscoelastic and orientation 
dependant material[93].  In the longitudinal orientation, a range of strengths has been 
reported for compact bone reported of 78.8 to 151 MPa and 131 to 224 MPa for 
tension and compression, respectively[94].  The elastic moduli for compact bone has 
been demonstrated to be 17.0 to 20.0 GPa in the longitudinal direction with a shear 
modulus of 3.30 GPa and a structural density of 1.80 g/cm3[94].  In contrast to compact 
bone, cancellous bone is spongy and highly porous with a structural density of 0.20 
g/cm3.  In general, cancellous bone is oriented along the principal stress directions 
due to the external loading environment[93].  The strength of cancellous bone is based 
upon its apparent density and has values of 2.00 to 5.00 MPa and 90.0 to 400 MPa for 
strength and modulus, respectively[95].   
 For proper tissue regeneration without significant deformation, it has been 
suggested a scaffold should provide a mechanical modulus of 10-1,500 MPa for hard 
tissues and 0.4 to 350 MPa for soft tissues[96].  Mechanical requirements are therefore 
very important for orthopaedic hard tissues and dictate the fabrication method of the 
polymer.  For example, it is suggested that fabrication with particulate leaching and 
gas foaming have a maximum compressive moduli of 0.4 MPa and therefore are not 
appropriate for scaffolds to be implanted for hard tissue regeneration[96].  The lack of 




emphasizes the utility of rapid prototyping techniques for bone tissue engineered 
scaffolds.  These precise methods of fabrication have the capability of creating 
scaffolds with significant mechanical stability.   
 Finally, scaffolds should provide interim support while the tissue regenerates.  It 
is important that the material does not degrade before the tissue can provide sufficient 
load-bearing support for the area and stress dissipation.  There are two common 
scaffold design properties to support bone ingrowth with proper mechanical support.  
One strategy is for the physical scaffold to provide mechanical support for the 
polymer/cell/tissue construct from initial seeding to remodeling by the host[97].  
Therefore, the scaffold matrix must provide sufficient mechanical support to 
withstand in vivo stresses and loading.  The other strategy imposes transitional 
support.  Here the scaffold provides mechanical support while cells proliferate and 
differentiate in vitro[97].  Once implanted, the scaffold is designed to degrade at the 
same rate as the cells produce the extracellular matrix for support. 
 
2.3.4 Biodegradation 
 The majority of tissue engineering scaffolds are designed to degrade so that when 
the tissue is completely formed, the scaffold should be wholly degraded.  For 
synthetic polymers, degradation occurs primarily by chemical hydrolysis of 
hydrolytically unstable polymer backbones[41].  The polymer can also be designed to 
degrade enzymatically relying on catalysts present in the surrounding environment or 
embedded within the scaffold.  Degradation can alter the mechanical properties of the 




the degradation products can modify the local environment of the implant.  This is 
dependant on the biocompatibility of the degradation products and whether they are 
harmful to the surrounding tissue.  Both of these properties are dependant on the 
structure, components, and fabrication techniques of the material and how it degrades 
over time.  In addition, degradation is dependant on the location and geometry of the 
implant as well as the presence of catalysts, impurities and other additives[41]. 
 Hydrolysis of the polymer backbone occurs in two phases[41].  First, water 
penetrates in the bulk of the polymer converting the long chains into shorter water-
soluble degradation products by attacking the chemical bonds in the amorphous 
phase.  Next, the fragments are enzymatically degraded causing a rapid decrease in 
polymer mass.  These two phases are part of two overall mechanisms of degradation.   
 In addition to the characteristics of polymer degradation, overall scaffold 
degradation has been well described in literature.  Polymeric scaffolds undergo bulk, 
or surface degradation, or a combination of both.  In bulk degradation, the erosion at 
the surface is slower than in the interior[41].  Initially the surface begins to degrade 
when the construct is in contact with water, then as water penetrates to the inside of 
the material, the bulk of the scaffold begins to degrade.  Bulk degradation is 
associated with a decrease in mass while the volume of the construct stays the same, 
which causes a decrease in density and as a result, mechanical strength.   
 One concern with bulk degradation is a phenomena known as the autocatalytic 
effect[98]. This often occurs with synthetic polymers whose degradation products are 
acidic.  When degradation occurs the interior degradation products are unable to 




elevated acidic environment causes a rapid increase in degradation by catalyzing 
hydrolysis of labile linkages.   
 Surface degradation of a scaffold is similar to the dissolution of soap.  In this 
mechanism, the rate at which the material degrades at the surface is constant.  As the 
size of the construct decreases or thins over time, the bulk integrity and structure is 
maintained.  This mechanism is common with polyanhydrides and polyorthoesters.  
These materials are hydrophobic, but highly susceptible to hydrolysis and degrade at 
the surface.  As the material degrades the size of the construct decreases as mass is 
loss allowing for constant density.  This property allows the polymer to maintain 
mechanical integrity, which can be critical for bone tissue engineering applications. 
 The preferable method of degradation varies between tissue engineering uses, the 
host tissue, and mechanical integrity requirements.  The speed at which a scaffold 
degrades can be engineered by varying the polymer properties.  For example, more 
hydrophilic monomers and acidic end groups, more hydrolytically reactive backbone, 
less crystallinity, and smaller device size all tend to increase the degradation rate of 
the material[41].  The location of the implant can also affect the speed of degradation.  
A poorly vascularized area with low diffusion will not be able to remove degradation 
products as quickly causing an increase in acidity, similar to the interior of the 
scaffold during bulk degradation, and an overall increase in degradation rate.  All of 
these factors are important in engineering an appropriate rate and method for 





2.3.5 Biocompatibility  
 All implanted materials elicit a reaction from the host, but materials vary in the 
degree of response produced.  Reactions to injury include inflammation, wound 
healing, and foreign body responses[99].  A material may be considered to be 
biocompatible if it produces minimal inflammatory and immune response, and is able 
to function properly without significant harm to the host.  The goal of designing a 
material for implantation is to minimize the magnitude of the response and its 
duration.   
 The response to an implanted scaffold can be divided into three phases[99].  Phase 
one occurs during the first one to two weeks after implantation and includes acute and 
chronic inflammatory responses.  Acute inflammation is short and generally lasts 
minutes to days and is dependant on the extent of the injury[100].  Chronic 
inflammation is due to long-term presence of inflammatory stimuli and is confined to 
the implant site.  In general, the phase one response is independent of the degradation 
rate of the polymer[99].  Initiation of phase two response occurs with an increase in 
monocytes and macrophages.  In addition, phase two includes the initiation of fibrous 
encapsulation of the foreign material.  In contrast to phase one, the length of phase 
two is a function of the rate of biodegradation of the scaffold[99].  Fibrous 
encapsulation continues in phase three.  The length of the phase is dependant on the 
degradation rate of the polymer.  Slowly degrading polymers have been shown to 
have a phase three response lasting several weeks to months and the phase three 




 The immune response has a direct effect on bone tissue engineering.  Specifically, 
degradation products are thought to be the cause of failure in many orthopaedic 
implants[101].  These degradation particles can be phagocytosed by macrophages when 
less than 20 m in diameter[101].  It is thought that these particles indirectly affect 
bone cells through the secretory products of macrophages drawn to the area from the 
immune response[101].  Studies have shown that microparticles of PLLA and PLGA 
suppress osteoblast differentiation early in culture[101].  Others suggest that 
degradation particles directly interact with osteoblasts and affect their 
proliferation[102].  In addition, dense fibrous capsule formation composed of 
macrophages and foreign body giant cells have formed in response to PLLA bone 
plates and screws[103].  Clearly biomaterial properties significantly affect the 
magnitude and duration of the host response.  Characteristics of the material that can 
alter the immune response include the size, shape, and chemical and physical 
properties[99].  Finally, when designing a biomaterial one must consider not only 
consider the initial properties of the scaffold but also the degradation products and 
their effect on the host. 
 
2.4 Summary 
 Scaffold design is an intricate process and must be tailored for different bone 
tissue engineering applications.  Scaffolds must be able to induce growth, support cell 
adhesion and proliferation, and provide mechanical stability as necessary for different 
locations.  Synthetic polymers can be easily modified to provide appropriate 




method:  both conventional and rapid-prototyping techniques have successfully 
produced viable bone tissue engineering scaffolds.  Fundamental design parameters 
are dependant of the needs of the regenerated tissue and include polymer assembly, 
curing methods, surface properties, macrostructure, mechanical properties, 

















Chapter 3: Regeneration of Orbital Floor Bone 
 Orbital floor fractures are a common form of craniofacial trauma and can 
result in significant functional limitation.  In addition, the floor is the orbital wall 
most likely involved in orbital trauma.  The thin bone of the orbital floor and the 
adjacent dead space of the maxillary sinus are not conducive to proper healing 
sometimes resulting in poor function and facial aesthetics; therefore a clinical 
intervention is often necessary.  Current clinical treatments have associated 
disadvantages, increasing the need for the development of an ideal implant. 
 
3.1 Orbital Bone Development and Anatomy 
The orbital region is central to the functional success and aesthetic features of 
the facial skeleton.[104]  Initially the ocular globes, as the growth center, grow rapidly 
causing an increase in the orbits.  The growth of this bony structure is 85% complete 
by 5 years and is finalized between seven years of age and puberty.[105,106] 
 The main purpose of the floor is to support the globe and separate the orbital 
contents from the maxillary sinus; it is therefore very thin, approximately 0.5 
mm.[105,107]  It is composed of portions of three bones, the maxilla, zygomatic, and 
palantine.[107,108]  The floor is not completely horizontal, but has a slight convex curve 
where the posteromedial section is higher than the flatter anterolateral area.[108]  The 
orbital floor is also lined on the ocular side by periosteum.[105,109]  In addition, when 




of deformation with static loading, possibly explaining the high number of orbital 
fractures associated with blunt trauma.[107] 
 
3.2 Orbital Floor Injuries and Mechanisms 
 Orbital floor injuries, most commonly caused by assault and traffic accidents, 
can be a devastating form of craniofacial trauma.[110,111]  Studies have shown that the 
floor is the wall most frequently involved in orbital trauma accounting for 
approximately 60-70% of all orbital fractures.[112,113](See Figure 1)  As the floor is 
continuous with the thin medial wall, it may also act as a natural crumple zone and be 
involved in significant orbital traumas.   
 
Figure 1:  CT Scan of an orbital floor fracture.  (An orbital roof fracture is also present)  
Image courtesy of Dr. Domenick Coletti 
 
If left untreated, orbital floor fractures might not provide adequate support to 




thin bone fragments often paired with injured periosteum and disrupted blood supply 
provides a poor conduit for bone healing.  Furthermore there is generally insufficient 
contact with surrounding bony edges to conduct bone formation which leads to 
fibrous scar formation.    This change in orbital architecture provides inadequate 
globe support and increased orbital volume, and as a result, altered globe function.  
Therefore, the endogenous response to orbital fractures, in contrast to many other 
bone fractures, is not sufficient for proper healing. 
 The majority of orbital floor injuries occur from trauma, and there are two 
main biomechanical mechanisms proposed to explain how orbital floor defects occur.  
The hydraulic theory suggests that force applied to the globe results in increased 
intraorbital hydraulic pressure and transmission of this pressure to the walls of the 
orbit results in the fracture at the weakest point, which is generally the thin orbital 
floor.[107,114,115]  The buckling theory offers that trauma to the infraorbital rim 
transmits force directly to the orbital floor, causing disruption of the bone without 
fracture of the rim and displacement of orbital contents.[107,114,115] 
 
3.3 Current Clinical Solutions 
 To treat a clinically significant orbital floor fracture, it is critical to restore the 
orbit to its original volume in order to ensure proper globe function.[107]  During 
surgery the herniated orbital tissues are repositioned into the orbit and an implant is 
used to span the defect in the floor to prevent reherniation.[116]  There are a wide 
variety of implants available, each associated with very specific advantages and 




alloplastic implants while plastic and craniofacial surgeons tend towards using 
autologous materials.[111,116]  The decision for which type of implant should take into 
consideration the size and shape of the defect, the presence or absence of peripheral 
bony ledges, the age of the patient, donor site issues, and to a degree, patient 
preferences. 
 There are a number of alloplastic implants that are currently in clinical use.  
Frequently used materials include Medpor (high-density polypropylene), poly(L-lactic 
acid) or poly(glycolic acid), and titanium (See Figure 2).[107,111,117]  The benefits of 
using alloplastic implants include their ease of availability, they can be adapted to 
fractures of any defect shape before use, and they are reasonably priced.[111,116]  
However, these implants are foreign bodies and following implantation, these 
relatively inert alloplastic materials develop a fibrous capsule.[116]  Other 
complications have been described with these implants including infection, implant 
migration or extrusion, extraocular muscle entrapment, cyst formation, residual 
diploplia, globe elevation, and visual loss.[111,116,118]  Treatment then involves 











Figure 2:  Orbital repair with titanium mesh.  Image Courtesy of Dr. Domenick Coletti. 
 
 Autologous grafts are frequently used for the repair of orbital floor defects, 
and a number of donor sites have been employed such as iliac crest, ribs, calvaria, 
maxillary bone, the outer cortex of the mandible, and also cartilage donor sites have 
been described.[111,119-122]  The advantages to using autologous grafts include good 
graft stability, reduced implant associated costs, and limited adverse reactions.[111]  
However, there are a number of associated disadvantages such as, morbidity of the 
donor site, increase in surgical time, limited availability, unpredictable resorption, 
adaptability, and the modeling properties of the graft.[111,118]  In addition, there may be 
significant risk to the donor site.  Furthermore, it is vital that the orbit is restored to its 
original volume to promote proper function and aesthetics. There are a number of 
variables that account for volume maintenance including position (inlay versus 
onlay), membranous or endochondral, cancellous or cortical, mechanical stress, 




periosteum, and rate of vascularization.[123]  However, grafts harvested from calvarial 
and facial sites tend to resorb less than those from rib, tibia, or iliac crest which is 
important to consider when choosing a donor site.[123] 
 Other grafts that have been used in the past, or are currently in use, however 
they are less common.  Allogenic implants, such as lyophilized dura mater was 
successfully used until cases involving disease transmission were reported.[111]  New 
sterilization techniques have shown promise with dura mater implants, however it is 
only appropriate for use with small to moderate-sized defects, and long-term outcome 
studies have not yet been completed.[118]  In addition, solvent preserved cadaveric 
calvarial bone grafts have been used with some success.[104]  These grafts showed 
implant vascularization and tissue ingrowth, however studies showing the effects of 
solvent treatment on graft survival are limited and long term effects of these implants 
still need to be studied.[104]  Other graft types including xenografts, specifically swine 
bone cortex, show good integration into the surrounding tissue, however they do not 
have good modeling properties.[111] 
 
3.4 Sequelae 
 The endogenous response to bone healing is not adequate for proper regrowth 
of the orbital floor causing a number of associated problems.  In addition, the current 
clinical solutions are not without their share of disadvantages.  Therefore there are a 
number of general sequelae that are associated with orbital floor injuries, with the two 
most frequent complications being enophthalmos and diploplia.[108,124]  Enophthalmos 




globe, and this is readily visible at greater than 3 mm.[111]  Enophthalmos is thought to 
be caused by changes in orbital volume, destruction of restraining ligaments, fat 
atrophy, and remodeling of the soft tissues into a more round shape.[104,108,111,124]  
Diplopia (double vision) is thought to be caused from extraocular muscle 
dysfunction; specifically, entrapment, ischemia, hemorrhage, or nerve injury.[125]  
Other common sequelae include decreased sensation on the injured side of the face 
(in the distribution area of the infraorbital nerve) and this is shown to be present in 
more than half of cases in recovery studies.[112,124,125]  In addition, unsatisfactory 
facial aesthetics have been associated with orbital floor fractures.[112]  Proper 
treatment alleviates sequelae by supporting the orbital contents, preventing soft tissue 
fibrosis, and restoring continuity of the orbital floor.[111] 
 
3.5 Tissue Engineering Approach 
 In order to create an improved orbital floor implant tissue engineering has 
been explored.     In bone tissue engineering, cells act as the osteogenic stimulation to 
form new bone.[123]  In contrast, specific growth factors and cytokines can act as the 
osteoinductive stimulation, which recruit and induce osteoprogenitor cells to grow 
into mature bone tissue through chemotaxis, mitosis, and differentiation.[123]  Finally, 
a scaffold acts as an osteoconductive medium where the scaffold serves as a surface 
on which the cells can attach, migrate, grow, divide, and new blood vessels can 
invade.[123] 
 The scaffold should provide enough structural support for the globe and 




original orbital volume to decrease the likelihood of enophthalmos.[107]  Also, the 
implant should degrade as the tissue grows.  Furthermore, it should only elicit a 
moderate immune response and not induce fibrous encapsulation.  Lastly, it should be 
easy to work with, easily molded and shaped to the floor defect, and easily placeable.  
A scaffold that has all of these properties would be the optimal device for orbital floor 
repair. 
 
3.5.1 Cell Source 
 In order to regenerate bone tissue an appropriate cell population needs to be 
delivered or recruited to the injured area.  A number of cell types have been used in 
craniofacial tissue engineering with success; however, the most widely investigated 
are mesenchymal stem cells (MSCs). 
 During natural injuries such as bone fractures, MSCs are recruited to the area 
and differentiate into osteoblasts through a number of environmental cues.[126]  MSCs 
have the ability to replicate as undifferentiated cells and also the potential to 
differentiate into a number of lineages such as bone, cartilage, adipose, tendon, 
ligament, and marrow stroma.[127,128]  However, in order to be induced down the 
osteogenic differentiation pathway, a sufficient and appropriate amount of 
extracellular signals must be available.[126] 
 MSCs are capable of proliferating in vitro allowing large numbers of cells to 
be cultured from a small harvest amounts.[129]  Furthermore, studies have 




response.[129]  Lastly, stem cells have been shown to withstand low-oxygen 
conditions, which may be present following transplantation.[129]  The ease of isolation 
and capacity to be induced down the osteogenic differentiation pathway make MSCs 
an ideal cell type for bone tissue engineering.[130-132] 
 
3.5.2 Signals 
 Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily 
and are known to be secreted signaling molecules.[133,134]  BMPs are present at 
different periods of growth: the early stages of embryogenesis, during the 
organogenesis phase and growth period, and in adults during fracture repair.[133,135]  
Currently, 16 BMPs have been identified, and the most widely investigated for bone 
tissue engineering are BMP-2, 4, and 7 (also known as osteogenic protein-1).[136-141]  
BMP-2 and BMP-7 are currently the only BMPs with recombinant human products 
developed for clinical applications[129,138,142]. 
 The family of BMPs is known to induce formation of cartilage, bone, and 
other like tissues of the skeleton through recruitment, commitment, and 
differentiation of osteoprogenitor cells.[133,141]  Specifically, BMP-2 through 7 and 
BMP-9 have demonstrated the ability to induce the differentiation of mesenchymal 
stem cells into osteoblasts.[138]  Furthermore, BMP-2 and 7 have both shown to have 
chemotactic effects on osteoblasts and osteoprogenitor cells.[143]  In addition, BMP-2 
is known to induce mesenchymal stem cell chemotaxis, proliferation, and 




 As related to orbital defects, many studies have demonstrated the use of BMPs 
in increasing bone formation in maxillofacial defects.[136]  In addition, when 
implanted in a defect, BMP-2 has demonstrated induction throughout the defects and 
bony healing.[133]  It has been shown that the amount of BMP required is small 
relative to the volume of bone it is capable of producing.[133]  However, a kilogram of 
bone contains only a few micrograms of BMPs, but milligram doses have been shown 
to be required for efficacy in human models.[145]   
 Other growth factors are being investigated for use in bone tissue engineering 
including: transforming growth factor-β (TGF-β), insulin like growth factor I (IGF-I), 
fibroblast growth factor (FGF), and platelet derived growth factor 
(PDGF).[126,139,140,146,147]  Together, these growth factors aid at the target site by 
increasing mesenchymal stem cells and osteoprogenitor cells to enhance bone 
formation and participate in the regulation of bone-specific genes responsible for 
maintaining the osteoblastic phenotype and mineralization.[140,147]  Furthermore, they 
can induce increased expression of the osteoblast phenotype including extracellular 
matrix molecules.[140]  Specifically, TGF-β1 is thought to increase differentiation and 
proliferation in osteoblasts, in addition to aid in increased bone formation in 
animals.[126]  Furthermore, TGF-β1 has been shown to play a role in bone graft 
incorporation.[148]  IGF-I has demonstrated a chemotactic effect while increasing 
proliferation and differentiation of osteoblasts.[126,148]  IGF-I is produced by 
osteoblasts and retained in the extracellular matrix.[147]  Here it has been shown to 
promote proliferation and synthesis of type I collagen, and decrease collagenase 




known to activate osteocalcin expression, a marker for mature bone.[147]  FGF has 
shown the ability to induce mesenchymal cell mitogenesis, and increase proliferation 
of osteoblasts.[126,139]  However, it is thought to slow the differentiation of 
osteoprogenitors.[126]  Additional studies have shown that FGF levels are increased 
during early stages of fracture healing, and that FGF upregulates osteocalcin 
expression.[147]  PDGF is known to increase proliferation of osteoblasts.[126,148]  In 
addition, it may also aid in recruiting bone cells during remodeling and repair.[148]  
 While there has been significant progress made in the field of bone tissue 
engineering with the use of growth factors, there are a number of concerns to working 
with these proteins.  Specifically, a number of the growth factors have a very short 
biological half-life, which may be as short as 2 minutes.[146]  This causes increased 
concern for the tissue engineer and the ability to deliver the appropriate dose to the 
target area.  Furthermore, BMPs are known to be osteoconductive with a dose-
response ratio and act locally.[138]  Therefore, it is important to supply above a 
threshold level of BMP at the target site to induce bone formation.  Thus far, in 
clinical settings rhBMPs have been used at concentrations 10 to 1000 fold higher than 
those of native BMPs.[138]  In order to deliver BMPs, and ideally reduce the amount of 
BMP needed, it should be combined with a matrix to allow for slow release and area 
retention.  When combined with a matrix, the BMP-matrix system allows for cell 
infiltration, retention of BMP at the site, and a substrate for cell growth and 
differentiation.[133]  All of these concerns highlight the importance of an adequate 




the scaffold and the ability of the construct to the deliver the growth factor at a 
therapeutic level and rate. 
 
3.5.3 Scaffold 
 Scaffold design is critical to the success of a tissue engineered construct.  In 
orbital bone tissue engineering, scaffolds act as a temporary framework for cells to 
grow and produce new matrix and functional tissue.  As the target tissue is 
regenerated, the scaffold should degrade to allow space for the new tissue to grow.  
There are several parameters involved in scaffold design, including polymer 
composition, biodegradation, biocompatibility, and mechanical strength.   
 Many strategies have been developed for bone tissue engineering using 
natural and synthetic polymers.  Natural polymers may be advantageous because they 
are often biocompatible and easily degraded by the body.  However, natural polymers 
tend to have a variable molecular structure.  In addition, they generally do not possess 
adequate mechanical integrity.  Synthetic materials have been widely investigated due 
to their reproducibility in the lab.  In addition, these materials can be modified to have 
desired properties including mechanical stiffness and degradation by tailoring the 
fabrication methods.  Furthermore, during synthesis, various bioactive molecules can 
be incorporated into the scaffolds through a number of techniques. 
 Many of the cells involved in bone tissue engineering are anchorage 
dependant, and therefore the scaffold should be engineered to aid in cell attachment.  




cells can attach more easily.  Furthermore, the surface has to be carefully designed as 
to how strongly cells attach.  Studies have shown that strong cell adhesion promotes 
cell proliferation while a rounded morphology demonstrates their differentiation.[43]  
However, the most significant surface property of polymers is the ability to provide 
an environment for scaffold-host interaction.  Advances in polymer synthesis allow 
for control of the polymer and side-chain architecture.  This enables inclusion of 
functional groups at the surface in addition to within the material.  The surface of the 
polymer can therefore be modified with short peptide sequences or long protein 
chains to promote interaction with the surrounding tissue.[89] 
 The scaffold macrostructure design is important to the success of a tissue 
construct as a highly porous scaffold allows cells to integrate into the porous void 
space.  Specifically, it has been shown that human osteoblasts can penetrate pores 
with a diameter of 20 µm, however a larger diameter is better.[149]  Migration studies 
with human mesenchymal stem cells have demonstrated that they can pass through 5 
µm pores.[150]  Other studies have demonstrated that interconnected pores with 
diameters greater than 50 µm are favorable to new bone formation.[98,149,151]  In 
addition, it has been shown that the minimum pore size for osteoconduction is 80-100 
µm.[149,152]  Lastly, for the scaffold to support new vasculature, it has been shown that 
the minimum pore size is 45-100 µm; however, scaffolds with pore sizes of 100-150 
µm resulted in a richer blood supply.[149,153]  Therefore, from these above studies it 





 As mentioned above, the ideal construct would degrade so that when the 
tissue is completely formed, the scaffold should be wholly degraded.  For synthetic 
polymers, degradation occurs primarily by chemical hydrolysis of hydrolytically 
unstable polymer backbones.[41]  Degradation can alter the mechanical properties of 
the construct, which subsequently can alter the effectiveness of the implant.  This is 
critical in orbital bone engineering because if insufficient mechanical support is 
provided, delayed enophthalmos could occur.  In addition, the degradation products 
can modify the surrounding environment of the implant.  This is dependant on the 
biocompatibility of the degradation products and whether they are harmful to the 
adjacent tissue.  Both of these properties are dependant on the structure, components, 
and fabrication techniques of the material.  In addition, degradation is dependant on 
the location and geometry of the implant as well as the presence of catalysts, 
impurities and other additives.[41] 
 All implanted materials elicit a reaction from the host, but there is variation in 
the degree of response produced based upon the material.  Reactions to injury include 
inflammation, wound healing, and foreign body responses.[99]  A material may be 
considered to be biocompatible if it produces minimal inflammatory and immune 
response, and is able to function properly without significant harm to the host.  The 
goal of designing a material for implantation is to minimize the magnitude of the 
response and response duration. 
 The immune response has a direct effect on bone tissue engineering.  
Specifically, degradation products are thought to be the cause of failure in many 




macrophages when less than 20 m in diameter.[101]  It is thought that these particles 
may indirectly affect bone cells through the secretory products of macrophages drawn 
to the area from the immune response.[101]  Studies suggest that degradation particles 
directly interact with osteoblasts and affect their proliferation.[102]  As mentioned 
above, biomaterial properties can affect the magnitude and duration of the host 
response.  Characteristics of the material that can alter the immune response include 
the size, shape, and chemical and physical properties.[99]   
 Mechanical properties are of great importance in designing a scaffold for 
orbital floor regeneration.  As the orbital floor acts as a natural crumple zone during 
trauma it is important to closely mimic the native tissue in order to restore this natural 
function.  An experimental study was completed qualitatively analyzing the forces 
applied to the orbital floor in the two proposed traumatic defect mechanisms as a 
result of direct injuries to the globe or orbital rim by placing strain gauges beneath the 
orbital floor[114,115].  In conditions simulating the buckling mechanisms, anterior 
strains exceeded 3756 µε and minimal strains detected posteriorly.  In the hydraulic 
simulation, significant anterior strains were reported; however, posterior gauge 
readings all exceeded 3756 µε.  In addition, the average energy required to fracture 
the orbital floor for each of the mechanisms was 1.54 J and 1.22 J for buckling and 
hydraulic mechanisms, respectively.  Other studies performed compared the orbital 
content weight and the load-resisting capabilities of common orbital reconstruction 
materials[154].  The investigation determined that the weight of the combined orbital 
contents was approximately 42.97 ± 4.05 g and all materials investigated provided 




mm) which exhibited a yield load of 11.93 ± 5.93 kg, a yield displacement of 1.70 ± 
0.17 mm, a maximum load of 12.48 ± 6.13 kg, and a maximum displacement of 2.35 
± 0.77 mm.  The scaffold designed should closely mimic the properties of orbital 
floor bone. 
 
3.6 Current Tissue Engineering Progress 
 There has been significant progress made in the field of orbital bone tissue 
engineering; however a fully developed, ideal scaffold has yet to be created.  This 
section reviews current progress achieved in orbital floor engineering and success in 
craniofacial engineering which may be applied to orbital floor regeneration (Table 2). 





None BMP-2 Orbital floor 
defects in rabbits 
[155] 
Porous PCL Bone marrow 
aspirate 
None Orbital defects in 
pigs 
[34] 









None Calvarial defect 
in rabbit [157] 
Porous PPF None None Cranial defect in 
rabbit 
[54] 
Porous PPF None Fibronectin, 
TGF-β1 







Bone marrow in 
porous PPF 
TGF- β2 Cranial defect in 
rabbit [158] 
 






3.6.1 EH-PEG Hydrogels  
 Investigators have developed a novel class of biomaterials based upon a cyclic 
acetal unit.  These materials may be advantageous since the cyclic acetal unit 
degrades by hydrolysis into neutral primary degradation products of diols and 
carbonyls, and thus may not experience a change in local acidity associated with 
many synthetic biomaterials.  The acidity of hydrogel degradation products may be a 
concern, for example, to the stable phenotypic function of encapsulated cell 
populations.  Furthermore, acidic byproducts are thought to increase the inflammatory 
response and slow wound healing.  In addition, an increase in acidity is associated 
with an increase in the degradation rate which may affect the mechanical support the 
construct is providing. 
 In order to create a cyclic acetal based hydrogel for cell encapsulation, the 
hydrophilic polymer poly(ethylene glycol) (PEG) was incorporated.  Specifically, by 
including poly(ethylene glycol) diacrylate (PEGDA) within the radical 
polymerization of the cyclic acetal monomer 5-ethyl-5-(hydroxymethyl)-β,β-
dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD), a water swellable EH-PEG 
hydrogel has been produced[159].  This hydrogel can act as a platform for orbital floor 
repair by the integration of mesenchymal stem cells and osteoinductive signals such 
as BMPs. 
 Studies with these EH-PEG hydrogels have demonstrated that components 
required for gel crosslinking do not affect metabolic activity, viability or expression 
of osteogenic markers of bone marrow stromal cells (BMSCs).[160]  Furthermore, 




viability.[160]  In addition, when implanted in orbital floor defects in vivo the tissue 
surrounding the EH-PEG constructs showed a positive progression from 7 to 28 d 
indicating that constructs were not eliciting a chronic inflammatory response.[155]  
Lastly, the data shows the ability for EH-PEG gels to deliver BMP-2 in vivo as shown 
by the new bone growth in the area surrounding the constructs containing high 
concentrations of BMP-2 at 28 d (See Figure 3).[155]  This demonstrates that EH-PEG 


















3.6.2 Polycaprolactone Scaffolds 
 A study has been completed investigating orbital defects in pigs where they 
coated polycaprolactone (PCL) with bone marrow to aid in regeneration.[34]  PCL is 
an advantageous material to work with because it has already been approved by the 
FDA as a bioresorbable polymer.  Furthermore these investigators used fused 
deposition modeling to create a porous and highly interconnected network which 
should aid in the osteoconductive capacity of the scaffold and allow for vascular 
ingrowth.  Scaffolds were implanted in medial wall defects and analyzed after three 
months using histology.   
All scaffolds showed a thin layer of fibrous encapsulation indicating a mild 
inflammatory response with no additional signs of infection.  PCL scaffolds without 
bone marrow were able to repair the defect and demonstrated the formation of new 
trabecular bone at the interface and within the scaffold, approximately 4.5%.  While 
PCL scaffolds loaded with bone marrow aspirate reconstructed the defect and also 
showed significantly increased bone growth into the implant of 14.1%.  In both 
conditions, the presence of giant cells was dismissed as not being clinically relevant, 
however; the researchers suggest that additional studies with more time points over an 
extended period might elucidate the foreign body reaction.  This study demonstrates 
the importance of including a cell source as shown by the increased bone growth in 
PCL scaffolds with bone marrow aspirates.  It is important to note that after three 
months, only 14.1% of the scaffold demonstrated new bone formation.  Additional 
modifications to the scaffold may be necessary to improve bone regeneration 




3.6.3 Polyglycolic Acid Constructs 
 Other investigators have focused on craniofacial applications, and some of 
their findings can be applied to orbital bone engineering.  Investigators harvested and 
expanded the periosteum in vitro.[156]  The periosteum is of interest because it is 
easily harvested, has been shown to contain osteoprogenitor and chondroprogenitor 
cells, and contributes to osteogenesis in bone development and fracture healing.  In 
this study, the periosteal cells cultured under osteogenic conditions were combined 
with resorbable polyglycolic acid (PGA) scaffolds and implanted in critical sized 
calvarial defects of rabbits.   
Investigators demonstrated that the periosteal cells showed an osteoblast 
phenotype in vitro by expression of osteocalcin in osteogenic conditions.  This 
corresponds with the literature that the periosteum contains osteoprogenitor cells.  In 
addition, pre-implantation analysis demonstrated adherence of the periosteal cells to 
the PGA matrix which is important in tissue engineering.  Furthermore, increased 
bone formation was found in groups with PGA scaffolds coated with periosteal cells 
as compared to untreated PGA implants in vivo by histology.  This study again 
demonstrates the importance of delivering a cell population to the target site to aid in 
regeneration.  While additional quantification of bone formation in the scaffolds may 
be beneficial in future studies, PGA is a promising scaffold for craniofacial tissue 





3.6.4 Polycaprolactone Seeded Scaffolds 
 Other studies were performed using the polymer polycaprolactone (PCL) 
described above.  However, this study focuses on calvarial defects.  Here the 
investigators compared rabbit bone marrow derived mesenchymal progenitor cells 
(MPCs) and calvarial osteoblasts in in vitro[161] and in vivo[157].  Investigators 
demonstrated the 2-D differentiation potential of MPCs and then loaded both cell 
types onto 3-D porous interconnected PCL scaffolds fabricated using fused deposition 
modeling where their osteogenic differentiation was measured.  Finally, the PCL 
scaffolds with a fibrin glue suspension were loaded with each cell type and implanted 
in critical-size calvarial defects in rabbits. 
First, in the in vitro study, when seeded on 3-D PCL scaffolds MPCs were 
shown to have slightly higher alkaline phosphatase expression when compared to 
osteoblasts, however osteocalcin expression demonstrated no statistical differences.  
This demonstrates that both cell types show potential for use in craniofacial tissue 
engineering.  In addition, continuous cell proliferation and homogenous cell 
distribution was seen throughout the PCL scaffolds.  Homogenous cell distribution is 
a vital property of a tissue scaffold, but more importantly, measurable cell 
proliferation is a positive result showing PCL scaffolds are a promising tissue 
engineering construct.  Further in vivo results demonstrated increased bone formation 
with cell-seeded scaffolds after three months, however there was no significant 
difference between scaffolds seeded with osteoblasts or MPCs as shown by histology 




successful in tissue engineering applications in vitro and in vivo and therefore it may 
be best to proceed with the cell type most easily harvested. 
 
3.6.5 Poly(Propylene Fumarate) Scaffolds 
 Much progress has been made with poly(propylene fumarate) (PPF) for use in 
craniofacial tissue engineering.  First, the soft and hard tissue responses to 
photocrosslinked PPF scaffolds were investigated in cranial defects using a rabbit 
model.[54]  Results show an organized connective tissue at 8 weeks.  Furthermore, the 
study demonstrated that PPF scaffolds elicit a mild immune response in both soft and 
hard tissues and that scaffold porosity and pore size did not significantly affect the 
tissue response as examined by histology.  This study indicates that PPF may be an 
appropriate scaffold for craniofacial tissue engineering.  Next, PPF scaffolds were 
treated with TGF-β1 and implanted into subcritical-size cranial defects in rabbits.
[42]  
Results show that constructs coated with TGF-β1 had significantly higher bone 
growth when compared to other groups that were not coated with TGF-β1 as 
demonstrated by analysis of histological images quantifying bone surface area, and 
bone area percentage.  This indicates TGF-β1 as an important growth factor in 
craniofacial tissue engineering.  Further studies with PPF were performed by creating 
a construct that combined PPF with β-tricalcium phosphate.[158]  In addition, these 
constructs were designed to contain a porous layer that was infused with bone 
marrow aspirate.  This study examined the inclusion of TGF-β2 to the constructs in a 
critical-size cranial defect in a rabbit model.  Results show more bone formation 




compared to other groups as supported by mechanical testing.  These above studies 




 Orbital floor fractures can be a severe form of craniofacial trauma.  In 
addition, the floor is the orbital wall most likely involved in orbital trauma.  
Unfortunately, the body’s natural healing response to orbital floor fractures does not 
always restore proper function and facial aesthetics; therefore a clinical intervention 
is necessary.  Current common clinical treatments include alloplastic implants and 
autologous grafts; however, each has associated disadvantages and sequelae.  Orbital 
bone engineering offers solutions to the current clinical techniques and can aid in 
regeneration of natural bone tissue that is similar in both form and function to the 
native orbital floor.  Tissue engineering utilizes cells, signals, and scaffolds, and this 
review has outlined necessary components for a successful construct for orbital floor 
repair.  In addition, current successes and progress in the literature specific to orbital 








Chapter 4:  Objective 
The goal of this project is to make use of tissue engineering strategies to 
regenerate orbital floor bone using a novel scaffold, known as a cyclic acetal 
biomaterial, utilizing an osteoprogenitor cell population and enhanced osteogenic cell 
signaling.  Objectives of this work were to isolate bone marrow stromal cells and 
demonstrate their osteogenic differentiation through coculture with chondrocytes and 
standard media supplements.  Next, bone marrow stromal cells were used to test the 
encapsulation potential of APS and TEMED as an initiator system for EH-PEG 
hydrogels.  Further studies were completed where EH-PEG hydrogels were used to 
deliver BMP-2 to an orbital floor defect in vivo.  To improve surrounding tissue 
interaction, macroporous EH-PEG hydrogels were created.  These macroporous EH-
PEG hydrogels were characterized using optical coherence tomography for porosity, 
pore size, and viability.  Finally, the architecture of macroporous EH-PEG hydrogels 










Chapter 5:  Osteogenic Differentiation of Bone Marrow Stromal 
Cells2 
5.1 Introduction 
 In recent years, the viability of tissue engineering approaches to treat bone 
defects and degenerative bone disease has been thoroughly demonstrated.  The 
capacity of mesenchymal stem cells (MSCs) to differentiate into various cell types of 
the osteogenic lineage, defined here as osteoinduction, offers a potentially limitless 
source of donor cells with which these strategies could be executed.[128], [127]  
However, complete success remains contingent upon the illumination of a well-
defined and fully understood protocol for guiding the differentiation of these 
progenitor cells destined for implantation into a defective site.  The development of 
such a protocol would allow for the in vitro proliferation of the desired cell-types 
from a pool of harvested cells, and minimize the complications of differentiation 
toward undesired lineages following transplant.[162,163]  To this end, a number of 
different strategies have been explored.  Various groups have demonstrated the 
osteoinductive potential of chemical compounds such as prostaglandin E2
[164,165], 
1,25-dihydroxyvitamin D3 
[166], as well as the often utilized pair of dexamethasone 
and Na-β-glycerolphosphate.[167]  Biomaterial matrices fabricated from collagen and 
modified with calcium[168,169] or chondroitin sulfate[170] have also demonstrated 
osteoinduction.  Reactive oxygen species[171-173] and even several forms of physical 
                                                 
2 As Published in AD Thompson*, MW Betz*, DM Yoon, and JP Fisher. Osteogenic Differentiation of 
Bone Marrow Stromal Cells Induced by Coculture with Chondrocytes Encapsulated in Three-
Dimensional Matrices. Tissue Engineering Part A. In Press. (Epub 2008 Oct 14) 




stimuli[174,175] have been investigated for their osteoinductive effects.  Finally, 
molecular signals from myeloma cells, vascular endothelial cells, and 
chondrocytes[176-178] have also been shown to have osteoinductive capabilities. 
 Of particular interest has been the application of coculture systems utilizing 
chondrocytes to control the differentiation of MSCs.  The majority of in vivo bone 
formation, during both embryogenesis and postnatal fracture repair, occurs by way of 
a process known as endochondral ossification.[179,180]  It begins as MSCs differentiate 
into chondrocytes and form a matrix template in the region of prospective bone.  
Then, as chondrocytes within this template progress through a spatially and 
temporally specific series of phases including proliferation, prehypertrophy, 
hypertrophy, and finally apoptosis, additional MSCs infiltrate the growth plate and 
begin to differentiate toward osteogenic lineages, replacing the cartilage template 
with ossified bone.[180]  As the patterning and differentiation of chondrocytes within 
this matrix template seem to guide the recruitment and differentiation of the 
osteogenic precursors, the hypothesis then follows that chondrocytes produce some 
signaling factor, or some set of signaling factors, that elicit this response.  
Accordingly, studies have confirmed this hypothesis and identified a number of 
potentially relevant factors.[177,178,180-182]  Within the generally osteoinductive 
subfamily of TGF-β signaling factors, known commonly as bone morphogenetic 
proteins[181,182], several have been identified as being highly expressed by 
chondrocytes during endochondral ossification.[180]  Transglutaminase enzymes, 
known to be upregulated in chondrocytes found in the hypertrophic zone of the 




preosteoblasts[178], and the expression of indian hedgehog, a potent inducer of 
osteogenic differentiation in MSCs[183], is upregulated by chondrocytes in the 
prehypertrophic zone of developing bone.[179] 
 Coculture methods have previously shown efficacy in inducing the 
differentiation of MSCs toward neuronal, cardiomyocytic, chondrocytic, as well as 
osteoblastic lineages.[176-178,184,185]  These methods have been direct in nature, 
entailing cell-cell contact between the two populations being cocultured, or indirect in 
nature, wherein a permeable membrane may separate the populations.  The physical 
contact of cells in direct coculture can lead to complications such as cell fusion[186], 
and ultimately necessitates separation of the two cell populations.[162]  Indirect 
cocultures avoid these problems, but have typically been conducted in systems 
entailing two populations culturing in monolayer, with one in a well plate and another 
upon the surface of a transwell membrane.  Unfortunately, this design imposes a 
spatial constraint on the mechanism of coculture limiting the number of cells that can 
be cultured to those that can adhere to the surface.  As such, coculture systems in 
which one or both cell populations are suspended in three-dimensional matrices could 
potentially prove to be more efficient allowing more cells to be cultured within a 
limited area.   
 In this work, bone marrow stromal cells (BMSCs) in monolayer were 
cocultured with chondrocytes suspended in three-dimensional matrices, preventing 
direct cell-to-cell contact between the two cell populations.  BMSCs are known to 
contain a population of MSCs and therefore have osteoprogenitor capabilities.[187]  




under the assumption that maintaining their natural morphology would be conducive 
to providing a more accurate simulation of an in vivo influence on bone formation.[188]  
The specific objectives of the study were (1) to determine whether chondrocytes 
cultured in alginate hydrogels could induce the osteogenic differentiation of BMSCs, 
(2) to compare the expression profiles of various osteoblastic markers for BMSCs 
cocultured with articular chondrocytes and BMSCs cultured in the presence of 
dexamethasone and Na-β-glycerolphosphate, and (3) to investigate the dependency of 




 Alginic acid sodium salt from brown algae, HEPES, ascorbic acid, sodium 
bicarbonate, bovine serum albumin, Na-β-glycerolphosphate, dexamethasone, alizarin 
red S, and formaldehyde were obtained from Sigma-Aldrich (St. Louis, MO).  Fetal 
bovine serum, penicillin/streptomycin, sodium pyruvate, α-minimal essential medium 
(α-MEM), and Dulbecco’s modified eagle’s medium: nutrient mixture F-12 ham 
(DMEM) were obtained from Gibco (Carlsbad, CA).  Collagenase P was obtained 
from Roche (Indianapolis, IN).  DNeasy isolation kits and RNeasy isolation kits were 
obtained from Qiagen (Valencia, CA).  Quant-iTTM  picogreen dsDNA assay kits were 
obtained from Molecular Probes (Carlsbad, CA).  All chemicals, reagents, and kits 





5.2.2 Bone Marrow Stromal Cell Isolation 
 BMSCs were obtained from young Wistar Hannover GALAS male rats 
weighing between 101 and 125g, following a University of Maryland approved 
IACUC animal protocol, as described previously.[189]  Briefly, rats were euthanized 
with CO2, and then both femurs and tibias were excised.  Remaining soft tissue was 
removed from the bones prior to three ten-minute washes with 10 mL of control 
media (described below) containing 10% penicillin/streptomycin.  Next, epiphysial 
plates were cleft and marrow was flushed out with control media using a syringe 
(18½ gauge).  All marrow isolated from a single subject was then combined and 
homogenized by mixing with a syringe preceding filtration through a 70 µm cell 
strainer.  The resultant solution was centrifuged for 5 minutes at 500g, and then 
resuspended in 5 mL of control media with 10% FBS and plated into a T-25 flask.  
After two days, a change of media isolated the adherent cells.  BMSCs were 
precultured for two weeks, passaged when confluent, and then plated into six-well 
plates at a density of 4.5 X104 per well. 
 
5.2.3 Articular Chondrocyte Isolation and Encapsulation 
 Chondrocytes were obtained according to a protocol also described 
previously.[190]  Briefly, cartilage was harvested from the metatarsal phalangeal joints 
of calves aged 15-18 weeks.  Excised cartilage was washed thrice in control media, 
and then digested overnight in a 0.2% Collagenase P solution at 37oC and 5% CO2.  
The following day, cells were filtered through a 70 µm cell strainer to rid the samples 




were then pooled and centrifuged at 500g for 5 minutes.  Alginate solution, prepared 
by heating 1.2% (w/v) alginic acid in a solution of 0.15M NaCl and 0.025 HEPES 
buffer, and filtered to achieve sterility (0.22µm pore size), was then used to resuspend 
the pelleted chondrocytes at a density of 2.25 x 106 cells/mL.  Chondrocytes were 
encapsulated in three dimensional hydrogels by dropping this solution, via syringes 
(18½ gauge), into a beaker of stirring 100mM CaCl2, which immediately crosslinked 
the alginate into beads.  This produced spherical hydrogels measuring approximately 
3 mm in diameter which contained chondrocytes at a density of 75,000 cells/bead.  
Cocultures were conducted with 20 beads/well, translating to a total density of 1.5 x 
106 chondrocytes/well.  
 
5.2.4 Cell Culture Conditions 
 Culture media for all five conditions consisted of a mixture of equal parts α-
MEM and DMEM.[191]  Prior to mixing, α-MEM was supplemented with 50 μg/mL 
ascorbic acid, 2.0 mg/mL sodium bicarbonate and 0.1% penicillin/streptomycin, 
while DMEM was supplemented with 50 μg/mL ascorbic acid, 1 mg/mL sodium 
bicarbonate, 0.1% penicillin/streptomycin, 1 mg/mL bovine serum albumin, and 0.1% 
sodium pyruvate.  For the osteogenic control condition, this α-MEM/ D-MEM blend 
was additionally supplemented with 10 mM Na-β-glycerolphosphate and 10-8 M 
dexamethasone.  Cells were cultured in six-well tissue culture plates at 37oC and 5% 
CO2, and media containing 10% FBS was changed every two days.  Controls did not 




Cocultures were executed using Corning transwell inserts (0.4 µm size 
exclusion) to separate any chondrocytes that detached from the bead from the BMSC 
population.  All three coculture conditions were conducted identically.  At day 0, 
coculture was initiated for all experimental groups.  For the 1-Day coculture 
condition, inserts along with chondrocytes were removed from the cultures after 1 
day.  For the 10-Day coculture condition, inserts were removed after 10 days, and for 
the 21-Day coculture condition, chondrocytes remained in the cultures until the final 
time point.  Due to the fact that a small number of chondrocytes did detach from the 
hydrogels and settled on the transwell membranes as the cultures progressed, 
transwell inserts were replaced at day 10 in the 21-Day condition, in order to 
minimize the number of adherent chondrocytes culturing on the membrane.  For the 
chondrocyte signaling study cocultures were initiated on day 0, and a control group 
with no BMSCs was also cultured. 
 
5.2.5 DNA Quantification  
 In order to normalize the calcium deposition described below, DNA was 
isolated from BMSCs at each time point and quantified via picogreen assay.  Briefly, 
samples were lifted in triplicate for each condition and DNA was isolated using the 
Qiagen DNeasy isolation kit according the manufacturer’s protocol.  DNA was then 
quantified using the Quant-iT picogreen kit by combining 100 µL of DNA isolate 
with 100 µL picogreen reagent, incubating at room temperature for 5 minutes, and 
then reading fluorescence at 480nm excitation and 520nm emission on an M5 




5.2.6 Quantitative rt-PCR 
 Chondrocytes were isolated from alginate beads by incubating in 0.1 M 
ethylenediamintetraacetic acid in PBS at 37oC for 15 minutes, and then pelleted by 
centrifugation.  RNA was isolated from BMSCs and chondrocytes at each time point 
using a RNeasy Mini Plus Kit, according to the manufacturer’s protocol.  This total 
RNA was reverse transcribed with a High Capacity cDNA Archive Kit, and then an 
ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, CA) was 
utilized to determine the expression levels of the proteins of interest via quantitative 
rt-PCR.   
BMSCs were analyzed for alkaline phosphatase (ALP), osteocalcin (OC), and 
bone morphogenetic-2 (BMP-2) mRNA with 18s ribosomal RNA served as an 
endogenous control in all samples, which were assayed in triplicate.  The negative 
control at day 1 was used as a calibrator for each set of gene expression data, 
containing all groups at all time points. All primer and probe sequences were 
designed for rat species; the 18S sequences were designed for eukaryotic cells.  
Primer and probe sequences for OC and BMP-2 were designed as follows: 
GGCTTCCAGGACGCCTACA (OC forward primer), 
GGGCAACACATGCCCTAAAC (OC reverse primer), CGCATCTATGGCACCAC 
(OC probe), TGCCCCCTAGTGCTTCTTAGAC (BMP-2 forward primer), 
CCCGGCCACCATGGT (BMP-2 reverse primer), ACTGCGGTCTCCTAAA (BMP-
2 probe).  The primers and probes used for ALP and 18s were obtained from Applied 




Chondrocytes were analyzed for transglutaminase 2 (TGM2), transforming 
growth factor-β2 (TGF-β2), and matrix metalloproteinase 13 (MMP13) with GAPDH 
as an endogenous control in all samples, which were assayed in triplicate.  The 
negative control at day 1 acted as the calibrator for each set of gene expression data.  
All primer and probe sequences were designed for bovine species.  Primer and probe 
sequences were designed as follows: CGAGAAACCCCTGTCCTAACC (TGM2 
forward primer), CAGCATAGGCAACTAAGGCTATTG (TGM2 reverse primer), 
CAGTGCCTAGACGTC (TGM2 probe), TCTCCAACCCAGCGCTACA (TGF-β2 
forward primer), TTCACCCTCTGCTCTGGTTTTC (TGF-β2 reverse primer), 
TGACAGCAAAGTCG (TGF-β2 probe), CCCTTGATGCCATAACCAGTCT 
(MMP13 forward primer), GCCGCCAGAAGAATCTGTCT (MMP13 reverse 
primer), CGCGGAGAAACACT (MMP13 probe). 
 
5.2.7 Calcium Deposition Assay  
 The deposition of calcium by BMSCs was assayed following the method 
described by Gregory et al.[192]  Cells were washed with phosphate buffered saline 
and fixed in 10% (wt/v) formaldehyde for 15 minutes at room temperature.  
Following a wash with excess water, 1 mL of 40 mM alizarin red S (ARS) (pH 4.1) 
was added to each well and cells incubated at room temperature, while shaking, for 
20 minutes.  A series of washes with excess water then removed unincorporated dye.  
Next, 800 µL of 10% (v/v) acetic acid was added to each well, and plates were 
allowed to incubate at room temperature for 30 minutes while shaking.  Cells were 




microcentrifuge tubes, vortexed thoroughly, wrapped in parafilm and heated to 85°C 
for ten minutes, then transferred to ice for 5 minutes.  After centrifugation at 20,000g 
for 15 minutes, 500 µL of supernatant was removed from each tube and combined 
with 200 µL of 10% (v/v) ammonium hydroxide.  Finally, 150 µL of this solution 
was then read (in triplicate) on the M5 SpectraMax plate reader at 405 nm.  A 
standard curve was created to determine ARS concentration.  Previous work has 
demonstrated that ARS binds approximately 2 mol Ca2+ per mol ARS in 
solution[193,194]. 
 
5.2.8 Statistical Analysis 
 Data from all studies was analyzed using ANOVA single factor analysis and 
Tukey’s multiple comparison test (p ≤ 0.05).  All results are reported as mean ± 
standard deviation.  Please note that only pertinent statistical relationships are noted 
in the figures. 
 
5.3 Results  
 Bovine derived chondrocytes were utilized in this study to induce the 
osteogenic differentiation of rat BMSCs.  The interspecies nature of this coculture did 
not appear to significantly affect the response of rat BMSCs to the osteoinductive 
influence of bovine chondrocytes.  Previous work has demonstrated that bovine BMP 




addition, rat osteoblasts and bovine chondrocytes have been shown to have reciprocal 
signaling effects in coculture.[191]  
 Qualitative micrographs were taken throughout the study to asses the cell 
populations.  Images of the chondrocytes in the beads indicate morphological changes 
by the end of the coculture (Figure 4).  In addition, the BMSCs were assessed to 
monitor morphological changes during the early stages of differentiation (Figure 5).   
 
Figure 4:  Phase contrast microscopy shows the chondrocytes culturing in alginate at (A) 
day 3, and (B) at day 19.  The morphology of the chondrocytes can be seen to have 





















Figure 5:  Phase contrast microscopy demonstrates the morphology of BMSCs at day 3 
cultured in (a) control conditions, (b) continuous coculture with chondrocytes, (c) 
osteogenic conditions and at day 7 in (d) control conditions, (e) continuous coculture, and 
(f) osteogenic culture conditions.  At day 3 the control condition morphology appears to 
be spindle-shaped, while the coculture and osteogenic conditions represent a more 
cuboidal population.  Day 7 again shows the maintained spindle morphology of the 
control condition.  The coculture and osteogenic conditions are more confluent, however 
it appears the populations demonstrate a cuboidal morphology.  Scale bars denote 250 
µm 
 
At day 3 the control condition morphology appears to be spindle-shaped, while the 
coculture and osteogenic groups represent a more cuboidal population.  Day 7 again 
shows the maintained spindle morphology of the control condition.  The coculture 
and osteogenic populations are more confluent; however, it appears that they both 
demonstrate a cuboidal morphology.  DNA quantification indicated that the 
populations were proliferating throughout the duration of the study.  However, trends 
between examined groups were not observed.  Specifically, at day 1 the 21-day 
coculture group and the osteogenic control were quantified to be 1.15 ± 0.01 and 1.35 
± 0.01 µg DNA/well, respectively.  At day 21 the 21-day coculture group and the 





 In order to quantify the changes in expression by the BMSCs, quantitative rt-
PCR was performed.  By isolating mRNA from the BMSCs, and using primers and 
probes designed for rat mRNA, only fold-changes that developed in the BMSC 
population were measured.  Many in vitro studies utilize protein assays; however, 
protein levels in the cocultures described in this study may be confounded with both 
chondrocyte protein expression and exogenous FBS proteins.  Therefore, the 
expression of osteoblastic markers was only studied through quantitative rt-PCR 
analysis and detection of mineralization. 
The expression of alkaline phosphatase mRNA was quantified at each time point 
as a marker for early stages of osteogenic differentiation.  Expression was 
upregulated most immediately in cells cultured in osteogenic medium, showing a 
significant increase over the other conditions at days 1, 8, and 14 (Figure 6).  All 
three of the coculture conditions demonstrated a statistically significant increase in 
expression over the negative control at day 8 and at day 14.  Similar levels of 
expression were exhibited by all three coculture conditions at both the onset of 
upregulation at day 8, as well as the peak expressions at day 14.  However, while 
cells cultured in the osteogenic medium demonstrated continued upregulated ALP 
expression at day 21, BMSCs in the coculture conditions demonstrated a marked 
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Figure 6:  Alkaline phosphatase expression levels of BMSCs as determined by 
quantitative rt-PCR analysis at days 1, 8, 14, and 21.  At days 8 and 14, the three 
coculture conditions have induced a significantly higher level of expression than the 
negative control, but a similar level of expression is observed in all three experimental 
conditions.  (*, #) indicate statistical difference from all other groups within timepoints.  
(Values reported as mean ± standard deviation, n = 3) 
 
 Similar trends were observed with BMP-2 expression as those seen with ALP.  
However, the upregulation of this marker in the osteogenic control condition was not 
as immediate; at day 1 all five conditions were at similar levels of expression.  
Nevertheless, the osteogenic control again demonstrated the quickest response, 
showing a significantly greater increase in expression over all other groups by day 8 
(Figure 7).  The three different coculture conditions also exhibited significantly 
increased expression over the negative control at day 8, but by day 14 all conditions 
had peaked at similar levels of expression.  Once again, the osteogenic control 
maintained nearly the same expression at day 21 as at day 14, whereas the 
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Figure 7:  Bone morphogenetic protein-2 expression levels of BMSCs as determined by 
rt-PCR analysis at days 1, 8, 14, and 21.  The experimental conditions induced higher 
levels of expression at days 8 and 14 compared to the negative control, but similar to that 
of one another.  (*, #) indicate statistical difference from all other groups within 
timepoints.  (Values reported as mean ± standard deviation, n = 3) 
 
Osteocalcin mRNA was quantified at all time points in order to assess the 
progression of BMSCs through later stages of osteogenic differentiation.  At days 1 
and 8, the expression of OC transcripts fluctuated variably at low levels, but by day 
14 significant upregulation was observed (Figure 8).  Again, the osteogenic control 
group elicited the strongest response, showing a significant increase over all other 
groups at both days 14 and 21.  However, for this marker, variable responses were 
observed within the three experimental groups.  At day 14, the 10-day and 21-day 
coculture conditions had induced significantly greater levels of OC expression 
compared with the 1-day coculture and the negative control.  At day 21, the 21-day 
coculture maintained a significantly increased level of OC expression, while the 
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Figure 8:  Osteocalcin expression levels of BMSCs as determined by rt-PCR analysis at 
days 1, 8, 14, and 21.  By day 14, all experimental conditions had induced a higher level 
of expression than the negative control, but the two extended coculture conditions had 
also induced a significantly higher level of expression than the single-day coculture.  
Additionally, at day 21, the 21-Day coculture condition maintained an upregulated 
expression, while the 1-Day and 10-Day conditions had dropped to baseline levels.  (*, ◊, 
#) indicate statistical difference from all other groups within timepoints.  (Values 
reported as mean ± standard deviation, n = 3) 
 
 Calcium deposition was measured throughout the study as a means to 
ascertain the density of mature osteoblasts.  After 8 days, a significant increase was 
observed in the 10-day and 21-day cocultures (Figure 9).  By day 14, the 21-day 
coculture condition and the osteogenic control had shown a much higher level of 
calcium deposition compared with the negative control and the 1 and 10-day 
coculture groups.  This difference expanded by day 21, with the osteogenic control 
and the 21-day coculture condition having accumulated significantly more calcium 
than the other three groups.  Micrographs were taken of the wells before quantitative 
measurement to qualitatively assess the calcium deposition (Figure 10).  The images 
demonstrate minimal staining in all groups at day 1.  Day 8 shows an increase in 







































and osteogenic groups.  Day 21 exhibits even staining for both groups, however it 










Figure 9:  Calcium deposition by BMSCs after days 1, 8, 14, and 21, normalized to DNA 
at each time point.  At day 8, calcium levels were significantly higher in the extended 
coculture conditions than in both controls and the 1-Day coculture.  By days 14 and 21, 
the 21-Day coculture condition had accrued more calcium than the 10-Day coculture, and 
the osteogenic control increased to levels of deposition greater than the 10-Day coculture 
and near those of the 21-Day coculture.  (‡) indicates no statistical difference between 

























Figure 10:  Phase contrast microscopy qualitatively demonstrates calcium deposition by 
BMSCs at day 1 (a) control, (b) continuous coculture, (c) osteogenic control, day 8 (d) 
control, (e) continuous coculture, (f) osteogenic control, and day 21 (g) control, (h) 
continuous coculture, (i) osteogenic control.  Day 1 depicts minimal levels in all groups.  
Day 8 demonstrates an increase in intensity from day 1, and also significantly more 
staining for the continuous coculture and osteogenic groups.  Day 21 shows even staining 
for both groups, however it appears that the coculture and the osteogenic groups have 
stained more intensely.  Scale bars denote 500 µm 
 
 A culture was also conducted in order to analyze the expression of 
transforming growth factor-β2, matrix metalloproteinase 13, and transglutaminase 2 
in chondrocytes cocultured with BMSCs (Figure 11).  TGF-β2 demonstrated an 
increase in mRNA expression at day 8 which then decreased to initial levels at day 14 
(Figure 11a).  MMP-13 showed steady levels at days 1 and 8 and a large increase at 
day 14 (Figure 11b).  TGM-2 displayed decreasing levels throughout the study with 







































































































































Figure 11:    (a) transforming growth factor-β2, (b) matrix metalloproteinase 13, and (c) 
transglutaminase-2 in chondrocytes cocultured with BMSCs.  TGF-β2 demonstrated an 
increase in mRNA expression at day 8 which then decreased to initial levels at day 14.  
MMP-13 showed steady expression levels at days 1 and 8 and a large increase at day 14.  




 Previous coculture investigations in this field demonstrate the ability of 
chondrocytes to induce the osteogenic differentiation of mesenchymal stem cells 
through continuous coculture[176,177].  This work further investigates the relationship 
between chondrocytes and the differentiation of BMSCs by varying the length of 
coculture time of chondrocytes with BMSCs.  Furthermore, this work cultures the 
chondrocytes in a three-dimensional environment to maintain phenotypic function 
and slow dedifferentiation of the cells which can occur in monolayer.  Specifically, 
the objectives of this of work were to demonstrate the potency of encapsulated 
articular chondrocytes in promoting the osteogenic differentiation of BMSCs, to 




the medium supplements Na-β–glycerolphosphate and dexamethasone, and to 
determine the dependency of this induction on the duration of coculture. 
 The osteoinductive capability of chondrocyte signaling was apparent 
throughout this study.  Qualitatively the micrographs depicting BMSC morphology 
transition from spindle to cuboidal was on the time scale presented in the 
literature.[196]  Previous reports had shown morphological changes by day 4, and this 
study demonstrated initial transitions by day 3 and a more complete cuboidal 
population by day 7.  Further quantitative data from differentiation markers assayed 
in this study supported the effects of chondrocytes on BMSCs.  The early markers 
ALP and BMP-2 were upregulated faster and peaked higher in the coculture 
conditions as compared with the negative control, and the later markers of OC 
expression and calcium deposition also showed increased differentiation in coculture 
conditions over the negative control.  Quantitative rt-PCR results indicate that the 
level of osteogenic differentiation seen in BMSCs cocultured with chondrocytes was 
not as great as that seen in BMSCs cultured in osteogenic control media.  Two 
alternatives may account for these results.  On the one hand, while encapsulating the 
chondrocytes in a three-dimensional hydrogel preserved the native morphology of 
these cells, the system of coculture executed in this study remains a simplified 
recreation of the naturally occurring process of bone formation.  For example, the 
forces acting upon a population of MSCs within developing or repairing bone are 
likely mediated not just by chondrocytes, but also by the mineralizing matrix 
surrounding these cells, blood vessels that begin to arborize as hypertrophic 




such as osteoclasts and haematopoetic stem cells.[179]  On the other hand, 
osteoinduction by Na-β-glycerolphosphate and dexamethasone may induce an 
artificially high response, and the coculture response described here might better 
reflect in vivo conditions.  Further studies are required to confirm one of the two 
alternatives.  Nevertheless, the results presented here do demonstrate the 
osteoinductive effects of hydrogel embedded chondrocytes. 
 The next objective of this experiment was to compare the two mechanisms of 
osteogenic induction examined in this study.  The glucocorticoid dexamethasone and 
Na-β–glycerolphosphate are widely used in cell culture experimentation as medium 
supplements intended to induce the osteogenic differentiation of BMSCs.  In this 
study, the similarities between chondrocyte-induced differentiation and supplement-
induced differentiation were readily apparent.  The onset of upregulation and the peak 
expression of various markers assayed were similar in the extended coculture 
condition and the osteogenic media condition, but an interesting difference appeared 
in the final stages of expression.  In cells cocultured with chondrocytes, the presence 
of transcripts for the early markers ALP and BMP-2 dropped off significantly, while 
cells cultured in osteogenic media decreased minimally.  Previous work has 
demonstrated that early markers for differentiation, such as ALP, peak between days 
8 and 12.[196,197]  Our study corresponds with a later peak expression for ALP and 
BMP-2; however due to experimental design the peak expression may have occurred 
between the measured timepoints at 8 and 14 days.    The variation between the 
coculture groups and the osteogenic control indicates a possible flaw of the 




BMSCs by the supplemented media is constant over the course of the experiment.  As 
media is replenished throughout the study, cells are subject to the same exact set of 
external stimuli from day 1 of the culture through day 21, resulting in continuous 
increased expression of factors that might only peak briefly during natural 
differentiation.  By comparison, the influence exerted on BMSCs by chondrocytes 
may be dynamic, where the chondrocytes act in a coordinated manner with the 
BMSCs to induce the expression of varying genes at different times.  Furthermore, as 
endochondral ossification involves several cell types in addition to MSCs and 
chondrocytes, the milieu of a differentiating MSC during in vivo osteogenesis can 
only be more complex by comparison.  For this reason alone, an awareness of the 
limitations of dexamethasone and Na-β–glycerolphosphate induced osteogenic 
differentiation should be maintained. 
In order to investigate the temporal nature of the chondrocyte signaling that 
induces osteogenic differentiation of BMSCs, cocultures were carried out for three 
different lengths of time.  Results showed that early stages of differentiation would 
progress regardless of the length of coculture; a single day of chondrocyte signaling 
was sufficient to induce upregulated expression of ALP and BMP-2 through day 14 
of the study (Figures 6, 7).  One possible implication of this data is that signals 
produced by the chondrocytes within the first 24 hours of coculture initiate the 
process of differentiation in BMSCs that continues via autocrine and/or paracrine 
signaling among the BMSCs themselves.  As such, ALP and BMP-2 expression 
remain increased in the 1-Day coculture condition even after culturing from day 1 




of BMSCs through later stages of osteogenic differentiation was dependent upon 
extended periods of coculture with chondrocytes.  Specifically, the only coculture 
condition that maintained an increased OC expression at day 21 was the 21-Day 
coculture condition (Figure 8).  Osteocalcin, a protein produced by mature osteoblasts 
during mineralization, is thought to signal bone turnover.[198] Therefore, the failure of 
the 1-Day and 10-Day conditions to maintain osteocalcin expression through day 21 
indicates that continuous exposure to morphogenetic signals from chondrocytes is 
necessary for BMSCs to continue expression of mature bone phenotype and 
indicators of late stage osteogenic differentiation.  This is supported by the fact that 
mineralization observed in 21-day coculture was significantly higher than that of the 
abbreviated coculture conditions at day 21 (Figure 9). 
 The dependency of BMSC osteogenic differentiation on extended chondrocyte 
coculture can be interpreted in several ways.  One possible explanation is that 
articular chondrocytes constitutively express the factors responsible for inducing the 
later stages of osteogenic differentiation, but differentiating BMSCs require 
prolonged exposure to these factors in order to benefit from their effects.  There may 
also be an issue of competence, such that BMSCs exposed to these factors during the 
early stages of differentiation may not be capable of responding to them.  However, 
the possibility also exists that the signaling factors in question are not expressed 
constitutively.  Their production may in fact be a result of interaction with the 
BMSCs.  If this were the case, the BMSCs in the 1-Day coculture condition may not 
have been exposed to these signals, and the cells in the 10-Day coculture condition 




known to progress through a series of phases during endochondral ossification.  
Indeed, the morphological appearance of the chondrocytes in this study changed 
drastically over the course of the 21-day coculture (Figure 4).  As chondrocyte 
morphology has been shown to be intimately linked to gene expression[188], then the 
inductive effects exerted by the chondrocytes may be changing throughout the 
coculture.  Comparing the osteogenic differentiation of BMSCs cocultured with 
articular chondrocytes and BMSCs cultured in chondrocyte-conditioned media might 
clarify this ambiguity. 
 As signaling is an aspect of this study, chondrocytes exposed to BMSCs were 
analyzed for signaling and hypertrophic factors.  TGF-β2 is secreted by chondrocytes 
and known to be involved in mesenchymal stem cell and chondrocyte proliferation as 
well as stimulate bone healing in fracture repair.[199]  In this study the chondrocytes 
demonstrated a 5-fold increase from day 1 to day 8 in TGF-β2 mRNA expression 
(Figure 11a) which may have caused increased proliferation in the cell populations.  
MMP-13 is expressed by chondrocytes and is known to be present during 
endochondral ossification[200] and also to be a hypertrophy-associated marker as it 
promotes the resorption of hypertrophic cartilage.[201,202]  In this study, MMP-13 
showed steady levels at the initial timepoints, with a significant increase at day 14 
(Figure 11b) which may be caused by a need to resorb surrounding collagen.  Lastly, 
TGM-2 was analyzed which is a marker of hypertrophic chondrocytes via the MAPK 
pathway and is involved in matrix calcification.[203]  The data demonstrates a decrease 
of TGM-2 expression over time (Figure 11c) suggesting the chondrocytes may not be 




5.5 Conclusions  
 Regenerative techniques aimed at repairing bone defects rely heavily on the 
ability to induce a population of progenitor cells to differentiate toward osteogenic 
lineages.  Ideally, the method employed to induce this differentiation would be 
identical to that which occurs in vivo, a mechanism inextricably tied to chondrocyte 
signaling.  In the study presented here, we demonstrate that coculturing chondrocytes 
encapsulated in alginate hydrogels with BMSCs can effectively induce differentiation 
in these osteoprogenitor cells, in a mechanism distinct from that of the media 
supplements dexamethasone and the Na-β–glycerolphosphate.  Furthermore, we 
characterized this interaction as having separate temporal components, with brief 
exposure proving sufficient to induce early stages of differentiation, but extended 



















Chapter 6: Cyclic Acetal Hydrogel System for Cell 
Encapsulation3 
6.1 Introduction 
 Many biomaterials, both natural and synthetic, have been developed for use in 
tissue engineering applications.  A number of laboratories have developed strategies 
utilizing natural polymers such as agarose[204,205], alginate[206,207], chitosan[208-210], 
collagen[211,212], hyaluronic acid[213,214], and silk[215,216].  However, natural polymers 
have a variable molecular structure and often do not possess sufficient mechanical 
rigidity, especially when exposed to significant compressive force.  Synthetic 
biomaterials have been investigated due to their reproducibility and modification 
capability.  These biomaterials can often be engineered to have desired properties, 
including mechanical stiffness and biodegradability, by tailoring both the component 
monomers and the material fabrication technique.  To this end, a number of synthetic 
polymers have been developed, including poly(D,L-lactic acid-co-glycolic acid)[45,46], 
poly(ε-caprolactone)[51], poly(propylene fumarate)[42,54], and poly(vinyl alcohol)[217].  
While a number of polymers are currently under investigation for biomedical 
applications, an ideal biomaterial has not been developed. 
 Our laboratory has recently developed a novel class of biomaterials based 
upon a cyclic acetal unit.  These materials may be advantageous since the cyclic 
acetal unit degrades by hydrolysis into primary degradation products of diols and 
carbonyls, and thus may not experience a change in local acidity associated with 
                                                 
3 As published in MW Betz, PC Modi, JF Caccamese, DP Coletti, JJ Sauk, and JP Fisher. Cyclic 
Acetal Hydrogel System for Bone Marrow Stromal Cell Encapsulation and Osteodifferentiation. 




many synthetic biomaterials.  The acidity of hydrogel degradation products may be a 
concern, for example, for the stable phenotypic function of encapsulated cell 
populations.  A cyclic acetal biomaterial in the form of a rigid plastic may be 
fabricated from the radical polymerization of the monomer 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD).[218]  This 
biomaterial has been shown to have controllable physical properties and can support 
the surface adhesion of bone marrow stromal cells (BMSCs).  However, many 
applications of biomaterials, including tissue engineering and cell-based sensors, may 
prefer the encapsulation of the cell population within the matrix of the material in 
order to deliver and/or maintain the population to a specific site based upon the 
degradation characteristics of the material.  As has been repeatedly demonstrated, cell 
encapsulation within biomaterials, especially biomaterials based upon synthetic 
polymers, poses a significant challenge. 
 In order to create a cyclic acetal based hydrogel for cell encapsulation, we 
followed the well described route of incorporating the hydrophilic polymer 
poly(ethylene glycol) (PEG).  Specifically, by including poly(ethylene glycol) 
diacrylate (PEGDA) within the radical polymerization of the EHD monomer, a water 
swellable EH-PEG hydrogel has been produced.[219]  However, further studies are 
required to extend this material for cell encapsulation applications. 
 To this end, a water soluble radical initiation system based on ammonium 
persulfate (APS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) was chosen 
for the fabrication of EH-PEG hydrogels for bone marrow stromal cell encapsulation.  




low equimolar concentrations the pH remains within a reasonable range for cell 
encapsulation.[220]  Specifically, TEMED is known to accelerate the homolytic 
scission of APS yielding sulfate (SO4
.-), hemiTEMED ((CH3)2NCH2CH2(CH3)-
NCH2
.), and hydroxyl (.OH) radical species which initiate crosslinking.[221-223]  In 
addition, the APS-TEMED system has also been used in hydrogel systems as a 
thermal initiator with high molecular weight polymers for osteogenic 
applications.[224,225] 
In order to develop the EH-PEG hydrogel for cell encapsulation, this paper 
examines the APS-TEMED initiation system and its effect on bone marrow stromal 
cells in order to optimize the concentration to be used to initiate crosslinking of EH-
PEG hydrogels.  Bone marrow stromal cells have the ability to replicate as 
undifferentiated cells and also the potential to differentiate into a number of lineages 
such as bone, cartilage, adipose, tendon, ligament, and marrow stroma.[127,128]  Due to 
this property, BMSCs have application in the field of bone tissue engineering which 
is of interest to our laboratory.  Specific objectives of this work were to determine (1) 
the effect of continuous exposure of the initiator system on the metabolic activity and 
viability of bone marrow stromal cells, and (2) the effect of short term exposure on 
expression of osteogenic differentiation markers, and (3) encapsulation potential of 







α-minimal essential medium, fetal bovine serum (FBS) penicillin-
streptomycin antibiotics, Trypsin/EDTA were obtained from Gibco (Carlsbad, CA).  
Collagenase P was purchased from Roche (Indianapolis, IN).  Wistar Hannover rats 
were purchased from Taconic (Hudson, NY). Ascorbic acid  Na-β-glyerophosphate, 
dexamethasone, ammonium persulfate (APS), N,N,N’,N’-tetramethylethylenediamine 
(TEMED), MTT kit, p-nitrophenyl phosphate liquid substrate system, PEGDA Mn~ 
700, 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate 
(EHD) were purchased from Sigma (St. Louis, MO).  The Live/Dead assay and 
Quant-iT PicoGreen Kit were ordered from Molecular Probes (Carlsbad, CA).  The 
DNeasy Tissue kit and RNeasy Mini Plus Kit were purchased from Qiagen (Valencia, 
CA).  The M-per Mammalian Protein Extraction Reagent was ordered from Pierce 
(Rockford, IL).  The High Capacity cDNA Archive Kit and TaqMan Gene Expression 
assays were purchased from Applied Biosystems (Foster City, CA). 
 
6.2.2 Bone Marrow Stromal Cell Isolation and Culture 
Bone marrow stromal cells were isolated from young Wistar Hannover GALAS 
male rats weighing 101-125g following NIH guidelines for the care and use of 
laboratory animals and under a University of Maryland approved IACUC animal 
protocol (R-04-61).  Rats were euthanized with CO2 and the femurs as well as tibias 




three times in 10mL of control media (without FBS) with 10% 
penicillin/streptomycin (v/v) under sterile conditions.  The epiphyseal plates were 
clipped and the bone marrow was flushed from the bone using 10 mL of control 
medium (without FBS) and filtered from a syringe, homogenized by mixing with the 
syringe, and passed through a 70 µm cell strainer.  After centrifugation at 300g for 8 
minutes, the pellet was resuspended in 10 mL of control media and plated in a T-75 
flask, with each flask containing BMSCs from only one subject.  The media was 
changed every 2 days and non-adherent cells were washed away after two media 
changes. 
 Cell culture control media consisted of α-minimal essential medium 
supplemented with 10 % (v/v) FBS, 0.2 mM ascorbic acid, and 1% (v/v) penicillin-
streptomycin antibiotics.  Osteogenic media was control media further supplemented 
with 10 mM Na-β-glyerophosphate and 10-8 M dexamethasone.  Cell cultures were 
maintained in an incubator at 37oC with 5% CO2 and passaged every 5-7 days using 
Trypsin/EDTA and 2.0% w/v Collagenase P. 
 
6.2.3 Metabolic Activity 
 Bone marrow stromal cells were harvested and cultured as described above.  
Cells were lifted, pooled, and plated at 1 x 105 cells/well in a 24-well plate and 
allowed to attach for 24 hours.  At this time, the media was removed and cells were 
then exposed to the initiator system consisting of APS and TEMED at 10 mM, 15 
mM, and 20 mM (final concentration of each initiator in control media) for 30 min, 1 




media and 0 mM initiators.  Metabolic activity was then assessed using a 
dimethylthiazolyldiphenyltetrazolium bromide (MTT) based in vitro toxicology kit 
following standard protocols.  Briefly, 100 µL of MTT reconstituted in control media 
(without FBS) was added to the cultures and returned to the incubator.  After 2.5 hr, 
the formazan crystals were solubilized and read at 570 nm using a GENESYS10 
spectrophotometer (Thermo Electron).  The study was completed with four replicates 
(n = 4). 
 
6.2.4 Viability 
 Bone marrow stromal cells were harvested and cultured as described above.  
Cells were lifted and plated in 96-well plates at 4 x 104 cells/cm2 and allowed to 
attach for 24 hours.  The media was then removed and cells were then exposed to 
APS and TEMED at 10 mM, 15 mM, and 20 mM (final concentration of each 
initiator in control media) for 30 min, 1 hr, and 3 hr in the incubator with a control at 
each timepoint consisting of control media and 0 mM initiators.  Viability was 
assessed using the Live/Dead assay according to standard protocols.  The media was 
removed, the Live/Dead reagents were added (4µm ethidium homodimer-1 and 2 µm 
calcein AM) and incubated at room temperature for 30 min.  Micrographs were then 
taken using a fluorescent microscope (Axiovert 40 CFL with filter set 23, Zeiss, 
Thornwood, NY) equipped with a digital camera (Diagnostic Instruments 11.2 Color 







 In order to simulate the initiator exposure the cells would experience during 
the encapsulation process, bone marrow stromal cells were exposed in monolayer to 
increasing concentrations of the initiator system for the approximate time it takes the 
gels to form.  However, it is important to note that during encapsulation the cell 
population may be exposed to an initiator concentration less than the initial 
concentration, due to the fact that the initiator is being used in the crosslinking 
reaction.  After exposure, the flasks were then washed with PBS to remove any 
residual initiator, similar to the procedure utilized after a gel is formed and before it is 
cultured. 
Bone marrow stromal cells were then harvested and cultured as describe above, 
and passaged once.  Cells were exposed to APS and TEMED at 10, 15, and 20 mM, 
final concentration of each initiator in control media, in T-75 flasks for 1 min.  (The 1 
min exposure time was based upon the approximate gelation time of the EH-PEG 
hydrogel using the APS/TEMED system.  Gelation time was characterized by 
creating a 1 mL gel in a 15 mL Falcon tube using a 1:50 molar EHD:PEGDA with an 
initiator concentration of 15 mM.  Gelation was then determined to be complete when 
the Falcon tube could be inverted and the gel components remained at the tip of the 
tube.)  After exposure, the cells were washed three times with 10 mL of PBS.  All 
flasks were then returned to the incubator with control media for 2 d.  At this time, 
the cells were lifted, and plated in 6-well plates at 1.5 x 105 cells/well.  All 
experimental groups and a positive control, which did not contain any initiator 




control consisted of control cell culture media and no initiator chemicals.  At 1, 4, and 
8 d BMSCs were lifted and analyzed using the assays described below. 
 
6.2.5.1 Deoxyribonucleic Acid Quantification 
 Deoxyribonucleic acid (DNA) was isolated from all samples to normalize the 
alkaline phosphatase assay described below.  Specifically, DNA was isolated using 
the DNeasy Tissue kit following standard protocols into 400 µL of eluate.  DNA was 
then quantified using the Quant-iT PicoGreen Kit following standard protocols for a 
200 µL sample volume.  Samples were incubated at room temperature for 5 minutes 
and read using the M5 SpectraMax plate reader (Molecular Devices, Sunnyvale, CA) 
with excitation/emission of 480/520 nm.  All samples were completed in triplicate (n 
= 3). 
 
6.2.5.2  Alkaline Phosphatase Assay 
 BMSCs were lifted and centrifuged at 2,500g for 10 min to form a pellet.  
Protein was extracted using the M-per Mammalian Protein Extraction Reagent 
following standard protocols.  Briefly, 50 µL of M-per was added to each cell pellet, 
and shaken for 10 min.  Cell debris was removed by centrifugation at 14,000g for 15 
min and the supernatant was used for analysis.  A p-nitrophenyl phosphate liquid 
substrate system (pNPP) was used to analyze intracellular alkaline phosphatase (ALP) 
concentrations from the extracted protein.  Briefly, the extracted protein sample was 
suspended in PBS and added to 100 µL of pNPP and incubated at room temperature 




absorbance was read using a M5 SpectraMax plate reader at 405 nm and normalized 
by the PicoGreen assay.  All samples were completed in triplicate (n = 3). 
 
6.2.5.3 Gene Expression 
 BMSCs were lifted and RNA was isolated using the RNeasy Mini Plus Kit 
following standard protocols.  The isolated total RNA was reverse transcribed using 
High Capacity cDNA Archive Kit.  The expression of 18S, ALP, and osteocalcin was 
then investigated by quantitative real time polymerase chain reaction (qrt-PCR) on an 
ABI Prism 7000 sequence detector (Applied Biosystems).  The primer and probe 
sequences, designed by our laboratory, used for osteocalcin included 
GGCTTCCAGGACGCCTACA (forward primer), GGGCAACACATGCCCTAAAC 
(reverse primer), and CGCATCTATGGCACCAC (probe).  A TaqMan Gene 
Expression assay was used to analyze ALP, while a predeveloped 18s rRNA was used 
as the endogenous control.  The sequences for the 18s and ALP primers and probes 
are proprietary.  All samples were completed in triplicate (n = 3). 
 
6.2.6 EH-PEG Hydrogel Encapsulation 
 To determine the effect of the encapsulation process on the viability of bone 
marrow stromal cells, cells were encapsulated, cultured, and analyzed using the 
LIVE/DEAD assay.  Specifically, the EH-PEG hydrogel constructs were prepared in 
a sterile environment using aseptic technique.  The two components used were EHD 
and PEGDA Mn~ 700 at 1:50 molar EHD to PEGDA.  APS and TEMED solutions 




gels, with a component to solvent ratio of 1:2 (water was used as the solvent).  
BMSCs were suspended in the gel solution at 2 x 106 cells/mL.  All components were 
vortexed together and a 12-well plate was used as a mold to create gels 2 mm thick.  
The crosslinking reaction was complete in approximately 1 min, smaller gel disks 
were punched out with a cork borer to create gels that were 6 mm in diameter.  The 
disks were washed in PBS for 15 minutes.  Gels were cultured in control media and 
analyzed immediately after encapsulation and 7 d post-encapsulation.  On d 7, the 
gels were soaked in PBS for 1 hr to remove FBS from the gel which can interact with 
the Live/Dead reagents.  The gels were incubated with the Live/Dead reagents (2.5 
µm ethidium homodimer-1 and 2.5 µm calcein AM) and incubated at room 
temperature for 30 min.  Micrographs were then taken using a fluorescent microscope 
equipped with a digital camera.  Viability of the gels was then determined using 
ImageJ (v1.37) cell counter plugin available from the National Institutes of Health.  
All samples were completed in triplicate.  (n=3) 
 
6.2.7 Statistical Analysis 
 Data from all studies was analyzed using ANOVA single factor analysis and 
Tukey’s multiple comparison test (p ≤ 0.05).  All results are reported as mean ± 
standard deviation.  In order to confirm the reproducibility of the observed trends, 
two identical and independent studies were performed.  Statistical analysis was 
performed within studies, but not across studies to elucidate trends and differences 




however, data was not pooled as the primary cell populations were used in these 
studies are variable in nature.  Therefore, only data from the second study is reported. 
 
6.3 Results 
6.3.1 Metabolic Activity and Viability  
 Bone marrow stromal cells were exposed continuously to the initiator system 
for 30 min, 1 hr, and 3 hrs to determine whether there was an effect on cell metabolic 
activity (Figure 12).  After 30 min and 1 hr of exposure, the 10 mM and 15 mM 
initiator experimental groups showed a metabolic activity that was not statistically 
different (p<0.05) from the control.  At the longer time point of 3 hr, the 10 mM and 
15 mM groups were still not statistically different (p<0.05), however they were 
significantly less than the control.  In all cases the metabolic activity of the 20 mM 
group was significantly less than the control and the 10 mM and 15 mM initiator 
concentrations.  Across all timepoints, the groups with higher initiators concentrations 




















































Figure 12:  Metabolic activity of BMSCs assessed after 30 min, 1 hr, and 3 hr with 
initiator system concentrations of 10 mM, 15 mM, and 20 mM.  Results indicate that over 
the shorter time points the metabolic activity of BMSCs exposed to initiator 
concentrations of 10 mM and 15 mM did not differ from the control group.  * indicates 
statistical difference, ‡ indicates no statistical difference.   (Values reported as mean ± 
standard deviation, n = 4.) 
 
 Similarly, the viability of bone marrow stromal cells was also assessed in 
monolayer after exposure to the initiator system.  Results qualitatively showed that 
after 30 min and 1 hr of initiator system exposure, BMSCs viability appeared similar 
across all initiator concentrations (See Figures 13 and 14; note that 1 hr images are 
not presented for brevity).  For all time points, some non-viable cells are apparent in 
the experimental groups, with higher numbers apparent in the higher concentrations, 
and there are morphological changes in the exposed cells.  However, in all groups, the 
majority of the cells are still viable.  At the later time point (3 hr), the LIVE dye, 


















Figure 13:  Viability of bone marrow stromal cells assessed after 30 min exposure to 
initiator system concentrations of (a) 0 mM, (b) 10 mM, (c) 15 mM, and (d) 20 mM by 
LIVE/DEAD assay.  The microscope images qualitatively demonstrate that a 30 min 
continuous exposure to the initiator system appears to have little effect on the bone 













Figure 14:  Viability of bone marrow stromal cells assessed after 3 hr with initiator 
system concentrations of (a) 0 mM, (b) 10 mM, (c) 15 mM, and (d) 20 mM by 
LIVE/DEAD assay.  The microscope images qualitatively demonstrate that continuous 
exposure to the initiator system for 3 hr appears to have a minimal effect on the bone 
marrow stromal cell viability.  (n = 3) 
 
6.3.2 Osteodifferentiation 
 Bone marrow stromal cells were exposed to the initiator system for 1 min to 
simulate the encapsulation process.  Differentiation was initiated and the early 
osteogenic marker alkaline phosphatase was measured to determine if the 
encapsulation process had an effect on osteodifferentiation (Figure 15).  Results 
showed that after 1 d, the ALP expression of the osteogenic control was not 
statistically different (p<0.05) from the 10 mM experimental group.  However, the 
ALP expression of the 15 mM and 20 mM groups were significantly less than that of 











































had lower expressions of ALP when compared to experimental groups with lower 
initiator concentrations.  After 4 and 8 d, the ALP expression of the osteogenic 










Figure 15:  Alkaline phosphatase expression of cells after 1 d, 4 d, and 8 d, normalized 
by DNA.  After 1 d, there was an early effect from the initiator system at higher 
concentrations on differentiation.  However, after 4 d and 8 d all experimental groups are 
similar to the osteogenic groups indicating that there are no long term effects for alkaline 
phosphatase activity on this time scale.  * indicates statistical difference, ‡, # indicate no 
statistical difference.  (Values reported as mean ± standard deviation n = 3) 
 
 To further asses the effect of the encapsulation process on differentiation, 
osteogenic markers alkaline phosphatase and osteocalcin were also measured at the 
mRNA level after exposure to the initiator system.  Results demonstrated that after 1 
d, all the experimental groups had an ALP expression that was not statistically 
different (p<0.05) from the osteogenic control (Figure 16).  After 4 d, the ALP 
expression of the osteogenic control is not statistically different (p<0.05) from the 10 
mM and 15 mM groups, while the ALP expression of the 20 mM experimental group 
is statistically higher than the osteogenic control.  After 8 d, the ALP expression of 




while the 10 and 15 mM groups had significantly higher expression than the 
osteogenic control.  In regards to the osteocalcin marker (Figure 17), after 1 d the 
osteogenic control was not statistically different (p<0.05) from the osteocalcin mRNA 
expression as the 15 mM group.  However, the 10 mM and 20 mM group’s 
osteocalcin expression was significantly higher than the osteogenic control at this 
timepoint.  After 4 d, all experimental groups had significantly higher osteocalcin 
expression than the osteogenic control.  Finally after 8 d, osteocalcin expression was 



































Figure 16:  Quantitative rt-PCR analysis of alkaline phosphatase expression after 1 d, 4 
d, and 8 d.  At all concentrations tested the initiator system did not have a negative effect 
on the expression of alkaline phosphatase.  * indicates statistical difference.  (Values 







































Figure 17:  Quantitative rt-PCR analysis of osteocalcin expression after 1 d, 4 d, and 8 d.  
All experimental groups were higher than the negative control, indicating that exposure 
to the initiator system allows osteodifferentiation as demonstrated by osteocalcin levels.  
(Values reported as mean ± standard deviation n = 3) 
 
6.3.3 EH-PEG Hydrogel Encapsulation 
 To determine the encapsulation potential of bone marrow stromal cells, cells 
were suspended in sterile liquid gel components and crosslinked using an initiator 
concentration of 15 mM (Figure 18).  Micrographs were quantified and the viability 
of the encapsulated cells immediately after crosslinking was 86.3% ± 2.6 
demonstrating that they are able to withstand the encapsulation process.  After 7 d, 
the viability slightly decreased to 80.2% ± 1.2; however, the majority of the cells 












           (a)                  (b) 
Figure 18:  Viability of EH-PEG hydrogel encapsulated BMSCs immediately after 
encapsulation (a) and after 7 d of culture by LIVE/DEAD assay.  Immediately after 
encapsulation, the image qualitatively shows that the majority of the cells are alive, 
(quantified to be 86.3% ± 2.6) demonstrating that many of the cells can survive the 
encapsulation process.  After 7 d of culture, the images qualitatively demonstrate that the 
majority of the cells are still viable (quantified to be 80.2% ± 1.2) within the EH-PEG 
hydrogels.  (n = 3) 
 
6.4 Discussion 
 The objectives of this work were to determine (1) the effect of continuous 
exposure of the initiator system on the metabolic activity and viability of bone 
marrow stromal cells, and (2) the effect of short term exposure on expression of 
osteogenic differentiation markers.  From these first two objectives, we anticipated 
that the results would indicate an appropriate initiator concentration to encapsulate 
bone marrow stromal cells in our EH-PEG hydrogel system.  Therefore, we finally 
aimed to demonstrate the encapsulation potential of bone marrow stromal cells in EH-
PEG hydrogels. 
 Results indicate that over the shorter time points the metabolic activity of 
bone marrow stromal cells exposed to initiator concentrations of 10 and 15 mM did 




considerably longer than the length of time required to form a hydrogel using this 
initiation system and components (approximately 1 min).  Furthermore, the optimal 
concentration chosen to form the hydrogels (see discussion below) was 15 mM which 
did show significantly different metabolic activity from the control group until 
continuous exposure of 3 hr.  Furthermore, microscope images of the Live/Dead 
assay qualitatively demonstrate that bone marrow stromal cells remain viable after 
continuous exposure to increasing concentrations of the initiator system.  A few non-
viable cells were apparent at all timepoints, although the majority of the cells 
remained viable.  The morphology of the cells did appear to change slightly over the 
longer timepoints indicating the continuous exposure to the initiator system was 
having an effect on the cells.  Specifically, it appears the calcein is being 
compartmentalized within the membrane-enclosed structures of the cells due to an 
increase of the dye within the cell.  This could be an indication of a compromised cell 
membrane allowing more dye into the cells.  Furthermore, the integrity changes of the 
membrane could be responsible for altering cell morphology in cells exposed to the 
initiator system.  However, overall the data indicates that the initiation system at the 
desired concentration does not have a detrimental effect on the metabolic activity or 
viability of the cell population in monolayer. 
 The osteodifferentiation of bone marrow stromal cells in monolayer was then 
assessed after a 1 min exposure to the initiation system, again chosen to simulate the 
length of time it takes for the EH-PEG hydrogels to crosslink using an initiator 
concentration of 15 mM.  Alkaline phosphatase levels were first assayed.  Results 




ALP expression (Figure 15).  However, on d 4 and d 8 all experimental groups are 
similar to the osteogenic groups indicating that these effects may be transitory.  The 
data does not specifically indicate whether this recovery is achieved on an individual 
or population basis.  The micrographs generally indicate a uniform response by the 
cell population, so there is some small evidence that the BMSC population may 
recover without individual cell death on a significant level. 
 Osteodifferentiation was also assayed by alkaline phosphatase mRNA level 
using qrt-PCR.  This data reported that after 1 d, all experimental groups were not 
statistically different (p<0.05) from the osteogenic control (Figure 16), in contrast to 
trends measured at the protein level.  This result implies that while mRNA production 
is minimally affected by the initiator system, downstream protein expression may be 
more sensitive to the initiator system.  As described above, after 4 and 8 d all 
experimental groups were not statistically different (p<0.05) from the osteogenic 
control, suggesting that the recovery described above may be realized in mRNA 
translation or further downstream processing.  Also, there is an apparent trend where 
the experimental groups express ALP at higher levels than the osteogenic control; 
however this difference is significantly less than that compared to the negative 
control.  Finally, osteocalcin results from the later stage of osteodifferentiation largely 
support the trends described by the ALP expression data that exposure to the initiator 
system allows osteodifferentiation as demonstrated by mRNA levels. 
 The objective of the first part of this work was to optimize the concentration 
to crosslink EH-PEG hydrogels.  Continuous exposure of BMSCs to the initiator 




metabolic activity at levels similar to the control group.  In addition, the protein and 
gene expression data collectively shows that BMSC exposure to the initiator system 
at concentrations of 10 mM and 15 mM groups performed similarly to the osteogenic 
control group for all time points and all genes.  From these results, we concluded that 
future studies could be achieved using an initiator system concentration ranging from 
10 mM to 15 mM.  However, as hydrogel gelation time generally decreases with an 
increase in initiator concentration, we chose to proceed using an initiator system with 
a 15 mM concentration. 
 Using this system, the viability of BMSCs was assessed after EH-PEG 
hydrogel encapsulation.  Results indicate that immediately after encapsulation, the 
majority of the cells are viable and therefore a large percentage of the encapsulated 
BMSC population can remain viable after exposure to the radical polymerization of 
the EH-PEG network.  After 7 d, the BMSCs still demonstrate significant cell 
viability within the EH-PEG hydrogel.  Published literature on short-term culture 
studies of adult human mesenchymal stem cells encapsulated within hydrogels 
indicate cells within Collagen-Agarose maintained viability within the range of 75-
90% for 8d[226], and exhibited a viability of approximately 75% after 7d within 
PEGDA with RGD.[227]  Our data from 7d appears to lie within the acceptable range 
of what has been published and what may be expected of a tissue engineered 
construct. 
 Previous work in this field has demonstrated that the APS-TEMED system 
can be used to crosslink hydrogels for bone tissue engineering applications through 




polymer components.[224,225]  However, this work investigates the effect the initiator 
system will have on the encapsulated cell population, and elucidates that the 
downstream ALP protein expression may be more sensitive to the initiator system as 
shown by the difference between the biochemical assay and the qrt-PCR data.  This 
study determined the optimal concentration of the initiator system to use for 
encapsulation to minimize differentiation effects, specifically for use with the EH-
PEG hydrogel developed in our laboratory.  This hydrogel is advantageous over other 
hydrogel systems because it is based upon a cyclic acetal unit which primary 
degradation products should not affect local acidity unlike most synthetic hydrogels. 
 
6.5 Conclusions 
 The objective of this study was to determine whether EH-PEG hydrogels, and 
their fabrication components, permit bone marrow stromal cell viability, metabolic 
activity, and osteodifferentiation.  The results demonstrate that the metabolic activity 
and viability of bone marrow stromal cells in monolayer are minimally affected by 
the APS-TEMED initiator system for extended time periods.  In addition, it shows 
that on the time scale required for encapsulation, the initiator system does not 
significantly affect expression of osteogenic markers, measured both at the mRNA 
and protein level.  From these results, an optimal initiator concentration can be 
chosen to crosslink EH-PEG hydrogels.  Finally, encapsulated bone marrow stromal 
cells were shown to survive in EH-PEG hydrogels crosslinked using the optimal 
APS-TEMED concentration for 7 d.  This demonstrates that EH-PEG hydrogels are a 




Chapter 7: Tissue Response and Orbital Floor Regeneration 
Using Cyclic Acetal Hydrogels4 
7.1 Introduction 
 Orbital floor injuries, most commonly caused by assault and traffic accidents, 
are a devastating form of craniofacial trauma.[110,111]  In addition, they account for 
approximately 60-70% of all orbital fractures.[113,228]  Orbital bone fractures, if left 
untreated, may not heal adequately through standard primary and secondary bone 
healing mechanisms.  In orbital fractures, only small and thin bone fragments might 
be present and there are generally few bony edges to conduct bone formation.  
Instead, a fibrous scar forms, lacking the support, architecture, and load bearing 
properties of bone.  Therefore, the endogenous response to orbital fractures, in 
contrast to many other bone fractures, is not sufficient for proper healing.  
Furthermore, a number of sequelae are associated with orbital floor injuries, the most 
common being unsatisfactory facial aesthetics, enophthalmos (sunken eye), and 
diplopia.[112,124,229] 
 The orbital floor is composed of portions of three bones, the maxilla, 
zygomatic, and palantine[107,108].  The main purpose of the floor is to separate the 
orbital contents from the maxillary sinus and it is therefore very thin, approximately 
0.5 mm[107,230].  The thinness of this structure makes it an excellent model for in vitro 
tissue engineering as experiments are able to be performed without the need for 
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bioreactors and additional attention to diffusion which is necessary in larger tissue 
engineered constructs. 
 Various reconstructive clinical treatments have been employed for orbital 
floor repair including poly (tetrafluoroethylene) (Teflon)[231], poly(ethylene) sheets 
(Medpor)[232-234], titanium mesh[235,236], and bone grafts[118,119,122]; however, these have 
been associated with lifelong risk of infection, loss of function, extrusion, as well as 
poor aesthetics[237].  The ideal implant would be resorbable, encourage bony healing 
of the orbital floor, and not threaten the globe in subsequent orbital trauma.  For this 
reason, and the above mentioned complications with current strategies, tissue 
engineering methods employing polymers may be a promising strategy for the 
treatment of orbital floor defects.  Many tissue engineering strategies utilize natural 
polymers such as agarose[204,205], alginate[206,207], chitosan[149,208,210], collagen[211,212], 
hyaluronic acid[213,214], and silk[215,216].  However, natural polymers tend to have 
variable composition between batches and often do not possess sufficient mechanical 
strength in hard tissue engineering applications.[238]  Synthetic biomaterials have been 
investigated due to their reproducibility and modification capability.  These 
biomaterials can often be engineered to preferred properties, including mechanical 
stiffness and biodegradability.  To this end, synthetic polymers have been developed, 
including poly(D,L-lactic acid-co-glycolic acid)[45,46], poly(ε-caprolactone)[51], 
poly(propylene fumarate)[42,54], and poly(vinyl alcohol).[217]  While a number of 
polymers are currently under investigation for tissue engineering applications, an 
ideal biomaterial with favorable tissue response and cellular interactions, mechanical 




 Our laboratory has developed a class of biomaterials based upon a cyclic 
acetal unit.  These materials may be advantageous since the cyclic acetal unit 
degrades by hydrolysis into primary degradation products of diols and carbonyls, and 
thus may not experience a change in local acidity associated with many degradable 
synthetic biomaterials.  The acidity of hydrogel degradation products may be a 
concern, for the stable phenotypic function of embedded cell populations, or 
surrounding tissue when implanted in vivo.  A cyclic acetal biomaterial in the form of 
a rigid plastic may be fabricated from the radical polymerization of the monomer 5-
ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) 
(Figure 19b).[218]  This biomaterial has been shown to have controllable physical 
properties and can support the surface adhesion of bone marrow stromal cells 
(BMSCs).[218] 
 To create a cyclic acetal based hydrogel that could be used for cell embedding 
and also growth factor delivery, we used the well described route of incorporating the 
hydrophilic polymer poly(ethylene glycol) (PEG).  Specifically, by including 
poly(ethylene glycol) diacrylate (PEGDA) (Figure 19a) within the radical 
polymerization of the EHD monomer, a water swellable EH-PEG hydrogel has been 
produced.[159]  A water soluble radical initiation system based on ammonium 
persulfate (APS) and N,N,N’,N’-tetramethylethylenediamine (TEMED) was chosen 
for the fabrication of EH-PEG hydrogels.  Previous work with this system has 
demonstrated that the metabolic activity, viability, and osteodifferentiation of BMSCs 




maintain viability in EH-PEG hydrogels for 7 d indicating this is a viable bone tissue 
engineering system.[239] 
 The overall objective of this work is to examine the utility of EH-PEG 
hydrogels in orbital bone repair.  To this end, we broadly investigated the tissue 
response to an unmodified EH-PEG hydrogel as well as an EH-PEG hydrogel loaded 
with bone morphogenetic protein-2 (BMP-2).  BMP-2 is well known to facilitate 
formation of bone in vivo[240] , and induces bone regeneration after injury[144] which is 
thought to be due to the fact that BMP-2 can direct the differentiation of 
mesenchymal stem cells into osteoblasts.[241]  However, BMP-2 is known to have a 
limited half-life requiring a carrier or high doses to maintain activity and therapeutic 
levels.[242,243]  Previous work has combined BMP-2 with the glycosaminoglycan 
heparin[244], and dextran-based polysaccharides[243].  Our laboratory will investigate 
BMP-2 adsorption onto EH-PEG hydrogels to prolong activity in an aqueous 
environment.  Therefore, specific objectives of this work were to (1) investigate the 
tissue response surrounding EH-PEG gels in vivo, (2) examine the release of a BMP-2 
from EH-PEG gels, and (3) investigate the ability of EH-PEG hydrogels to deliver 




Ammonium persulfate (APS), N,N,N’,N’-tetramethylethylenediamine 
(TEMED), PEGDA Mn~ 700, 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-




Sigma (St. Louis, MO)  Recombinant human BMP-2 (containing BSA as a carrier), 
and a Quantikine BMP-2 immunoassay ELISA kit were purchased from R&D 
Systems (Minneapolis, MN).  OCT embedding compound and SuperFrost glass slides 
were purchased from Fisher Scientific (Pittsburgh, PA). 
 
7.2.2 Hydrogel Formation 
The EH-PEG hydrogel constructs were prepared in a sterile environment 
using aseptic technique.  The two components used were EHD and PEGDA (Figure 
19) at 1:50 molar EHD to PEGDA with a total 10% w/v in water.  APS and TEMED 
solutions were prepared and sterile filtered, a final concentration of 15 mM was used 
in the gels.  All components were vortexed and a large Petri dish was used as a mold 
to create gels 2 mm thick.  The crosslinking reaction was complete in approximately 
1 min, and PBS was used to wash the surface of the gel.  Smaller gel disks were 
punched out with a sterile cork borer to create gels that were 12 mm in diameter.  The 



















7.2.3 BMP-2 Loading 
The hydrogels were loaded with BMP-2 in a sterile environment 
approximately 12 hours before use.  Specifically, hydrogels were patted dry to 
remove surface PBS.  Next, to load each hydrogel, a concentrated solution containing 
a final concentration of 0, 0.25, or 2.5 µg BMP-2/implant resuspended in 4 mM HCl 
with 0.1% BSA was added to the top of the hydrogel.  Each implant received the 
same amount of suspension solution to minimize effects that may be caused by BSA.  
Gels were then left in the biosafety cabinet for 30 minutes to evaporate the majority 
of the suspension solution.  Gels were then placed in falcon tubes overnight at 4oC. 
 
7.2.4 BMP-2 Release Study 
Hydrogel constructs were created and loaded with BMP-2 as described above.  
The constructs were then placed in 1.5 mL of PBS at 37oC and assayed at 0.25, 0.5, 
0.75, 1, 2, 4, 6, and 12 h for BMP-2 using a quantikine ELISA kit according to the 
manufacturer’s instructions and read using a M5 SpectraMax plate reader (Molecular 
Devices, Sunnyvale, CA).  Percentage of BMP-2 released was calculated as (ng 
BMP-2 released/ng BMP-2 loaded) x 100.  (n=5) 
 
7.2.5 Rabbit Orbital Defect Model 
 All work was performed following animal protocols approved by the University 
of Maryland Medical School IACUC as well as the University of Maryland College 




facilities at the University of Maryland Medical School and under veterinary 
supervision.  Briefly, adult male, New Zealand White rabbits (3.0 – 3.5 kg) were 
anesthetized with intramuscular injection (0.6 ml/kg) of a solution of 91% ketamine 
hydrochloride (100 mg/ml; Ketaset, Aveco Co.) and 9% xylazine (20 mg/ml; 
Rompun, Mobay Corp.).  A 0.1 ml dose of the anesthesia cocktail was injected 
intramuscularly as needed for continued anesthesia.  The animals were placed on their 
side and covered with sterile drapes.  The surgical site was prepped and draped in the 
usual sterile/surgical fashion.  An infraorbital surgical approach was performed to 
access the orbital floor.  Using a rotary instrumentation and round burs, the perimeter 
of the socket floor was cut, thus releasing the socket floor.  An 8 mm defect, 
approximately 50% of the surface area of the socket floor, was then removed (Figure 





Figure 20:  Surgical field (a), intact orbital floor (b), and orbital floor defect (c).  OR: 
orbital rim, OF: orbital floor, OD: orbital defect. 
 
Copious saline irrigation was administered as needed to prevent adjacent tissue 
necrosis.  For the experimental group and the control groups, the defect was closed by 
implanting the hydrogel construct along the orbital floor with the top of the gel facing 
the globe.  Following current clinical procedures with many biomaterial implants, no 
fixation device was utilized to keep the implant in place.  Soft tissue was replaced and 
sutured as necessary.  The total length of the surgery was approximately 10 minutes.  
The animals were allowed to recover on a water heating pad and covered with a 
blanket.  Once ambulatory, the animals were given 0.03 mg/kg of buprenorphine HCl 




The following day during routine follow-up, the animals were given an additional 
0.03 mg/kg of buprenorphine HCl subcutaneously. The rabbits were observed post-
operatively twice daily until the end of the experiment. 
 
7.2.6 Euthanasia and Tissue Harvest 
 The animal subjects were then euthanized to allow for tissue harvest.  Briefly, a 
dose of a ketamine, acepromazine cocktail was first given for deep sedation.  After 
sedation, an intravenous injection of an overdose of a pentobarbital preparation (100 
mg/kg) was given to euthanize the animal.  The sample and surrounding bone tissue 
were then dissected intact using a surgical saw and scalpel. 
 
7.2.7 Tissue Preparation 
 The harvested tissues were immediately placed into 120 ml of freshly prepared 
paraformaldehyde-lysine-phosphate (PLP) fixative solution at a pH of 7.4 for 48 
hours.  Samples were removed from the PLP fixative, and rinsed 5 times in 0.01M 
PBS (pH 7.4).  A 5% (v/v) formic acid solution was used as the decalcifying agent for 
the bone tissue.  Samples were removed from the PBS and placed into the 5% formic 
acid decalcifying solution.  The solution was changed daily until the decalcification 
process was complete (approximately 4 and 6 days).  The end point was reached 
when confirmed by ammonium hydroxide/ ammonium oxalate testing and the 
samples were easily cut with a razor blade.  Samples were then removed from the 5% 




were equilibrated in 30% sucrose in 0.01M PBS at 4oC and then washed for 1-2 hours 
in 1:1 of 30% sucrose in PBS:OCT on a shaker plate at low speed.  Then, the tissue 
samples were placed into plastic molds filled with OCT compound.  The samples 
embedded in OCT were quick frozen with liquid nitrogen and stored at -80oC until 
sectioning.  Frozen sections were cut in the coronal plane on a HM 550 Microm 
cryostat system at 12-16 µm and placed on Superfrost glass microscope slides.  The 
sections were stored at -20oC until staining.  Sections from each sample were stained 
using hematoxylin and eosin. 
 
7.2.8 Semi-Quantitative Histological Scoring 
 After staining, each sample was semi-quantitatively scored[54,245] in a blinded 
study for tissue response, capsule thickness, and bone growth as outlined in Tables 3, 
4, and 5, respectively.  To remove bias, a predetermined scheme was developed to 
determine the location of each scoring region (Figure 21b).  In particular, each sample 
was scored at the interface between the sample and surrounding tissue, with one 
region located at the interface midline and two regions located lateral to both sides of 
the midline.  Furthermore, each sample was scored on the globe side of the implant as 









Cannot be evaluated due to infection or other factors not necessarily 
associated with the implant 
1 
Interface contains inflammatory cells with little or no signs of 
organized connective tissue 
2 
Capsule tissue is dense, containing both fibroblasts and many 
inflammatory cells 
3 
Capsule tissue is fibrous, but immature organization into a capsule, 
less inflammatory cells 
4 
Capsule tissue is fibrous, mature, little to no inflammatory cells 
surrounding capsule 
 
Table 3: Scoring method used for semi-quantitative analysis of tissue response 
surrounding the implant. 
 




















1 Fibrous tissue capsule 
2 Localized fibrous tissue not arranged as a capsule 
3 
Remodeling lacuna with osteoblasts and/or osteoclasts at the surface 
of the bone, near the gel 
4 
Remodeling lacuna with osteoblasts and/or osteoclasts at the surface 
of the bone, adjacent to the gel 
 




Figure 21:  Stained section demonstrating the scoring scheme for each slide.  Figure (a) 
shows the orientation of an example slide, while (b) demonstrates where the slide would 




7.2.9 Histomorphometric Analysis 
Each sample was examined at locations using the predetermined scheme 
outlined above.  Micrographs were taken using a digital camera and analyzed using 
SpotSoftware (Diagnostic Instruments Inc) and the measurement function.  Bone 
percent was determined by (bone area/(total tissue area))x100.  Each slide analyzed 
was approximately 750 µm by 560 µm. 
 
7.2.10 Statistical Analysis 
 Data from all studies was analyzed using ANOVA single factor analysis and 




The rabbit orbital defect was found to be a functional model for the in vivo 
evaluation of tissue engineered constructs.  The rabbit orbital floor is readily 
accessible, as each surgical procedure lasted approximately ten minutes; however, the 
defect location is somewhat inhibited by the height of the orbital rim as well as the 
size of the orbital floor.  Furthermore, in the rabbit, the globe is supported by both 
soft and hard tissue.  In this model, construct implantation was easily achieved; 
although it should be noted that the limited amount of soft tissue sometimes caused 
migration of the implant. 
 An initial microscopic inspection of all the sample slides after histological 




21a).  The EH-PEG stained a light purple, whereas the surrounding tissue stained a 
darker purple and pink color.  In addition, the tissue-implant interface was easy to 
identify.  Lastly, construct shape was observed to be similar to the original 
implantation shape, and rarely were minimal deformations present.  It should be noted 
that degradation studies have not been completed on EH-PEG hydrogels.  However, 
similar hydrogels composed of a copolymer of EHD and PEG had approximately 
80% remaining mass after one month under physiological conditions.[246] 
The overall tissue response to the implanted EH-PEG hydrogels appeared to be 
mild.  In addition, there was minimal cellular invasion around the edges of the 
implant.  Furthermore, the implants had initial masses surrounding the tissue which 
are likely to be fibrin clots.  The experimental implants showed a mild inflammatory 
response, as evidenced by a lack of significant number of macrophages and foreign 
body giant cells.  At the later timepoints, some implants were surrounded by a 
moderate amount of fibrous encapsulation.  Lastly, new bone formation was present 
in the BMP-2 loaded implants at the later timepoint with increasing amounts present 
with higher concentrations of BMP-2. 
 In order to provide a semi-quantitative description to the implanted EH-PEG 
hydrogels, the tissue response to the surrounding area was scored according to Table 
3 and shown in Figures 22 and 23.  The control constructs showed an initial response 
at 7 d of little surrounding connective tissue and then a statistically significant 
improvement in surrounding tissue quality to fibrous encapsulation by 28 d.  In 
addition if analyzed more closely, there appeared to be a spatial disparity present in 




levels of fibroblasts, while the orbital floor surface of the gel presented tissue more 


























Figure 22:  Response of surrounding tissue to EH-PEG constructs with 0, 0.25 and 2.5 
µg BMP-2 /implant at 7 and 28d scored according to Table 3 and Figure 21b.  The 
control constructs showed an initial response of no connective tissue at 7 d and then 
progressed to fibrous encapsulation at 28 d which was statistically higher than all groups.  
There was a spatial disparity noted with the control constructs.  The BMP-2 loaded 
constructs were surrounding by fibroblasts at the initial timepoint and only increased 
slightly at 28 d.  However, the tissue response surrounding all BMP-2 loaded constructs 
were not statistically different throughout the study.  (*, #) indicate statistical difference 
among averages across both timepoints.  G: Globe surface, F: Orbital floor surface, A: 






Figure 23:  Hematoxylin and eosin staining of samples demonstrating the scores for 
Table 3.  (a): a score of 1 demonstrating some inflammatory cells with no connective 
tissue, (b): a score of 2 showing dense surrounding tissue containing both fibroblasts and 
inflammatory cells, (c): a score of 3, representing fibrous but immature tissue, and (d): a 
score of 4 showing mature, fibrous tissue. 
 
The EH-PEG constructs were further analyzed for capsule thickness according to 
Table 4 and shown in Figures 24 and 25.  At 7 d there was very minimal capsule 
formation; however, by 28 d, there was a significant increase in the control 
constructs.  Furthermore, it was again apparent that there was a spatial difference and 
that the orbital floor surface of the gel had a higher degree of fibrous encapsulation 















































Figure 24:  Capsule thickness surrounding EH-PEG constructs with 0, 0.25 and 2.5 µg 
BMP-2/implant at 7 and 28d scored according to Table 4 and Figure 21b.  At 7 d all 
groups showed minimal capsule formation.  There was a slight increase in the BMP-2 
loaded groups at 28 d, but the most significant increase was with the control groups.  All 
BMP-2 loaded groups were not statistically different during the study, and the control 
group showed significantly higher capsule formation than all groups.  The spatial 
disparity was also present with the capsule thickness.  (*, #) indicate statistical difference 
among averages across both timepoints.  G: Globe surface, F: Orbital floor surface, A: 






Figure 25:  Hematoxylin and eosin staining of samples demonstrating scores for Table 4.  
(a): a score of 1 showing 1-4 cell layers, (b): a score of 2 showing 5-9 cell layers; here 
pieces of the EH-PEG gel were encapsulated by the surrounding tissue, (c); a score of 3 
representing 10-30 cell layers, and (d): a score of 4 demonstrating >30 cell layers. 
 
In addition, the area surrounding the EH-PEG gels was analyzed for bone growth 
according to Table 5 and is shown in Figures 26 and 27.  At 7 d all groups had scores 
close to zero representing inflammation.  However, by 28 d, there was an increase in 
scoring averages of all groups.  However, the control group increase was due to 
fibrous capsulation located near the orbital floor surface edge of the EH-PEG 



































Figure 26:  Bone growth surrounding EH-PEG constructs loaded with 0, 0.25 and 2.5 µg 
BMP-2 /implant at 7 and 28d scored according to Table 5 and Figure 21b.  Results show 
that at 7 d all groups showed inflammation, however there was an increase at 28 d.  Here 
the control constructs showed fibrous tissue capsule formation in the control group, some 
bone growth in the 0.25µg BMP-2 group, and significant bone growth in the 2.5µg BMP-
2 group.  (*) indicates statistical difference among averages across both timepoints, (‡, #) 
indicate statistical differences among globe surfaces at 28 d.  G: Globe surface, F: Orbital 






Figure 27:  Hematoxylin and eosin staining demonstrating scores for Table 5.  (a) a score 
of 0 showing inflammation, (b) a score of 1 showing a fibrous tissue capsule, and (c) a 
score of 3 showing new bone growth near the gel.  Please note that scores of 2 and 4 were 
not observed in this study. 
 
 As one objective of the study was to determine the efficacy of growth factor 
release from EH-PEG hydrogels for the initiation of bone formation, it was therefore 
necessary to characterize growth factor release profile for the EH-PEG hydrogels.  To 
this end, BMP-2 was released in vitro over a period of 12 hours and assayed using an 
ELISA kit (Figure 28).  The constructs loaded with 0.25 µg BMP-2/implant showed a 
steady release over the first 4 hours and then leveled off to a 10% final release.  
Therefore, the 0.25 µg BMP-2/implant constructs had a final release of approximately 
25 ng.  Furthermore, the 0.25 µg/implant construct showed no statistical difference in 




hours.  The 2.5 µg BMP-2/implant constructs showed a slight, increasing release 
trend up to 2 hours and held level with a total release of approximately 25%, or 625 
ng.  In addition, the final percent released was significantly different between the 0.25 





























Figure 28:  Release of BMP-2 from EH-PEG hydrogels.  Hydrogels were loaded with 
0.25 and 2.5 µg BMP-2/implant and the amount of BMP-2 was assayed using an ELISA 
kit over 12 hours.  Approximately 25 % of the amount loaded was released from the 2.5 
µg/implant construct as compared to 10 % for the 0.25 µg/implant constructs.  The final 
percent released was significantly different between groups.  In addition, the 0.25 
µg/implant construct showed no statistical difference when compared at 4, 6, and 12 
hours indicating that release occurred in the first 4 hours.  (*) indicates statistical 
difference. (n = 5). 
 
 The tissue response to the BMP-2 loaded EH-PEG hydrogels was also scored 
according to Table 3 and is shown in Figure 22.  The BMP-2 loaded groups were 
mostly surrounded by fibroblasts and did not show much increase in semi-
quantitative scoring between the timepoints.  The EH-PEG constructs were further 
analyzed for capsule thickness (Table 4, Figure 24).  At 7 d there was slight capsule 




groups.  However, for both tissue response and capsule thickness, all BMP-2 groups 
were not statistically different throughout the study.  In addition, the spatial disparity 
that was present in the control group for tissue response and capsule thickness was 
not present in the BMP-2 loaded constructs.  The area surrounding the EH-PEG gels 
was also analyzed for bone growth (Table 5, Figure 26).  It is important to note that 
scores 2 and 4 were not found in this data set.  At 7 d all groups had scores close to 
zero representing inflammation.  However, by 28 d, there was an increase in the 
averages of all groups.  The 0.25 µg BMP-2/implant group had a significant increase 
on the globe surface when compared to the control at 28 d, due to new bone growth 
near the construct.  Furthermore, the 2.5 µg BMP-2/implant group had significantly 
higher levels of new bone growth on globe surface when compared to the 0.25 µg 
BMP-2/implant group at 28 d.  Histomorphometric analysis (Figure 29) at day 28 
demonstrates significant increases in bone percentages in the 2.5 µg BMP-2 group 
both at the globe interface and average of globe and floor surfaces compared to the 

































Figure 29:  Histomorphometric analysis surrounding EH-PEG constructs loaded with 0, 
0.25 and 2.5 µg BMP-2 /implant at 28d showing bone percent.  Results demonstrate 
significant increases in bone percentages in the 2.5 µg BMP-2 group both at the globe 
interface and average of globe and floor surfaces compared to the control and the 0.25µg 
BMP-2 group.  (*) indicates statistical difference among averages, (‡) indicates statistical 
differences among globe surfaces.  G: Globe surface, F: Orbital floor surface, A: Average 
of globe and floor surfaces (n = 15). 
 
7.4 Discussion 
Orbital floor injuries are a devastating form of facial trauma and when left 
untreated often do not heal properly and form nonfunctional scar tissue.  Many 
clinical methods have been employed to treat orbital floor defects; however these are 
associated with a number of sequelae.  Therefore, our laboratory proposes a tissue 
engineering strategy utilizing EH-PEG hydrogels. 
 Our first objective was to describe the tissue response surrounding EH-PEG 
hydrogels implanted into a rabbit orbital defect.  To this end, constructs were 




23 and 25).  Results indicated an initial mild response to the control constructs as well 
as a low level of fibrous encapsulation.  Furthermore, Figure 22 presents an increase 
in semi-quantitative scoring for these implants from 7 to 28 d, indicating that the 
surrounding tissue has a favorable response to the EH-PEG constructs over time and, 
more specifically, do not appear to induce a chronic inflammatory response. 
 An interesting development was the spatial disparity that was present between 
the tissue surrounding the globe surface and the orbital floor surface of the control 
constructs.  For example, in Figure 24 capsule thickness was analyzed and showed 
minimal levels for all groups at all timepoints, however an increased thickness at 28 d 
for the orbital floor edge of the control group was observed.  We speculate this 
response may be due to the differences in vascularization, where the tissue adjacent to 
the orbital floor surface of the construct is likely more vascularized than the tissue 
adjacent to the globe surface.  In particular, the latter would require vascular 
development due to the creation of the defect which may have disrupted vascular 
support to the globe surface, in addition to the EH-PEG construct acting as a barrier 
to vascular growth from the orbital floor side.  We must also note that while the 
constructs are uniform, the control groups did also receive a control solution loaded 
with BSA on the globe surface, and this experimental procedure may contribute to the 
differences in tissue response. 
 In order to examine our second objective, the in vitro release of BMP-2 from 
EH-PEG gels, BMP-2 was loaded onto the gels and the concentration of BMP-2 in 
the surrounding PBS was measured over time (Figure 28).  The 0.25 µg/implant had a 




The difference in release percentages could be due to the stability of the BMP-2 at 
different concentrations, where BMP-2 is more stable when at a higher concentration 
(R & D Systems).  This concentration effect upon stability could therefore be realized 
both during the loading process and during the release process.  Alternatively, the 
surface loading process may have allowed the high concentration implants to 
minimize BMP-2’s interactions with the hydrogel, as BMP-2 molecules accumulate 
on each other on the surface of the hydrogel.  This phenomenon would likely allow 
the high concentration implants to demonstrate quicker release, as some BMP-2 
molecules need only to solubilize rather than diffuse through the surface of the EH-
PEG hydrogel, as well as a higher percentage release, as BMP-2 molecules observe 
less physical interactions during the release process.  Indeed, both quicker and 
increased BMP-2 released was observed by the high concentration implants (Figure 
28).  Nevertheless additional studies, beyond the scope of this work, are required to 
fully address the relationship between loading concentration and release profile.  
Finally, we do note that the use of an ELISA to detect BMP-2 concentrations allows 
for not only the detection of the growth factor, but also some confidence that the 
growth factor remains in a biologically active form.  It is also important to note that in 
both conditions 100% protein recovery was not observed.  This may be due to BMP-2 
degradation, as proteins tend to be unstable at low concentrations, and also the ELISA 
assay’s specificity to protein structure. 
 Lastly, our third objective was to investigate the ability of EH-PEG hydrogels 
to deliver BMP-2 to an orbital defect in a rabbit model and facilitate bone formation.  




implant as well as the capsule thickness surrounding the implant (Figures 22 and 24).  
In addition, results showed that BMP-2 delivery was associated with increased bone 
formation (Figure 26) and bone percentage (Figure 29).  Here the 2.5 µg BMP-
2/construct had the most significant bone growth at 28 d, demonstrating the ability of 
EH-PEG gels to deliver biologically active BMP-2 to a rabbit orbital defect.  
Furthermore, it was apparent in both of the BMP-2 loaded groups that the majority of 
bone growth appeared on the globe surface of the construct.  As described in the 
methods section, BMP-2 was loaded on the top of the gel, and this side was placed 
facing the globe during surgery.  We predicted that diffusion as well as the relatively 
small defect size would allow BMP-2 to be adequately transported throughout the 
defect volume; however, the results indicate that the majority of the growth was 
immediately adjacent to the BMP-2 loaded surface.  We do note that in the 2.5 µg 
BMP-2/implant group at 28 d, there were some instances of new bone growth near 
the orbital floor surface of the gel, although these were not as common as those near 
the globe surface. 
 
7.5 Conclusions 
 The objectives of this study were to investigate the tissue response to EH-PEG 
hydrogels, characterize the release of BMP-2 from EH-PEG hydrogels, and analyze 
their ability to deliver BMP-2 in vivo and facilitate bone formation.  The results 
indicate that the tissue surrounding the EH-PEG constructs showed a positive 
progression from 7 to 28 d indicating that constructs were not eliciting a chronic 




hours, and happened more quickly at the higher concentration.  Lastly, the data shows 
the ability for EH-PEG gels to deliver BMP-2 as shown by the new bone growth in 
the area surrounding the constructs containing high concentrations of BMP-2 at 28 d.  
This demonstrates that EH-PEG constructs are a viable option for use in vivo and for 







Chapter 8: Characterization of Macroporous Cyclic Acetal 
Hydrogels 
8.1 Introduction 
An important aspect of tissue engineering is the scaffold which can act as a 
support medium to deliver cell populations or induce surrounding tissue ingrowth.  
The construct typically acts as a template which facilitates cell attachment and matrix 
deposition.  Scaffold properties directly determine the success in tissue engineering 
and must be designed for each purpose.  In many applications, including bone 
regeneration, porosity, pore size, and interconnectivity are key parameters as they 
allow for improved cell migration, proliferation and vascularization.   
A number of polymers are currently under investigation for tissue engineering 
applications; however an ideal biomaterial has not been developed.  Our laboratory 
has developed a class of biomaterials based upon a cyclic acetal unit.  These materials 
may be advantageous for tissue engineering applications as they degrade 
hydrolytically to form primary degradation products of diols and carbonyls, and thus 
should not affect the local acidity of the implant or phenotypic function of the 
delivered cell population.  A cyclic acetal biomaterial in the form of a rigid plastic 
may be fabricated from the radical polymerization of the monomer 5-ethyl-5-
(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD).[218]  Here, the 
EHD monomer and PEGDA polymer were fabricated into a macroporous EH-PEG 




Macroporous biomaterials have been created using a number of techniques 
including porogen-leaching as a common method for use with non-water soluble 
polymers.  However, to create macroporous water-swollen hydrogels, freeze drying, 
stereolithography, and gas-foaming are frequently used.[20-22,24,25,247,248]  Using 
porogen-leaching to create a macroporous hydrogel is not an established technique 
even though it may be easily implemented.  Here, the EHD monomer and PEGDA 
polymer were fabricated into a macroporous EH-PEG hydrogel by radical 
polymerization using porogen-leaching.  In this study, saturated salt was used as the 
water component of the gel to slow the dissolution of the salt and maintain porogen 
integrity during crosslinking. 
There are a number of methods available for measuring porosity within 
scaffolds, each with associated advantages and disadvantages.  Mercury intrusion 
porosimetry is a technique that has been commonly used, and is based upon the 
infusion of mercury within the scaffold under increasing pressure to determine the 
porosity and estimate pore sizes.[249-252]  While this technique may give reasonable 
estimate of porosity and pore size, the use of mercury is not ideal.  The liquid 
displacement method is a technique that is also frequently used.  Here the construct is 
submerged in a volume of liquid and is brought through a series of evacuation-
repressurization cycles to force liquid into the pores.[249]  The porosity can be 
estimated from the amount of liquid that was taken up into the construct.[253-255]  
However, it can be difficult to find a proper solvent that will not affect the biomaterial 
and can be forced into the pores.  In addition, sensitive biomaterials may compress 




techniques may not be appropriate.  Image analysis has also been used to measure 
porosity and more frequently, pore size.  In particular, scanning electron microscopy 
is a commonly used technique.[255-257]  The sample has to be dried and the surfaced 
coated, commonly with gold-palladium, which limits the type of biomaterial that can 
be analyzed by this method.  Other imaging techniques such as microcomputed 
tomography have been used to analyze bone morphology, and are beginning to be 
used to determine porosity and pore sizes in scaffolds where 2D images are 
reconstructed to generated 3D images.[258]  It is important to note, that many of these 
above techniques are invasive, discrete methods of analysis.  Therefore, an optimal 
method is not widely available for analysis of engineered tissues. 
Optical coherence tomography (OCT) is a promising technique that 
overcomes many of the negative aspects of the previous techniques.  This method 
allows for noninvasive cross-sectional imaging of material architecture by measuring 
optical reflections.[259]  OCT is based upon the idea of optical ultrasound.[260]  For this 
technique near-infrared light is shone upon a sample, and the morphological features 
can be elucidated from the variations in their corresponding refractive index.[260,261]  
Specifically, the intensity of the backreflected light is measured using 
interference.[259,260,262]  OCT has been used previously in vivo to image 
microstructures of various tissues including the eye, skin, gastrointestinal tract, and 
the nervous system.[261-263]  However, OCT is still an emerging technology for the in 
vitro analysis of tissue engineered scaffolds. 
OCT is an ideal technique for imaging tissue engineered scaffolds for many 




resolution of 3-15µm which is significantly improved over other techniques.[260]  This 
allows for analysis at the cellular level and visualization of the extracellular 
matrix.[260]  Furthermore, OCT does not rely on exogenous agents such as fluorescent 
dyes to provide contrast which allows for maintained cell viability during imaging 
and repeated analysis.  OCT eliminates the needs for specimen fixation and 
processing which reduces any artifacts that can occur during these procedures, and 
allows for real-time imaging.  Specifically, when compared to histology, OCT is 
capable of demonstrating the same morphological features in tissue without the 
extensive processing necessary for histological sample preparation.[259]  In addition, 
OCT is capable of performing repeated observations within the same sample for a 
time-lapse analysis.  Lastly, OCT is relatively low cost when compared to other 
imaging techniques.[262] 
In this work, for the first time, macroporous EH-PEG hydrogels were 
characterized using OCT.  Objectives of this study were to (1) create water-swollen 
macroporous EH-PEG hydrogels using porogen-leaching, (2) use optical coherence 
tomography to characterize EH-PEG hydrogel architecture, specifically for pore size 
and porosity, and (3) combine OCT with confocal microscopy to demonstrate viable 






8.2.1 Hydrogel Formation 
Macroporous EH-PEG constructs were crosslinked using ammonium 
persulfate and N,N,N’,N’-tetramethylethylenediamine at 15 mM using a sodium 
chloride-leaching technique.  A saturated salt solution was used as the water 
component of the gel to slow the sodium chloride crystals from dissolving into the gel 
solution.  The constructs were prepared using EHD and PEGDA Mn~ 700 at 1:10 
molar EHD to PEGDA with 30 wt% initial monomer components.  Sieves were used 
to sort sodium chloride to specified sizes.  Gels were created in Petri dishes by 
spreading the salt evenly and dispersing the gel solution over the salt before cross 
linking.  Gels were allowed to crosslink and smaller gels were cut to 8 mm diameter 
with a cork borer.  The sodium chloride was leached out over 2 days in water with 
multiple washes while on an orbital shaker.  Gels were sterilized in 70% ethanol, 
washed four times in PBS and presoaked in control media plus FBS for four hours 
before cell loading.  EH-PEG hydrogels were created with the following 
formulations:  100 µm/65%, 100 µm/70%, 250 µm/70%, 250 µm/75% where 100 µm 
hydrogels were fabricated with salt that had been collected between sieves of 106-150 
µm and 250 µm hydrogels between 250 and 300 µm and the reported porosities are 





8.2.2 Optical Coherence Tomography (OCT) 
This study is performed with a Fourier-domain OCT system.[264]  The fiber-
based high-speed, high-resolution OCT system utilizes a wavelength-swept laser as 
the light source.  It generates a broadband spectrum of 100 nm at 1300 nm, which 
provides an axial resolution of 8 m in the tissue. The laser operates at a sweep rate 
of 16 kHz (equivalent to an imaging speed of 15 frames per second for a 1024 axial-
line image) with an average output power of 12 mW. The system sensitivity is 95 dB. 
A Michelson interferometer composed of one circulator and a fiberoptic 50/50 splitter 
is used to generate the Fourier-domain OCT signal. The OCT interference signal 
returned from the sample and reference arms is detected by a balanced photodetector. 
A Mach-Zehnder interferometer (MZI) with a fixed path difference is used to 
generate an optical frequency clock. Data acquisition is triggered by the zero-crossing 
points of the MZI fringes, which are evenly spaced in optical frequency (k). Discrete 
Fourier transform (DFT) is performed on the data to generate an axial depth profile. 
Three-dimensional (3D) images were acquired using a pair of galvanometer mirrors. 
 
8.2.3 OCT Image Processing and Analysis 
The 3D OCT volumetric images of the hydrogel measured 2.5 mm x 2.5 mm x 
2.5 mm with 512 x 512 x 512 pixels. The image processing was performed on the en 
face OCT images. First, the en face images were segmented with MATLAB based on 
the different back-scattering intensities of the porous and mass regions. The 
segmentation process formed a binary image. Next, the pore size and the porosity 




the average between the longest and shortest lengths that could be measured on a 
pore. The porosity was expressed in the ratio of volume divided by the total volume. 
Multiple measurements were performed and the means and standard deviations of 
those measurements were obtained.    
 
8.2.4 Combined OCT/Confocal Microscopy System   
In order to detect cells within the scaffolds, OCT was combined with 
fluorescence confocal microscopy (FCM).  The FCM system is combined with the 
OCT system using a dichroic filter which passes through the visible and near-infrared 
light used for FCM, and deflect the 1.3 µm light used in OCT. The FCM system uses 
a continuous-wave laser diode as the excitation source. Different excitation 
wavelengths can be chosen depending on specific fluorescence marker under 
investigation. The excitation light is focused by a microscope objective. The 
fluorescence light is collected back by the objective and directed into the emission 
filter by another dichroic filter which separates the excitation light from the 
fluorescence emission light. The fluorescence signal is then collected by a multimode 
fiber, and detected by photomultiplier tubes.  To generate an en face confocal 
fluorescence image, the illumination point is raster-scanned by a resonance scanner 
and a galvanometer mirror to achieve a real-time speed of 8-10 Hz. 
We performed combined OCT/FCM imaging of scaffolds containing hMSCs. 
Cells can be stained with the Live/Dead assay. Due to the current laser source only 
one dye can be imaged at a time.  In this study the co-registered OCT/FCM provides 




8.2.5 Human Mesenchymal Stem Cell Culture   
hMSCs were purchased from Lonza and cultured according the 
manufacturer’s specifications and as described in the literature.[265]  Prior to the study, 
the hMSCs were cultured in control media composed of high glucose DMEM with 4 
mM L-Glutamine, 0.1 mM non-essential amino acids, 1% penicillin/streptomycin 
(v/v) and 10% MSC qualified FBS.  hMSCs were added to sterile, presoaked 
hydrogels in a concentrated cell solution.  The cells were allowed to attach for 4 hours 
before filling the well with media.   
 
8.2.6 Viability   
Gels were cultured and analyzed using the LIVE/DEAD assay.  Before 
analysis, the gels were soaked in PBS for 1.5 hrs to remove FBS from the gel which 
can interact with the Live/Dead reagents.  As only one dye can be read at a time due 
to the microscopy setup, the gels were incubated with the Live reagents (2.5 µm 
calcein AM) at room temperature for 30 min.   
 
8.2.7 Statistical Analysis 
 Data from all studies was analyzed using ANOVA single factor analysis and 
Tukey’s multiple comparison test (p ≤ 0.05).  All results are reported as mean ± 
standard deviation.  Please note that only pertinent statistical relationships are noted 






EH-PEG hydrogels with varying pore sizes and porosities were created, 
imaged using OCT, and analyzed with image processing.  Three-dimensional 
reconstruction was performed from binary images to visualize the pores (Figure 30).  
From both the cross-sectional and en face images, results qualitatively show a 
difference in pore size between the 100 μm and 250 μm EH-PEG hydrogels.  




Figure 30: Cross-sectional OCT (top row) and en face OCT (middle row) images of cell 
scaffolds with varying pore sizes and porosities: (a) 100 μm/65%, (b) 100 μm/70%, (c) 
250 μm/70%, (d) 250 μm/75%.  Bottom row of images depicts 3D visualization of pores 





Figure 31 shows the quantified pore sizes as measured from the average 
between the longest and shortest lengths in the pore.  For the 100 µm pore size, the 
measured sizes were 132 ± 22.5 µm and 144 ± 31.2 µm for 65% and 70%, 
respectively and are not statistically different.  These two values both lie within the 
range of expected values dependant on the starting size of the salt used to create these 
hydrogels.  For the 250 µm pore size, the quantified pore sizes were 295 ± 63.9 µm 
and 239 ± 54.3 µm for 70% and 75%, respectively which are again within the 
expected range and are not statistically different.  When comparing between the 100 



























Figure 31:  Average pore size of EH-PEG hydrogels was quantified using OCT images.  
Measured pore sizes fall in the predicted ranges for all experimental groups.   
 
Porosity was also analyzed based upon the three-dimensional reconstructions.  




be different as they are derived from volume.  For the 100 µm pore size, calculated 
volume porosities were 70.2 ± 11.6 % and 73.7 ± 10.7% for the mass porosities 65% 
and 70%, respectively (Figure 32).  The 250 µm pore size hydrogels demonstrated 
calculated volume porosities of 51.7 ± 9.4 % and 62.7 ± 8.9% for the mass porosities 
70% and 75%, respectively.  It is important to note that there is a trend between 
groups of the same pore sizes in that hydrogels with a higher mass porosity 
demonstrated higher volume porosity both for the 100 µm and 250 µm pore size 
hydrogels.  When comparing between hydrogels of different pore sizes, the 100 µm 
70% hydrogel showed higher volume porosity than the 250 µm 70%, however they 






















Figure 32:  Measured volume porosity of EH-PEG hydrogels quantified from OCT 
images.  Within gels of the same pore size, gels with a higher predicted porosity 
demonstrated a higher porosity.  In addition, both gels with 70% mass porosity 





Fluorescence confocal microscopy (FCM) was also combined with OCT to 
image live cells within the scaffolds (Figure 33).  The 2D image is of the top face of 
the scaffold and can be used to qualitatively visualize cell distribution and viability.  
For all the scaffolds, viable cells can be seen spread across the surface and within the 
pores.   
 
Figure 33: OCT/FCM images of hMSCs stained with LIVE dye within EH-PEG 
hydrogels.  Results show the top view of the scaffolds and demonstrate viable cells 
spread across the constructs and within the pores.  (a) 100 μm/65%, (b) 100 μm/70%, (c) 






Objectives of this study were to (1) create water-swollen macroporous EH-
PEG hydrogels using porogen-leaching, (2) use optical coherence tomography to 
characterize EH-PEG hydrogel architecture, specifically for pore size and porosity, 
and (3) combine OCT with confocal microscopy to demonstrate viable cells within 
the scaffolds.   
This study demonstrates the use of porogen-leaching to create macroporous 
water-swollen hydrogels.  Other methods have been employed to create macroporous 
hydrogels; however each has associated disadvantages.  Freeze drying uses 
temperature changes to create porous structures.[20]  Pore size is controlled by altering 
the freeze rate, however better success occurs when combined with porogen-
leaching.[38]  Gas foaming is also commonly used with hydrogels where pores result 
from bubbles created in a chemical reaction or gasses under pressure.[24]  Variations 
in pore size are controlled by altering gas volume, rate of gas nucleation, and 
diffusion.[25]  Again, to improve pore size control, gas foaming can be combined with 
porogen-leaching.[25]  Laser stereolithography is also employed to create porous 
structures.  Here complex internal structures can be produced through computer aided 
design.[266]  While this technique allows for excellent repeatability between scaffolds, 
it requires the use of a computer and intricate machinery.  The simple porogen-
leaching method presented in this paper allowed for the creation of macroporous 
hydrogels in a simple technique and produced pores of the desired size. 
OCT was used to analyze EH-PEG hydrogel architecture, specifically for pore 




pore size and demonstrated the EH-PEG hydrogels had pores in the expected range.  
This indicates that the fabrication method succeeded in slowing the dissolution of 
sodium chloride into the aqueous gel solution before crosslinking.  Further analysis 
allowed for the quantification of volume porosity, which is an important parameter in 
tissue engineering scaffolds.  The volumes reported were low for the 250 µm pore 
sizes indicating that they might not be optimal for use as tissue engineering 
constructs.  However, the 100 µm EH-PEG hydrogels reported volume porosities in 
the range of 70% which is reasonable for tissue engineering applications. 
OCT was also combined with FCM demonstrating the capability of the system 
to visualize cells within the scaffolds.  These results qualitatively show viable cells 
across the surface and within the pores of the constructs.  Further image 
reconstruction will allow for 3D rendering to demonstrate a global view of viable 
cells within the construct.  This will allow for elucidation of cellular interactions with 
the scaffold.  As OCT is a non-invasive imaging technique, long term migration 
studies could be completed with this system to better understand the proliferation of a 
cell population over time as well as long term viability within the scaffolds. 
 
8.5 Conclusions 
Scaffold properties are important parameters in the success of tissue 
engineering applications.  In this work, macroporous EH-PEG hydrogels were 
produced using porogen-leaching demonstrating a simple technique for fabrication.  
OCT was used to quantify pore size and volume porosity.  Reported pore sizes were 




ability of OCT analysis to quantify pore size.  In addition, OCT image analysis was 
able to be used to characterize volume porosity, a parameter not previously known.  
Further work combined OCT with FCM where viable cells were visualized within the 




Chapter 9:  Macroporous Cyclic Acetal Hydrogels for Orbital 
Floor Repair 
9.1 Introduction 
Orbital floor injuries are a devastating form of craniofacial trauma and 
account for approximately 60-70% of all orbital fractures.[113,228]  Injury to the orbit is 
commonly caused by blunt force through assault and traffic accidents.[110,111]   Orbital 
bone fractures, if left untreated, may not heal adequately.  Generally, only small bone 
fragments and few bony edges are present to conduct bone formation and restore 
orbital volume.  Instead, a fibrous scar forms which lacks the support, architecture, 
and load bearing properties of bone.  Therefore, the endogenous response to orbital 
fractures, in contrast to many other bone fractures, is not sufficient for proper healing.  
In addition, when treated inadequately, a number of sequelae are associated with 
orbital floor injuries including unsatisfactory facial aesthetics, enophthalmos (sunken 
eye), and diplopia.[112,124,229] 
The orbital floor is composed of portions of three bones, the maxilla, 
zygomatic, and palantine.[107,108]  The orbital floor is a very thin plate, approximately 
0.5 mm, and its main purpose is to separate the orbital contents from the maxillary 
sinus.[107,267]  Given that the orbital floor is a thin structure, it is an excellent model for 
in vitro tissue engineering as experiments are able to be performed without the need 






Bone morphogenetic proteins (BMPs) are some of the most promising growth 
factors involved in bone tissue engineering.  BMPs are members of the TGF-β 
superfamily and are known to be secreted signaling molecules.[133]  The family of 
BMPs is known to induce formation of cartilage, bone, and other tissues of the 
skeleton.[133]  Specifically, BMP-2 is known to increase mesenchymal stem cell 
proliferation and differentiation into osteoblasts.[144]  In addition, it has chemotactic 
effects on human osteoblasts.[143]  The BMP receptors play an important part in the 
signaling ability of the molecule.  There are two types of BMP receptors, Type I and 
Type II, and both are able to bind the ligand.[133]  It is thought that signal transduction 
requires the formation of a complex between the Type I and Type II receptors before 
ligand binding, and binding initiates a signal cascade within the cell.[133,135,268]  
Furthermore, BMP signaling has been shown to be involved in a number of functional 
osteoblast pathways including bone matrix proteins, osteogenic regulatory genes, 
BMP inhibitory factors, and osteogenic transcription factors.[268]     
Current alloplastic implants that are available for clinical use in orbital floor 
repair include Teflon, silicone, Gelfilm, Medpor (high-density polypropylene), and 
titanium.[107,111,116,117]  However, an ideal biomaterial with favorable cellular 
interactions, mechanical strength, degradation and degradation products, is not 
available.  To this end, our laboratory has developed a class of biomaterials based 
upon a cyclic acetal unit.  Cyclic acetals may be preferred for tissue engineering 
applications as they hydrolytically degrade to form diol and carbonyl primary 
degradation products, which should not affect the local acidity of the implant or 




form of a rigid plastic may be fabricated from the radical polymerization of the 
monomer 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate 
(EHD).[218]  The hydrophilic polymer poly(ethylene glycol) (PEG) was incorporated 
to create a cyclic acetal based hydrogel that could be used to deliver cell populations 
and growth factors.[219]  Previous work has demonstrated that EH-PEG hydrogels 
support long term viability of encapsulated bone marrow stromal cells.[269]  In 
addition, EH-PEG hydrogels were able to deliver bone morphogenetic protein-2 in an 
orbital floor defect model supporting new bone growth indicating EH-PEG hydrogels 
are a viable craniofacial bone tissue engineering system.[155] 
In order to improve bone regeneration and tissue integration, the scaffold 
should mimic bone morphology, structure, and function.[249]  An important aspect of 
bone morphology is the pores which facilitate both molecular diffusion and cell 
migration.  Furthermore, scaffold porosity allows vascularization as well as improves 
mechanical stability between the implant and surrounding native bone.[270]  There are 
a number of studies in the literature reporting minimum pore sizes for osteogenesis.  
It has been demonstrated that interconnected pores with diameters greater than 50 µm 
are favorable to new bone formation, while the minimum pore size for 
osteoconduction is 80-100 µm.[98,151,152,209]  Lastly, for the scaffold to support new 
vasculature, it has been shown that the minimum pore size is 45-100 µm; however, 
scaffolds with pore sizes of 100-150 µm resulted in a richer blood supply.[153,209] 
While studies have been completed on scaffolds with micropores (<10 µm) and in 
macroporous 500 µm pores structures, the above results indicate that a minimum pore 




Many techniques have been utilized to create porous scaffolds for tissue 
engineering applications.  Porogen-leaching has been implemented frequently with 
non-water soluble polymers.  While to create macroporous water-swollen hydrogels, 
freeze drying, stereolithography, and gas-foaming are commonly used.[20-22,24,25,247,272]  
However, using porogen-leaching to create macroporous water-swollen hydrogels is 
not an established technique even though it may be easily implemented.  The EHD 
monomer and PEGDA polymer may be fabricated into a macroporous EH-PEG 
hydrogel by radical polymerization using salt-leaching.  Here, saturated salt was used 
as the water component of the gel to slow the dissolution of salt and maintain porogen 
integrity.   
Macroporosity within hydrogels may facilitate both molecular diffusion and 
cell migration.  This environment should promote cellular interactions and signaling, 
and as a result, differentiation.  However, high porosity scaffolds can be associated 
with poor mechanical integrity.  Engineering these properties to allow for appropriate 
diffusion and mechanical strength are important challenges in the construction of 
bone tissue engineering scaffolds.  In this work, for the first time, the effect of 
scaffold architecture in macroporous EH-PEG hydrogels on osteogenic signaling of 
hMSCs was investigated. Specifically, the objectives of this work were to (1) 
investigate the effects of scaffold architecture, through porosity and pore size, in EH-
PEG hydrogels on osteogenic signal expression, (2) examine the effect of adhesion 
through incorporating the extracellular matrix protein fibronectin in EH-PEG 
hydrogels on osteogenic signal expression, and (3) investigate the strength of EH-






Ammonium persulfate (APS), N,N,N’,N’-tetramethylethylenediamine 
(TEMED), PEGDA Mn~ 700, benzoyl peroxide, N,N-Dimethyl-p-toludine, ascorbic 
acid  Na-β-glyerophosphate, dexamethasone, trizol, Isobutyraldehyde, formaldehyde 
(37% aqueous solution), trimethylolpropane, triethylamine, hydroquinone and 
acryloyl chloride  were purchased from Sigma (St. Louis, MO).  Potassium carbonate, 
sodium sulfate, ethyl ether, silica gel (60-200 mesh) and stainless steel sieves in the 
appropriate sizes were purchased from Fisher Scientific (Pittsburg, PA).  Human 
fibronectin and Quantikine BMP-2 immunoassay ELISA kit were purchased from 
R&D Systems (Minneapolis, MN).  The DNeasy Tissue kit and RNeasy Mini Plus 
Kit were purchased from Qiagen (Valencia, CA).  The Live/Dead assay and Quant-iT 
PicoGreen Kit were ordered from Molecular Probes (Carlsbad, CA).  High-glucose 
DMEM, MSC-qualified fetal bovine serum (FBS), penicillin-streptomycin antibiotics, 
L-glutamine, and non-essential amino acids were obtained from Invitrogen (Carlsbad, 
CA).  The M-per Mammalian Protein Extraction Reagent was ordered from Pierce 
(Rockford, IL).  The High Capacity cDNA Archive Kit and TaqMan Gene Expression 





9.2.2 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate 
Synthesis 
5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate (EHD) was 
synthesized based on previous protocols described by Kaihara et al.[246]  Potassium 
carbonate (18.9 g, 0.25 equiv) was added to isobutyraldehyde (50 ml, 1 equiv) and 
formaldehyde (37% aqueous solution, 40.8 ml, 1 equiv) and the solution was stirred 
at 0°C overnight.  The product 3-hydroxy-2,2-dimethylpropinaldehyde (HDP) was 
extracted three times with chloroform and then washed with water and brine.  The 
chloroform layers were combined and dried with sodium sulfate and the solvent was 
evaporated under reduced pressure to obtain solid HDP.   HDP (32.9 g, 1 equiv) and 
trimethylolpropane (86.6 g, 2 equiv) were dissolved in 1 M hydrochloric acid (200 
ml) and stirred for 2 hrs at 80C.  The solution was then neutralized with sodium 
hydroxide and the product 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-
ethanol (HEHD) was extracted three times with chloroform and washed with water 
and brine.  The chloroform layers were combined and again dried with sodium sulfate 
and evaporated under reduced pressure to obtain solid HEHD.  The HEHD was 
purified using an ethyl ether wash to remove undesired byproducts and was dried 
under reduced pressure.  HEHD (31.3 g, 1 equiv) was dissolved in chloroform and 
trimethylamine (65.4 ml, 3 equiv) and hydroquinone (0.034 g, 0.002equiv) were 
added.   Acryloyl chloride (38.1 ml, 3 equiv) was added dropwise as the reaction was 
stirred at 0C for 2 hrs.  The insoluble salts were removed through filtration and the 
product, 5-ethyl-5-(hydroxymethyl)-β,β-dimethyl-1,3-dioxane-2-ethanol diacrylate 




The chloroform layers were combined and dried with sodium sulfate and evaporated 
under reduced pressure.  The EHD was further purified by silica gel column 
chromatography using a chloroform/ethanol (10:1, v/v) as the eluent.  The fractions 
that contained EHD were determined by thin layer chromatography and NMR. 
 
9.2.3 Hydrogel Formation 
Porous EH-PEG constructs were crosslinked using ammonium persulfate and 
N,N,N’,N’-tetramethylethylenediamine at 15 mM using a sodium chloride-leaching 
technique.  A saturated salt solution was used as the water component of the gel to 
slow the sodium chloride crystals from dissolving into the gel solution.  The 
constructs were prepared using EHD and PEGDA Mn~ 700 at 1:10 molar EHD to 
PEGDA with 30 wt% initial monomer components.  Sieves were used to sort sodium 
chloride to specified sizes.  Gels were cut to 8 mm diameter with a cork borer and 
sodium chloride was leached out over 2 days in water.  Gels were sterilized in 70% 
ethanol, washed in PBS and presoaked in control media plus FBS before cell loading.  
In order to demonstrate the method of macroporous fabrication, EH-PEG 
hydrogels were imaged using Field Emission Environmental Scanning Electron 
Microscope (FE-ESEM) (FE-ESEM; Quanta 200F, FEI).  Dried gels were placed on 
individual FE-ESEM sample stubs which were pre-coated with carbon adhesive. The 
stubs were mounted on a sample holder and loaded into the FE-ESEM.  Each sample 





9.2.4 Human Mesenchymal Stem Cell Culture 
hMSCs were purchased from Lonza and cultured according the 
manufacturer’s specifications and as described in the literature.[265]  Prior to the study, 
the hMSCs were cultured in control media composed of high glucose DMEM with 4 
mM L-Glutamine, 0.1 mM non-essential amino acids, 1% penicillin/streptomycin 
(v/v) and 10% MSC qualified FBS.  During the study, the osteogenic groups were 
supplemented with 100 nM dexamethasone, 10 mM Na-β-glyerophosphate, and 0.2 
mM ascorbic acid.  hMSCs were added to sterile, presoaked hydrogels in a 
concentrated cell solution.  The cells were allowed to attach for 4 hours before filling 
the well with media.  The media was changed every two days throughout the study. 
 
9.2.5 Fibronectin Loading 
The hydrogels were loaded with fibronectin in a sterile environment before 
use.  Specifically, surface liquid was removed from hydrogels, and allowed to dry in a 
sterile environment for 1 hour.  Then a concentrated solution of fibronectin was added 
and allowed to absorb for approximately 1 hour for final concentrations of 0.5, 2.5, 
and 10 µg fibronectin/gel.  Then the hMSCs were added as previously described. 
 
9.2.6 Deoxyribonucleic Acid Quantification  
Deoxyribonucleic acid (DNA) was isolated from all samples to normalize the 
ALP and ELISA assays described below.  Specifically, DNA was isolated using the 




then quantified using the Quant-iT PicoGreen Kit following standard protocols for a 
200 µL sample volume.  Samples were incubated at room temperature for 5 minutes 
and read using the M5 SpectraMax plate reader (Molecular Devices, Sunnyvale, CA) 
with excitation/emission of 480/520 nm.  All samples were completed in triplicate (n 
= 3). 
 
9.2.7 Alkaline Phosphatase Assay 
Protein was extracted using the M-per Mammalian Protein Extraction Reagent 
following standard protocols.  Briefly, 50 µL of M-per was added to each sample and 
shaken for 10 min.  Cell debris was removed by centrifugation at 14,000g for 15 min 
and the supernatant was used for analysis.  A p-nitrophenyl phosphate liquid substrate 
system (pNPP) was used to analyze intracellular alkaline phosphatase (ALP) 
concentrations from the extracted protein.  Briefly, the extracted protein sample was 
suspended in PBS and added to 100 µL of pNPP and incubated at room temperature 
for 30 min.  The reaction was stopped by adding 50 µL of 2M NaOH.  The 
absorbance was read using a M5 SpectraMax plate reader at 405 nm and normalized 
by the PicoGreen assay.  All samples were completed in triplicate (n = 3). 
 
9.2.8 Bone Morphogenetic Protein-2 Study 
Hydrogel constructs were created, loaded with cells, and cultured as described 
above.  At each time point, the media was removed and centrifuged to remove 




quantikine ELISA kit according to the manufacturer’s instructions and read using a 
M5 SpectraMax platereader.  Data was normalized to the DNA quantities as 
determined by the PicoGreen assay.  All samples were completed in triplicate (n = 3). 
 
9.2.9 Viability 
Gels were cultured and analyzed throughout the study using the LIVE/DEAD 
assay as described previously.[269]  At each timepoint, the gels were soaked in PBS for 
1.5 hrs to remove FBS from the gel which can interact with the Live/Dead reagents.  
The gels were incubated with the Live/Dead reagents (2.5 µm ethidium homodimer-1 
and 2.5 µm calcein AM) at room temperature for 30 min.  Micrographs were then 
taken using a fluorescent microscope equipped with a digital camera.   
 
9.2.10 Gene Expression  
RNA was isolated from cells in monolayer using the RNeasy Mini Plus Kit 
following standard protocols.  The RNA was isolated from the hMSCs in EH-PEG 
hydrogels using trizol and purified using the RNeasy mini kit following standard 
protocols.  The isolated total RNA was reverse transcribed using High Capacity 
cDNA Archive Kit.  The expression of BMP-2, BMP-RIA, BMP-R2, and osteocalcin 
was then investigated by quantitative real time polymerase chain reaction (qrt-PCR) 
on an ABI Prism 7000 sequence detector (Applied Biosystems) with GAPDH as an 
endogenous control.  TaqMan Gene Expression assays were used for all genes and the 




9.2.11 Tri-Layer Formation 
Tri-layer scaffolds were constructed from two layers of porous EH-PEG 
bound to a central layer of porous EH polymer using a sodium chloride leaching 
technique. The EH-PEG layers were crosslinked using ammonium persulfate and 
N,N,N’,N’-tetramethylethylenediamine at 40 mM.  The constructs were prepared 
using EHD and PEGDA Mn~ 700 at 1:10 molar EHD to PEGDA with 30 wt% initial 
monomer components in a 40% acetone solution.   The EH layer was crosslinked 
using 7 wt% benzoyl peroxide and 8 µL of N,N-Dimethyl-p-toludine per gram of 
EHD in acetone.  Sieves were used to sort sodium chloride to specified sizes.  Tri-
layers were created with varying porosity and pore size; for all conditions the EH-
PEG layer was held constant at 75 wt% while the EH layer was varied.  The 
experimental groups included 70%, 75%, and 80% porosity at 250µm and 65%, 70%, 
and 75% porosity for 100µm.  The two control groups were constructed from three 
layers of porous EH-PEG at each of the two pore sizes, lacking the central EH layer. 
Molds were used to construct each scaffold with the dimensions of 47 x 10mm.  The 
scaffolds were constructed layer-by-layer, with the EHD being initiated as soon as 
polymerization of the bottom EH-PEG layer took place. The EH layer was then 
monitored closely and upon polymerization the final EH-PEG layer could be added to 
the top. Previous testing confirmed that interaction between the layers is time 
dependent. Following polymerization, the scaffolds were soaked in acetone for 15 





9.2.12 Mechanical Testing 
Each scaffold was tested for flexural properties using a three-point bend test 
based on ASTM D 7264 Standard Test Method for Flexural Properties of Polymer 
matrix Composite Materials.  An INSTRON 5565 mechanical tester was employed 
and Bluehill software was used to record load data until breaking. The pre-load was 
set at 0.01N and the extension rate at the standard 1 mm/min.  Samples were prepared 
at a thickness of 4 mm (1.333 mm per layer) and a support span-to-thickness ratio of 
8 was used for testing.  Flexural strength was calculated as σfs=(3FfL)/(2bd
2) where Ff 
is the load at fracture, L is the distance between support points, and b and d are the 
width and height of the specimen, respectively.[273]   
 
9.2.13 Statistical Analysis  
 Data from all studies was analyzed using ANOVA single factor analysis and 
Tukey’s multiple comparison test (p ≤ 0.05).  All results are reported as mean ± 
standard deviation.  Please note that only pertinent statistical relationships are noted 
in the figures. 
 
9.3 Results 
Creating macroporous hydrogels through porogen leaching is not an 
established technique.  Here we implemented the use of a saturated salt solution for 
the water component of the gel in order to maintain porogen integrity by slowing the 




the technique we analyzed the EH-PEG hydrogels using FESEM and phase contrast 






Figure 34:  Micrographs of porous EH-PEG hydrogels with (a) FESEM and (b) phase 
contrast.  Scale bar denotes 40 µm for FESEM and 200 µm for phase contrast. 
 
We then investigated the effect of varying scaffold architecture.  hMSCs were 
loaded into EH-PEG hydrogels with pore size/porosities of: 250 µm/75%, 250 
µm/70%, 100 µm/70%, 100 µm/65%.  The viability of hMSCs in EH-PEG hydrogels 
were analyzed throughout the study using the LIVE/DEAD assay, only images from 
the first and last timepoint are included for brevity (Figure 35).  After one day of 
culture the cell populations appear viable in all groups independent of pore size and 
porosity.  This was maintained throughout the study, and is represented by Figure 35 
e-h at day 12 when the majority of the hMSCs appear viable in the EH-PEG 
hydrogels.  It is important to note that during the study, while the hMSCs are viable in 
the EH-PEG hydrogels, they do not demonstrate a high degree of spreading common 














Figure 35:  Viability of hMSCs in EH-PEG hydrogels.  After one day of culture (a-d), 
and after twelve days of culture (e-h) the majority of the cell populations remain viable.  
(a, e) 100µm 65%, (b, f) 100µm 70%, (c, g) 250µm 70%, (d, h) 250µm 75%.  Scale bar 
denotes 250µm.  
 
Alkaline phosphatase levels were analyzed on days 1, 4, 8, and 12 days and 
normalized by DNA (Figure 36).  The control groups were cultured in monolayer for 
all studies.  The results indicate moderate changes from day 1 to day 4 for all groups.  




expression than the controls at day 8 demonstrating a large increase from day 4.  This 
represents a faster rate of expression when compared to the hMSCs in the 250 µm 
EH-PEG gels and the osteogenic control.  From day 8 to day 12, the hMSCs in the 
100 µm EH-PEG hydrogels decreased indicating the ALP expression had peaked for 




















































Figure 36:  Alkaline phosphatase expression of cells after 1, 4, 8, and 12 d normalized by 
DNA.  The results indicate moderate changes from day 1 to day 4 for all groups.  The 
hMSCs in the 100µm EH-PEG gels showed a significant increase in expression from day 
4 with a peak a day 8 demonstrating a faster rate of expression as compared to the 
osteogenic control. (‡) denotes statistical significance within that timepoint. 
 
Bone morphogenetic protein-2 levels were measured by ELISA and 
normalized by DNA after 1, 4, 8, and 12 days (Figure 37).  The results indicate 
similar levels for all groups at day one; however by day 4 the hMSCs in EH-PEG 
hydrogels show significantly higher levels as compared to the controls with no 




and maintained throughout the study, where at day 12 hMSCs within EH-PEG 
hydrogels show BMP-2 levels approximately 40-fold higher than that compared to 









































Figure 37:  Bone morphogenetic protein-2 levels measured by ELISA and normalized by 
DNA after 1, 4, 8, and 12 days.  The results indicate similar levels for all groups at day 
one; however by day 4 the hMSCs in EH-PEG hydrogels show significantly higher levels 
as compared to the controls.  These elevated levels are maintained throughout the study.  
(‡, *) denote statistical significance within that timepoint. 
 
hMSCs were cultured within EH-PEG hydrogels and analyzed on days 1, 4, 8, 
and 12 to investigate the effects of porosity and pore size on osteogenic signal 
expression.  BMP-2 expression shows significantly elevated levels in all groups over 
the controls by day 1 and throughout the study independent of pore size or porosity 
(see Figure 38a.)  Specifically, at day 12 hMSCs in the 250 µm EH-PEG gels had 
fold changes of 67 and 64 for 75 and 70%, respectively, and in the 100 µm EH-PEG 
gels a fold change of 26 and 90 for 70 and 65%, respectively over the monolayer 




with an increase in BMP receptor expression (Figures 38b, c) as demonstrated by 
significantly increased levels of BMP-RIA and BMP-R2.  The increase in receptor 
expression was again independent of scaffold architecture; however the increase was 
not to the same magnitude as the BMP-2 increase as all groups demonstrated a fold 
change of approximately 2 at day 12.  Osteocalcin expression was also analyzed; 
however only low levels were detected indicating the hMSCs were not expressing the 
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Figure 38:  Quantitative RT-PCR analysis after 1, 4, 8, and 12 days for (a) bone 
morphogenetic protein-2, (b) bone morphogenetic protein- receptor type IA, and (c) bone 
morphogenetic protein- receptor type 2.  BMP-2 expression shows significantly elevated 
levels over all controls throughout the study independent of pore size and porosity.  The 
increase of BMP-2 correlated with a significant increase in receptor expression (b, c).  
The elevated levels of BMP receptor expression is maintained throughout the study and is 
independent of pore size and porosity.  (‡, *) denote statistical significance within that 
timepoint. 
 
From the previous studies we chose to move forward with the 100µm 65% 
EH-PEG hydrogels and added fibronectin at concentrations of 0.5, 2.5, and 10 µg/gel.  
The viability of EH-PEG hydrogels with increasing concentrations of fibronectin was 
assessed throughout the study using the LIVE/DEAD assay.  For the duration of the 
investigation the majority of the hMSCs appeared viable as shown in Figure 39 where 
at days 4 and 8 the populations of hMSCs are fluorescing green.  In addition, the 
hMSCs on EH-PEG hydrogels with higher concentrations of fibronectin 

































































Figure 39: Viability of hMSCs in EH-PEG hydrogels with increasing concentrations of 
fibronectin.  After four days of culture (a-d) and after eight days of culture (e-h) the 
majority of the cell populations were viable.  Higher concentrations of fibronectin 
demonstrate cell spreading.  (a, e) 0.5µg fib/gel, (b, f) 2.5µg fib/gel, (c, g) 10µg fib/gel, 
(d, h) osteogenic control.  Scale bar denotes 250µm.  
 
hMSCs were cultured on EH-PEG hydrogels and analyzed on days 1, 4, and 8 
to investigate the effects of fibronectin concentration on osteogenic signal expression.  
BMP-2 expression shows significantly elevated levels in all groups over the controls 




addition, at day 4 and day 8, the hMSCs in EH-PEG gels with the highest 
concentrations of fibronectin demonstrated the highest expression of BMP-2.  
Specifically, at day 8, the hMSCs cultured in the 10µg fibronectin/gel EH-PEG gels 
showed a fold change of 60 over the control.  Further analysis showed that the 
increase in BMP-2 expression correlated with an increase in BMP receptor expression 
(Figures 40b, c) as demonstrated by significantly increased levels of BMP-RIA and 
BMP-R2.  For days 1 and 4 the increase in receptor levels is independent of 
fibronectin concentration.  However, at day 8 the increase appears to be dependant on 
fibronectin concentration, where the higher concentrations demonstrate significantly 
higher receptor level expression for both BMP-RIA and BMP-R2 as compared to the 
other concentrations.  As shown in the previous section, the increase in receptor 
expression was not to the same magnitude as the BMP-2 increase where the BMP-
RIA increase was approximately two-fold and the BMP-R2 increase was 













































































Figure 40:  Quantitative RT-PCR analysis after 1, 4, and 8 days for (a) bone 
morphogenetic protein-2, (b) bone morphogenetic protein- receptor type 1A, and (c) bone 
morphogenetic protein- receptor type 2.  BMP-2 expression shows significantly elevated 
levels over all controls throughout the study, with a slight increase from day 1 to day 4.  
The increase of BMP-2 correlated with a significant increase in receptor expression (b, 
c).  The elevated levels of BMP receptor expression is maintained throughout the study 
and appears to have a slight dependence on fibronectin concentration, where the higher 
concentrations demonstrate higher receptor expression.  (‡, *) denote statistical 




























































































Tri-layer scaffolds were created with varying porosity and pore size to test for 
flexural properties using a three-point bending test (Figure 41).  The results indicate 
that the scaffolds showed increasing strength with decreasing porosity when 
comparing scaffolds with the same pore size (Figure 42).  The tri-layer scaffolds at 
250 µm did show a slight increase in strength over the EH-PEG control.  However, 
the tri-layer scaffolds at 100 µm showed significantly higher strength when compared 










Figure 41:   Scaffolds for mechanical testing.  Tri-layer scaffolds (a, c) and control EH-




















Figure 42:  Tri-layer scaffolds with varying porosity and pore size were created and a 
three-point bend test was performed to analyze flexural strength.  The results indicate 
increasing strength with decreasing porosity with the same pore size.  The tri-layer 
scaffolds at 100 µm showed significantly higher strength when compared to the control 
and to the 250 µm scaffolds.  (*) denotes statistical significance within that pore size. 
 
9.4 Discussion 
Scaffold architecture is important in determining the success of a tissue 
engineering construct.  Specifically, the porosity of a scaffold is essential as it 
supports integration with the surrounding tissue.  Furthermore, increased porosity 
allows for cellular infiltration and therefore increased cell density within the scaffold.  
This change in cell density will augment cell interaction and, as a result, cell 
signaling. 
The objective of this work was to (1) investigate the effects of scaffold 
architecture, through varying porosity and pore size, in EH-PEG hydrogels on 












































indicate an optimal architecture for the EH-PEG hydrogels to use in further 
investigations.  Therefore, our next objective was to (2) examine the effect of cell 
adhesion through incorporation of fibronectin in EH-PEG hydrogels with an optimal 
architecture on osteogenic signal expression.  Lastly, as varying architecture can alter 
the strength of the scaffold, we (3) investigated the strength of EH-PEG scaffolds 
with varying pore size and porosity. 
First, we created macroporous EH-PEG hydrogels using porogen leaching, 
and demonstrated the success of the technique through FESEM and phase-contrast 
microscopy (Figure 34).  To maintain porogen integrity, a saturated salt solution was 
used as the water component which slowed the dissolution of salt during crosslinking.  
As this technique is easily used, it should be considered when making macroporous 
hydrogels.   
In order to evaluate the effect of varying architecture on osteogenic signal 
expression of hMSCs, cells were seeded on EH-PEG scaffolds with varying porosity 
and pore size and compared to cells cultured in monolayer.  Viability was monitored 
throughout the study, and results demonstrated that the cell populations maintained 
viability throughout the study independent of architecture.  When analyzing the 
morphology of the cells, the hMSCs do not appear as spread as in standard cultures, 
indicating a modification to the scaffold may be necessary.   
Next, hMSCs within EH-PEG hydrogels were analyzed for alkaline 
phosphatase expression, an early osteogenic marker.  The results demonstrate higher 
expression for the EH-PEG hydrogels when compared to the monolayer controls.  In 




100 µm show higher expression at day 8 as compared to all other groups and also 
represent a faster rate of expression.  This difference, dependent on scaffold 
architecture, could be due to a decrease in proliferation or cell aggregation caused by 
the smaller pores. 
  hMSCs were also loaded in EH-PEG hydrogels and analyzed for osteogenic 
signal expression as measured by BMP-2, BMP-RIA, and BMP-R2 expression levels.  
BMP-2 showed increased expression for all groups independent of pore size and 
porosity over the controls.  Furthermore, this large increase in BMP-2 expression was 
associated with approximately a two-fold increase in receptor expression for all 
groups.  This demonstrates that the increase in BMP-2 signal expression does not 
require an equal increase in receptor expression to aid in signal transduction.  While it 
is clear that the EH-PEG hydrogels significantly enhance osteogenic signal 
expression of hMSCs, it does not appear to be dependent on scaffold architecture.   
Studies have demonstrated the ability of substrate stiffness to impact the 
differentiation of hMSCs.[274]  Specifically, after several weeks in culture, cells 
commit to a lineage specified by matrix elasticity.  While, this may have an effect on 
the hMSCs in our EH-PEG hydrogels, the osteogenic signal expression increased 
significantly by day one, so there may be other factors involved as well, such as 
proliferation rates and possible cell aggregation.  Osteocalcin expression was also 
measured; however, only low levels were detected revealing that the late osteogenic 
marker is not being expressed.  This indicates that over the length of this study, the 




as demonstrated by the early osteogenic marker alkaline phosphatase and the early 
signaling expression of BMP-2 and the related receptors. 
Results from the previous studies indicate that the ideal EH-PEG architecture 
to use for hMSC culture was 100 µm/65% porosity.  We then chose to add the 
extracellular matrix protein fibronectin to the EH-PEG hydrogels, as fibronectin is 
known to aid in hMSC attachment.[275,276]  This environment is conducive to 
differentiation and therefore may enhance osteogenic cell signaling.   
First, results indicate that the majority of the cells remained viable during the 
8 days, independent of fibronectin concentration.  Furthermore, the morphology of 
the cells was altered when compared to the previous studies.  The hMSCs with higher 
concentrations of fibronectin demonstrated more cell spreading as compared EH-PEG 
hydrogels with no fibronectin, consistent with what is predicted from the literature.   
Next, the effect of fibronectin addition to EH-PEG hydrogels on osteogenic 
signal expression was investigated.  At day one there was a significant increase of 
BMP-2 expression over the controls with no dependence on fibronectin 
concentration.  From day one to four the expression of BMP-2 increased and was 
maintained through day 8.  At these last timepoints the highest level of BMP-2 
expression correlated with the highest concentration of fibronectin concentration, 
however there does not appear to be a trend.  This was also present in the receptor 
expression levels where at day one there was increased receptor expression 
independent of fibronectin concentration, but at the later timepoints, the highest 




fibronectin may play a role in promoting the early osteogenic signaling which is 
involved in osteodifferentiation. 
The importance of cell adhesion was investigated through the addition of 
fibronectin to the EH-PEG hydrogels.  As demonstrated by the above results, when 
compared to monolayer controls, hMSCs cultured in EH-PEG hydrogels exhibit 
increased osteogenic signaling as shown by BMP-2 expression and BMP receptor 
expression.  It is important to note that the increase in expression as a result in the 
change in architecture was similar to the increase shown by the hMSCs cultured on 
EH-PEG hydrogels with fibronectin.  As these expression levels are both compared to 
hMSCs cultured in monolayer it can be determined that the increase in expression is 
predominately due to the change in architecture rather than as a result of an increase 
in cell adhesion from the incorporation of fibronectin in EH-PEG hydrogels. 
As altering architecture can decrease the strength of the scaffold, it is 
important that the construct performs as required for the desired application.  For 
orbital floor regeneration, the purpose of the orbital floor is to support the orbital 
contents.  Therefore, one objective of this study was to modify the hydrogels by 
introducing a stiff, but still porous, central layer to improve support.  The resulting 
tri-layer scaffolds were tested in a three-point bend test for flexural properties which 
simulate the physiological stresses in situ for orbital floors. 
Tri-layer scaffolds were created with varying pore size and porosity.  The 
results indicate increasing strength with decreasing porosity, as expected.  
Furthermore, the 250 µm tri-layer scaffolds did show some increase over the 250 µm 




showed significant improvement over the 100 µm EH-PEG hydrogel with the 
addition of the porous EH layer.  In addition, the 100 µm scaffolds were significantly 
stronger than the 250 µm tri-layer scaffolds.  It is possible that the scaffolds with the 
larger pore sizes and higher porosities may have improved interconnectivity which 
may cause decreased strength. 
While it is interesting to see the difference in strength between the scaffolds 
with varying architecture, the most important question is whether the construct will 
support the orbital contents.  It is difficult to perform mechanical studies on the 
human orbital floor as it is composed of portions of three bones, and the anatomy is 
difficult to simulate in animal models.  However, the literature has reported that the 
combined weight of the human orbital contents is approximately 42.97 ± 4.05 g.[154]  
From this data, we can estimate the orbital contents would apply approximately 0.13 
MPa which can be supported by our 100 µm scaffolds, but exceeds the strength of the 
250 µm scaffolds.  This analysis indicates that the 100 µm scaffolds are an 
appropriate construct for orbital floor repair, while the 250 µm scaffolds may need 
more adjustments before use.    
 
9.5 Conclusions 
The objectives of this work were to investigate the effects of varying pore size 
and porosity in EH-PEG hydrogels and incorporation of fibronectin on osteogenic 
signal expression, and investigate the strength of EH-PEG scaffolds with varying pore 
size and porosity.  Alkaline phosphatase levels increased for hMSCs in EH-PEG gels 




elevated levels for all EH-PEG groups as demonstrated by BMP-2, BMP-RIA, and 
BMP-R2 expression levels.  Further work demonstrated the inclusion of fibronectin in 
EH-PEG hydrogels shows increased hMSC attachment and spreading with increased 
fibronectin concentration.  In addition, the increase in osteogenic signal expression in 
EH-PEG hydrogels with fibronectin is comparable to the increase seen when 
comparing expression levels of hMSCs in porous EH-PEG hydrogels to cells cultured 
in monolayer. This indicates the increase in expression may be due to the change in 
architecture rather than adhesion.  Lastly, mechanical testing demonstrated the ability 
to increase the strength of EH-PEG hydrogels by creating a tri-layer scaffold with the 
central layer composed of a stiff, porous, EH sheet.  This demonstrates that the EH-













Chapter 10:  Summary  
 The goal of this project was to utilize tissue engineering strategies to regenerate 
orbital floor bone using a novel cyclic acetal scaffold with an osteoprogenitor cell 
population through enhanced osteogenic cell signaling.  Construct design is an 
intricate process and must be tailored for different bone tissue engineering 
applications.  Orbital bone engineering offers solutions to the current clinical 
techniques and can aid in regeneration of natural bone tissue that is similar in both 
form and function to the native orbital floor. 
 The first objective of our work was to harvest primary bone marrow stromal 
cells and induce differentiation through coculture with chondrocytes and the standard 
osteogenic media supplements dexamethasone and the Na-β–glycerolphosphate.  We 
demonstrated that coculturing chondrocytes encapsulated in alginate hydrogels can 
effectively induce differentiation in a mechanism distinct from that of the media 
supplements dexamethasone and the Na-β–glycerolphosphate.  Furthermore, we 
characterized this interaction as having separate temporal components, with brief 
exposure proving sufficient to induce early stages of differentiation, but extended 
exposure necessary for mature osteogenic development. 
 Next, we wanted to investigate whether EH-PEG hydrogels, and their fabrication 
components, permit bone marrow stromal cell viability, metabolic activity, and 
osteodifferentiation.  The results demonstrated that the metabolic activity and 
viability of bone marrow stromal cells in monolayer are minimally affected by the 
APS-TEMED initiator system for extended time periods.  In addition, it shows that on 




affect expression of osteogenic markers, measured both at the mRNA and protein 
level.  From these results, an optimal initiator concentration was chosen to crosslink 
EH-PEG hydrogels.  Finally, encapsulated bone marrow stromal cells were shown to 
survive in EH-PEG hydrogels crosslinked using the optimal APS-TEMED 
concentration for 7 d.  This work demonstrated that EH-PEG hydrogels are a viable 
platform for encapsulation and osteodifferentiation of bone marrow stromal cells. 
 Our next objective was to investigate the tissue response to EH-PEG hydrogels, 
characterize the release of BMP-2 from EH-PEG hydrogels, and analyze their ability 
to deliver BMP-2 in vivo and facilitate bone formation.  The results indicate that the 
tissue surrounding the EH-PEG constructs showed a positive progression during the 
study, indicating that constructs were not eliciting a chronic response.  In addition the 
release of BMP-2 from the construct was complete in 2-4 hours, and happened more 
quickly at the higher concentration.  Lastly, the data shows the ability for EH-PEG 
gels to deliver BMP-2 as shown by the new bone growth in the area surrounding the 
constructs containing high concentrations of BMP-2 at 28 d.  This demonstrates that 
EH-PEG constructs are a viable option for use in vivo and for delivery of BMP-2 in 
vivo. 
 The next objective of our work was to fabricate macroporous EH-PEG hydrogels 
and characterize the architecture using optical coherence tomography.  In this work, 
macroporous EH-PEG hydrogels were produced using porogen-leaching 
demonstrating a simple technique for fabrication.  OCT was used to quantify pore 
size and volume porosity.  Reported pore sizes were within the expected range, as 




pore size.  In addition, OCT image analysis was able to be used to characterize 
volume porosity, a parameter not previously known.  Further work combined OCT 
with confocal microscopy where viable cells were visualized within the scaffolds.     
Last, we investigated the effects of varying pore size and porosity in EH-PEG 
hydrogels and incorporation of fibronectin on osteogenic signal expression, and 
investigate the strength of EH-PEG scaffolds with varying pore size and porosity.  
Alkaline phosphatase levels increased for hMSCs in EH-PEG gels with 100 µm 
pores.  Furthermore, osteogenic signal expression analysis showed elevated levels for 
all EH-PEG groups as demonstrated by BMP-2, BMP-RIA, and BMP-R2 expression 
levels.  Further work demonstrated the inclusion of fibronectin in EH-PEG hydrogels 
shows increased hMSC attachment and spreading with increased fibronectin 
concentration.  In addition, the increase in osteogenic signal expression in EH-PEG 
hydrogels with fibronectin is comparable to the increase seen when comparing 
expression levels of hMSCs in porous EH-PEG hydrogels to cells cultured in 
monolayer. This indicates the increase in expression may be due to the change in 
architecture rather than adhesion.  Lastly, mechanical testing demonstrated the ability 
to increase the strength of EH-PEG hydrogels by creating a tri-layer scaffold with the 
central layer composed of a stiff, porous, EH sheet.  This demonstrates that the EH-
PEG hydrogels are a viable option for orbital floor repair. 
 These studies have demonstrated the use of EH-PEG hydrogels as a tissue 
engineering construct with application for orbital floor repair.  Specifically, through 




minimal tissue response in vivo, and enhanced osteogenic signaling of cell 
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